Use of an aromatase inhibitor for ovarian synchronization in cattle by Zwiefelhofer, Eric M 1992-
 
 
USE OF AN AROMATASE INHIBITOR FOR OVARIAN                   
SYNCHRONIZATION IN CATTLE 
 
 
A Thesis Submitted to the College of  
Graduate Studies and Postdoctoral Studies 
In Partial Fulfillment of the Requirements 
For the Degree of Doctor of Philosophy 
Department of Veterinary Biomedical Science 
University of Saskatchewan 










© Copyright Eric M Zwiefelhofer, January 2020. All rights reserved 
 i 
PERMISSION TO USE 
 
In presenting this thesis in partial fulfillment of the requirements for a Postgraduate degree from 
the University of Saskatchewan, I agree that the Libraries of this University may take it freely 
available for inspection. I further agree that permission for copying of this thesis in any manner, 
in whole or in part, for scholarly purposes may be granted by the professor or professors who 
supervised my thesis work or, in their absence, by the Head of the Department or the Dean of the 
College in which my thesis work was done. It is understood that any copying or publication or 
use of this thesis or parts thereof for financial gain shall not be allowed without my written 
permission. It is also understood that due recognition shall be given to me and to the University 
of Saskatchewan in any scholarly use which may be made of any material in my thesis. 
 
Request for permission to copy or to make other use of material in this thesis in whole or part 
should be addressed to: 
 
Head of Department of Veterinary Biomedical Sciences 
Western College of Veterinary Medicine 
52 Campus Drive 
University of Saskatchewan 
Saskatoon, Saskatchewan 




Dean of College  
College of Graduate and Postdoctoral Studies 
University of Saskatchewan 
116 Thorvaldson Building, 110 Science Place 







Letrozole is a third-generation aromatase inhibitor approved for use in post-menopausal 
women to treat hormone-responsive breast cancer. Letrozole is used off-label in women for the 
induction of ovulation and for use in ovarian stimulation. The overall objective of this thesis was 
to determine the effect of letrozole on ovarian function using the bovine model. 
In the first study, letrozole was formulated into a silicone intravaginal device consisting 
of a small or a large surface area compared to a wax-based device or a control intravaginal 
device given for 8 days in pubertal heifers. The large-surface area device resulted in the greatest 
plasma letrozole concentration throughout the treatment period. The biological effect on the 
ovaries was also most profound in the large surface area group where the dominant follicle was 
largest at the time of device removal and plasma estradiol concentrations decreased the most 
during device insertion. 
In the second study, letrozole residues in milk were characterized in lactating dairy cattle. 
A silicone letrozole-releasing device (LRD) was inserted for 4 days, blood and milk sampling 
were performed at 12-hour intervals, and a partial validation for letrozole in milk was done using 
tandem mass spectrometry. Although letrozole was detected in milk, maximum concentration of 
letrozole was significantly lower in milk than in plasma. There were no differences in the 
elimination half-life or time to maximum concentration for letrozole in milk or plasma.  
The objective of the third study was to determine if letrozole would increase the 
superovulatory response in cattle. Non-lactating cows were given an LRD or a sham device at 
the time of transvaginal follicular ablation to induce wave emergence. At wave emergence, cows 
were given 8 doses of follicle-stimulating hormone at 12-hour intervals and were artificially 
inseminated 48 hours after prostaglandin (PGF). The LRD group exhibited estrus significantly 
 iii 
later and estrus was more synchronous than the sham group. However, the LRD group had a 
lower proportion of quality one embryos and transferable embryos than the sham group.  
The objective of the fourth study was to characterize the effect of letrozole on follicular 
function and oocyte competence in cattle in three experiments. In the first experiment, 
transvaginal ablation was done to induce wave emergence and an LRD or sham device was given 
for 4 days followed by follicular aspiration to obtain granulosa cells for gene expression. In the 
second experiment following a 4-day LRD or sham device, frequent blood collections were done 
for analysis of plasma luteinizing hormone (LH) concentrations. Oocytes were collected that 
were either immediately denuded and stained or underwent 24 hours of in vitro maturation 
followed by staining. In the last experiment, following aspiration, oocytes were subjected to in 
vitro maturation, fertilization, and culture. There was no difference between treatments for gene 
expression from granulosa cells. Heifers in the LRD group had a significantly higher LH area 
under the curve and pulse amplitude than the sham group. The oocytes from the LRD group in 
vitro matured for 24 hours had the highest proportion of oocytes in the MII stage than the other 
groups. The LRD group following in vitro fertilization had a greater proportion of blastocysts 
and transferable embryos than the sham group. 
The objectives of the fifth study were to determine the interval to ovulation following 
LRD treatment, compare an LRD-based synchronization to commercially used protocols for 
fixed-time artificial insemination (FTAI), and to develop a new LRD designed to reduce 
vaginitis and increase letrozole release. In the first experiment, a 4-day LRD was given at 
random stages of the estrous cycle followed by PGF at device removal. Cattle (n=10/group; 6 
groups) were given GnRH at 48- or 60-hours after PGF, or no GnRH. In the second experiment, 
the 48-hour interval from PGF to GnRH following a 4-day LRD treatment was chosen for a 
 iv 
FTAI trial to compare pregnancy per AI (P/AI). In the third experiment, heifers (n=10/group) 
were given a newly designed LRD or an LRD designed in study one and frequent blood 
sampling was performed along with assessment of vaginitis. The 48-hour GnRH cow group 
ovulated more synchronous than the other groups. Following FTAI, the LRD group had 
significantly lower P/AI than the other two protocols. The newly designed LRD significantly 
increased plasma letrozole concentrations and numerically lowered the vaginitis score at device 
removal.  
The objectives of the last study were to determine the: interval to estrus following a 4-day 
LRD or sham device and PGF at device removal, effect of estrous cycle stage when letrozole 
treatment was initiated on P/AI, and to compare a newly developed LRD protocol to a 
progesterone-based protocol. Following PGF, no difference was detected in the interval to estrus 
between the LRD and sham groups. When LRD treatment was initiated during the proestrus 
period, it did not prevent ovulation. However, treatment during the metestrus period resulted in 
the highest P/AI. There was no difference in P/AI between a newly developed LRD-based 
protocol compared to a progesterone-based protocol.  
In summary, we have determined that intravaginal letrozole treatment can control ovarian 
function in cattle. Letrozole is not deleterious on the ability of the oocyte to undergo fertilization 
and can be used for FTAI protocols in cattle. Future studies should address the effect of letrozole 
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1. CHAPTER 1: GENERAL INTRODUCTION, HYPOTHESES, AND OBJECTIVES 
 
 
Controlling ovarian function is vital to implement advanced reproductive technologies in 
cattle. According to the National Animal Health Monitoring System in the United States, 
artificial insemination (AI) is only used in 8% of beef operations in comparison to 89% of dairy 
operations (Johnson and Dahlke, 2015; USDA, 2018). The low percentage of beef operations 
utilizing AI was credited to its time, labor, and difficulty in implementation. In the United States, 
synchronization protocols involving estradiol are not approved for use in cattle and in Canada 
estradiol-based protocols can only be used following veterinarian prescription. Therefore, 
producers continue to search for alternatives that are effective yet require minimal handling.  
The aromatase inhibitor, letrozole, is approved for use in postmenopausal women for the 
treatment of hormone-dependent breast cancer. It functions by blocking the conversion of 
androgen into estrogen, depleting the body of estrogens and suppressing tumor growth (Chumsri 
et al., 2011). However, letrozole has been used off-label for ovulation induction and ovarian 
stimulation in premenopausal women. The use of letrozole for the control of ovarian function in 
cattle has been recently investigated (reviewed in Yapura et al., 2018). It was discovered that by 
releasing the negative feedback of estradiol on the hypothalamus, luteinizing hormone (LH) 
secretion (but not follicle-stimulating hormone FSH) increased, which prolonged the length of 
dominance of the dominant follicle. An increased diameter of the corpus luteum (CL) was also 
attributed to a luteotropic effect of LH. However, initial fertility trials involving fixed-time 
artificial insemination after letrozole treatment resulted in a low pregnancy per AI (P/AI) 
(Yapura et al., 2016). The reasoning behind this low P/AI was unknown, but most likely due to 
an effect of low estradiol at the time of artificial insemination.  
 2 
In the following section, current knowledge of bovine female reproduction and synchronization 
strategies implemented for advanced reproductive programs in cattle, along with the use of 
aromatase inhibitors in women will be reviewed.    
1.1. Bovine reproductive physiology 
1.1.1. Ovarian follicular dynamics 
 
Before the utilization of transrectal ultrasonography, ovarian follicular dynamics in cattle 
was a challenging concept. Individual assessment of ovaries after euthanasia on specific days 
after estrus led to the initial hypothesis that follicles ≥5 mm show two waves of growth during 
the estrous cycle (Rajakoski, 1960). Others refuted this study and claimed that follicular 
development is continuous and independent of the cycle (Choudary et al., 1968; Donaldson and 
Hansel, 1968). Following the advent of real-time ultrasonography, it has become accepted that 
wave emergence occurs when 8 to 41 small follicles (3 to 4 mm in diameter) are detected 
following a surge in FSH (Pierson and Ginther, 1987a; Sirois and Fortune, 1988; Adams et al., 
1992b).  The majority of bovine estrous cycles are composed of 2 or 3 follicular waves with the 
first wave occurring at the time of ovulation (Day 0). The emergence of the second wave occurs 
on Days 9 or 10 and Day 8 or 9 in two- and three-wave cycles, respectively. The third wave 
occurs on Day 15 or 16 in three-wave cycles (Ginther et al., 1989). Luteolysis commences on 
Day 16 and Day 19 in two- and three-wave cycles, respectively, resulting in a shorter inter-
ovulatory interval in two- vs three-wave cycles (i.e. 19-20 vs 22-23 days).  
Follicular waves result from the negative feedback of estradiol and inhibin (produced 
from granulosa cells of follicles in the wave, and especially the dominant follicle) on FSH 
release (Kaneko et al., 1995; Mihm et al., 1997). When the dominant follicle ovulates or 
undergoes atresia, a surge of FSH occurs initiating wave emergence approximately 12 to 24 
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hours later (Adams et al., 1992b). The dominant follicle of the first wave exhibits a larger 
diameter in comparison to the subsequent dominant follicle(s) in the cycle, which is attributed to 
lower levels of circulating progesterone during its growth (Adams et al., 1992a). More recent 
research has indicated that progesterone plays an inhibitory role on LH release from the pituitary 
(Bergfeld et al., 1996). As the dominant follicle grows, it acquires more LH receptors on the 
granulosa cells than the subordinate follicles and is able to shift its dependence from FSH to LH 
during the time of follicular deviation (Adams et al., 2008). The increase in understanding of 
ovarian follicle wave dynamics has led to the development of estrus synchronization protocols to 
maximize pregnancy success in cattle. 
 
1.2. Exogenous control of the estrous cycle in cattle 
1.2.1. Prostaglandin- and gonadotropin-releasing hormone-based protocols 
 
The the ability of the uterine horn ipsilateral to the CL to respond to oxytocin and shorten 
the estrous cycle in cattle was first identified in the late 1960’s (Ginther et al., 1967). 
Prostaglandin F2a (herein referred to as PGF), a product from oxytocin receptors in the 
endometrium, was later identified as the luteolytic agent and, when given exogenously, could 
induce luteolysis so that AI could be done (Hafs et al., 1974; Thatcher and Chenault, 1976). 
However, the CL is refractory to a single administration of PGF for 5 to 6 days after ovulation 
(Levy et al., 2000). Discovery of the ability of the gonadotropin-releasing hormone (GnRH) 
agonist (Buserelin) to elicit both LH and FSH release and subsequent ovulations showed promise 
to initiate fixed-time artificial insemination (FTAI) (Macmillan and Thatcher, 1991).  
Taken together, the luteolytic properties of PGF, understanding of follicular waves, and the 
ability of dominant follicles to ovulate following the administration of exogenous GnRH laid the 
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groundwork for the first ovulation synchrony protocol coined “Ovsynch” (Pursley et al., 1995). 
At random stages of the estrous cycle, lactating dairy cows were given GnRH, followed by PGF 
7 days later. Forty-eight hours later, cattle were given GnRH again, and FTAI was done 24 hours 
later with a P/AI of 55%. This FTAI protocol eliminated the need for estrus detection and 
significantly increased the number of pregnant cows at 100 days in milk (Pursley et al., 1997). 
Unfortunately, ovulation synchrony around the time of AI was dependent upon ovulation 
following the first GnRH given at random stages of the cycle. Subsequent studies showed that 
GnRH given at random stages of the estrous cycle results in 44% to 54% of ovulations in dairy 
cows (Bello et al., 2006; Colazo et al., 2009), but 95% when given 5 to 8 days after estrus 
(Vasconcelos et al., 1999). Using this knowledge, Pre-synch, in which PGF was given twice 14 
days apart, before initiating Ovsynch 12 to 14 days after the second PGF was developed 
(Moreira et al., 2001). Although this approach increased the P/AI following AI, anovular cows 
did not respond to the Pre-synch. To address this problem, an additional Ovsynch protocol, 
Double-Ovsynch, was developed (Souza et al., 2008). This protocol resulted in higher P/AI, 
especially in primiparous cows, in comparison to Pre-synch/Ovsynch. Utilization of Ovsynch 
protocols has greatly reduced the number of days not pregnant in lactating Holsteins (reviewed in 
Wiltbank and Pursley, 2014), but the adaptation of these protocols for beef cattle is not feasible 
due to handling requirements.  
Cosynch (performing AI and giving GnRH concurrently) was developed for use in beef 
and dairy cattle to reduce the number of handlings needed (Geary et al., 1998). Many adaptations 
of Cosynch exist including protocols with or without an intravaginal progesterone device (Lamb 
et al., 2001), 5- or 7-day interval from GnRH to PGF (Bridges et al., 2008), or no GnRH given at 
the time of a progesterone device insertion (Colazo and Ambrose, 2011). By lengthening 
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proestrus (i.e., the interval from progesterone device removal and PGF to AI and GnRH) some 
studies have shown an increase in P/AI in dairy cattle (Santos et al., 2010; Lima et al., 2011). 
However, as seen with Ovsynch protocols, synchronized wave emergence is only achieved when 
ovulation occurs following the first GnRH; therefore following device removal and PGF, 
variable intervals to estrus exist between cattle following Cosynch protocols (Larson et al., 
2006).  
1.2.2. Progesterone and estradiol-based protocols 
 
The role of exogenous progesterone and estradiol for the control of follicular wave 
emergence has led to the increased use of advanced reproductive technologies in cattle 
worldwide. Estradiol-17b, given exogenously induced atresia of the dominant follicle in rhesus 
monkeys (Hutz et al., 1988). The impact of estradiol on follicular dynamics in cattle was first 
observed in the early 1990s. In an effort to increase the superstimulatory response, cows were 
treated with a progesterone ear implant and given estradiol valerate on Day 2 or 7 (Day 0 = 
estrus) with superstimulation induced on Day 9. Treatment with estradiol induced atresia of the 
dominant follicle approximately two days after administration and the Day 2 group resulted in a 
greater number of CL and embryos following collection compared to the Day 7 group (Bo et al., 
1991). Subsequent studies showed that estradiol valerate caused atresia of the dominant follicle 
in early- and mid-growing phases, and following atresia, resulted in an early surge of FSH and 
the emergence of a new follicular wave. In that study, LH surged following the administration of 
estradiol valerate, in the early- and mid- growing stages but not in the late growing stage (Bo et 
al., 1993). The elicitation of the LH surge was understood in the following study in which heifers 
were given either a progesterone ear implant or not at the time of ovulation (Day 0) followed by 
5 mg of estradiol-17b on Day 1 (Bo et al., 1994). Although no difference in plasma estradiol 
 6 
following treatment, progesterone plus estradiol prevented the LH surge, caused atresia of the 
dominant follicle, and elicitation of an FSH surge 3 days later. Subsequently, the second 
follicular wave emerged early and synchronously. A single dose of 5 mg of estradiol-17b was as 
effective as increased dosages or repeated dose regimens in causing synchronous wave 
emergence 4 to 5 days later (Bo et al., 1994).  
The ability to exogenously control wave emergence with estradiol and progesterone was 
soon adapted for superstimulatory protocols. Treatment with estradiol plus progesterone at 
random stages of the estrous cycle followed by superstimulation 4 days later resulted in a 
comparable number of ova/embryos but a higher percentage of fertilizable ova recovered 
compared to superstimulation initiated 8 to 12 days after estrus (Bo et al., 1995, 1996). This 
allowed donors to be managed as a group and eliminated the need for a reference estrus before 
superstimulation. Initial pilot studies using E-17b  plus progesterone for estrous synchronization 
protocols showed that P/AI were high (80%) following progesterone device removal and PGF-
induced luteolysis followed by artificial insemination 12 hours after estrus (Martinez et al., 
2000). No difference was detected for conception rates in beef heifers treated with E-17b and 
then treated with an intravaginal progesterone device or melengestrol acetate prior to 
synchronization of ovulation with estradiol benzoate and FTAI (Martinez et al., 2002). When 
additional progesterone (100 mg in oil) was given im at the time of estradiol treatment plus a 
new or used intravaginal progesterone device, there was no effect on P/AI following FTAI 
(Colazo et al., 2004). Some studies have shown that the dominant follicle did not regress in cattle 
given estradiol cypionate plus progesterone treatments giving around the time of spontaneous 
luteolysis and an aged (persistent) follicle ovulated following removal of the intravaginal device 
(Colazo et al., 2003).  
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Due to the development of estradiol- and progesterone-based protocols, the number of 
FTAI, fixed-time embryo transfer, and superstimulatory treatments in cattle have increased, 
particularly in South American countries. A total of 11 million cattle underwent FTAI in Brazil 
in 2016 with a majority utilizing estradiol- and progesterone-based protocols (Mapletoft et al., 
2018). Utilization of these protocols in the United States, Europe, Australia (dairy) and New 
Zealand (dairy) has been banned due to the public’s concern of steroid use in food-producing 
animals (Lane et al., 2008), but can still be used in Canada following veterinary prescription.  
 
1.3. Estradiol production in cattle 
1.3.1. Steroidogenic pathway of estradiol production 
The synthesis of estradiol (Figure 1.1) begins with the parent molecule, cholesterol, 
which is derived from low-density lipoproteins from dietary cholesterol (Gwynne and Strauss, 
1982). Cholesterol is transported into the outer mitochondrial membrane during the first stage of 
steroidogenesis (Chang et al., 2006). Subsequently, the steroidal acute regulatory protein (StAR) 
facilitates the transport of cholesterol into the inner mitochondrial membrane. Conversion of 1 
mole of cholesterol to pregnenolone requires 3 moles of NADPH (Miller and Auchus, 2011). 
This reaction, occurring in the mitochondria, in a rate-limiting and hormonally regulated step 
utilizing the P450 side-chain cleavage (P450scc; CYP11A1 encoding gene) enzyme (Stone and 
Hechter, 1955) and occurs in three successive steps: 1) the hydroxylation on C22 of cholesterol, 
the hydroxylation of C20 of the intermediate, followed by oxidation of the C20-22 bond (i.e. the 
side-chain cleavage event, which yields pregnenolone and isocaproaldehyde (Miller and Auchus, 
2011). At this point, pregnenolone can either be converted to 17a-hydroxypregnenolone or 
progesterone, by the enzymes 17a-hydroxylase (CYP17A1 gene encoding) and 3-beta-
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hydroxysteroid dehydrogenase (3b-HSD), respectively. Progesterone and 17a-
hydroxypregnenolone can be converted further into 17a-hydroxyprogesterone by the enzymes 
17a-hydroxylase and 3b-HSD, respectively. Similarly, 17a-hydroxypregnenolone and 17a-
hydroxyprogesterone yield dehydroepiandrosterone (DHEA) and androstenedione, respectively, 
with the use of the enzyme 17,20 lyase. At this point, DHEA can either be synthesized into 
androstenediol via 17b-HSD or synthesized into androstenedione via 3b-HSD. Both 
androstenediol and androstenedione can be transformed into testosterone by 3b-HSD and 17b-
HSD, respectively. Estrogens are subsequently synthesized with the use of the aromatase enzyme 
(P450arom; gene encoding CYP19A1) of androstenedione and testosterone into estrone and 
estradiol, respectively. Finally, estrone can be converted to estradiol by 17b-HSD (Stone and 
Hechter, 1955; Chang et al., 2006; Miller and Auchus, 2011). 
 
Figure 1. 1. Steroidogenic synthesis of estrogens beginning with cholesterol utilizing the 
enzymes (bolded): P450 side cleavage chain (P450scc), 3b-hydroxysteroid dehydrogenase (3b-




















1.3.2. Hypothalamus-pituitary-ovarian axis  
Neurological control of the female bovine reproductive system encompasses both the 
brain and ovaries, which play a vital role in the secretion of GnRH from the mediobasal 
hypothalamic region of the diencephalon (Dees and McArthur, 1981; Leshin et al., 1988). 
Following its release into the hypothalamic-hypophyseal portal vein, GnRH reaches the 
adenohypophysis, binds to the GnRH-receptors, and subsequently discharges LH and FSH into 
the systemic circulation. These gonadotropins bind to receptors on the granulosal (FSH) and 
thecal (LH) cells of individual follicles. The original “two-cell, two-gonadotropin” model was 
proposed in 1977 (Armstrong and Dorrington, 1977). The two-cell, two-gonadotropin model 
states that increased circulating LH stimulates the CYP 17, 20 lyase enzyme activity found 
exclusively in theca cells and subsequently increases androgen production. Estrogens are then 
synthesized in the granulosa cells where the CYP19 (aromatase) enzyme is stimulated by FSH 
from the locally produced androgens (Hillier et al., 1994). Therefore, androgens exert a paracrine 
effect within the ovary, while estrogens (primarily estradiol) exert an endocrine feedback effect 
on gonadotropin secretion.  
Both estradiol and progesterone exert positive and negative feedback on the 
hypothalamus. Progesterone inhibits the frequency of LH release, which is hypothesized to be 
mediated by opioid peptides in the hypothalamus (Bergfeld et al., 1996; Goodman et al., 2002). 
The negative feedback of estradiol on LH is more complex and appears to be regulated by 
progesterone as well. During the luteal phase, estradiol enhances the progesterone inhibition of 
LH pulsatility (Skinner et al., 1998), but when concentrations high enough to induce an LH surge 
occur, estradiol reduces the frequency of LH release (Kesner et al., 1981; Evans et al., 1994). 
During luteolysis, as progesterone drops, estradiol begins to rise and LH frequency increases. 
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The positive feedback of estradiol is achieved by the activation of estradiol receptor neurons in 
the hypothalamus. The estradiol signal is then transmitted to GnRH neurons, which stimulate the 
surge release of GnRH at the median eminence resulting in the preovulatory LH and FSH surge 
from the anterior pituitary (Evans et al., 2002). The regulation of FSH secretion from the 
pituitary (non-GnRH mediated) remains unclear. The follicle-produced hormones, estradiol and 
inhibin act as endocrine factors regulating FSH release from the anterior pituitary. It appears that 
negative feedback of estradiol on the anterior pituitary is due to the inhibition of FSH-b 
expression. Similarly, heifers that were immunized against inhibin had increased FSH 
concentrations and a higher number of small follicles in the ovaries (Medan et al., 2004). 
Moreover, inhibin does not affect LH release and does not act on the hypothalamus for control of 
GnRH secretion (Sharma et al., 2012). Using an ovariectomized animal model, a combination of 
estradiol and inhibin was shown to be needed for the full inhibition of FSH release (Martin et al., 
1988). Although a great understanding of the HPO axis has been achieved in the past 30 years, it 
is clear that increased comprehension of neurological control of the HPO axis is still needed.     
1.3.3. Estrogen receptors 
In cattle, estrogen receptors consist of 2 subunits: estrogen receptor a and b (ERa and 
ERb) and their respective encoding genes: ESR1 and ESR2. In ovarian tissues, ERa is localized 
mainly in theca cells, stromal cells, interstitial glands, and germinal epithelium while ERb is 
localized mainly in granulosa cells of growing follicles (Rosenfeld et al., 2001; Berisha et al., 
2002; Van Den Broeck et al., 2002; Amrozi et al., 2004). Estrogen has been shown to 
downregulate granulosa cell expression in ERb (Sharma et al., 1999). In cattle given an 
ovulatory dose of LH, ovarian ERb does not change, although it decreases in rats (O’Brien et al., 
1999; Rosenfeld et al., 2001). Following studies with the intrafollicular administration of an ER-
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antagonist, it was concluded that both ERs are needed for the development of a dominant follicle 
in cattle (Rovani et al., 2014). An increase in intrafollicular levels of estrogens increases 
granulosa cell sensitivity to LH and FSH due to the increase of LH- and FSH-receptors. 
Similarly, in vitro models indicate that estradiol increases steroidogenesis and preantral follicle 
growth (Rosenfeld et al., 2001). The ESR1 knockout mouse model indicates that females are 
infertile and non-receptive to males, indicating the effect of ESR1 in the central nervous system 
(Lubahn et al., 1993). It was concluded, therefore, that ERa controls the estrogen feedback in the 
hypothalamus (Glidewell-Kenney et al., 2007). Similarly, ESR2 knockout mice have a lower 
number of growing follicles and decreased litter size indicating a role in follicular development 
(Krege et al., 1998).  
1.3.4. Role of estradiol during proestrus and estrus 
The expression of estrus is associated with improved pregnancy success following FTAI. 
However, many preceeding endocrinological events must transpire before estrus can occur. 
Estradiol from the dominant follicle is needed to stimulate PGF secretion from the endometrium, 
leading to induction of luteolysis (Araujo et al., 2009). As progesterone decreases, pulse 
frequency of LH increases, further fueling the growth of the dominant follicle. This continuous 
cascade leads to both increased androgen production from the theca cells as well as upregulation 
of FSH-receptors, increasing the aromatization of androgens to estrogens in the granulosa cells 
(Weil et al., 1999). Estrous behavior is then prompted by peak plasma estradiol levels (Henricks 
et al., 1971).  Similarly, once peak estradiol levels are achieved, a surge of GnRH is produced in 
the hypothalamus, and subsequent surges of LH and FSH are released from the anterior pituitary 
gland. The LH surge results in disruption of the cumulus-oocyte complexes (COC) from the 
granulosa cells, inducing meiotic maturation of the COC, depleting estradiol production in the 
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granulosa cells, followed by subsequent ovulation of the dominant follicle 24 to 30 hours later 
(Hyttel et al., 1997; Komar et al., 2001). 
1.3.4.1. Sperm transport 
Not only does estradiol contribute to endocrinological control of estrus and ovulation, but 
it is also important in sperm and oocyte transport through the female tubular genitalia. 
Transportation of sperm is hypothesized to occur in two phases: 1) a rapid initial phase where a 
small fraction of sperm reach the uterine tubes within minutes, and 2) a slower movement of an 
increased number of sperm through the uterus and uterine tubes (Hawk, 1983).  Following 
copulation in sheep, semen is deposited in the anterior portion of the vagina, followed by a large 
number of sperm found in the uterine tubes within 5- or 10-minutes (Mattner and Braden, 1963). 
Propulsion from the sperm itself is not a limiting factor, as non-motile, dead ram sperm have 
been found in the uterine tubes within minutes of insemination. The prolonged period is 
characterized by an ever-increasing number of sperm in the uterine tubes maximized 
approximately 22 to 24 hours following copulation (Hunter, 1975). When estradiol was given 
exogenously to sheep within 18 hours after natural mating, there was an eightfold increase in the 
number of sperm recovered from the uterus and uterine tubes compared to non-treated control 
animals (Hawk and Cooper, 1975). Therefore, the effect of estradiol on the contractile movement 
of the uterus is necessary for sperm transport to the uterine tubes for in vivo fertilization. 
1.3.4.2. Uterine environment 
Estradiol also has a profound effect on the uterine lumen pH. A lower pH in the uterine 
lumen has been shown to affect motility and longevity of bull sperm (Jones and Bavister, 2000). 
Interestingly in cattle, the uterine pH was negatively correlated to estradiol, and the pH reached a 
nadir at the time of estrus (Perry and Perry, 2008). Therefore, it was hypothesized that a low pH 
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might extend the longevity of sperm due to the prolonged period from estrus to ovulation (i.e., 24 
to 30 hours; (Komar et al., 2001)). To mimic this environment, exogenous estradiol was given 12 
hours after PGF, which increased the proportion of cows in estrus and decreased uterine pH 
(Perry and Perry, 2008). Similarly, exogenous estradiol given 24 hours before GnRH/AI 
increased the P/AI of beef cows that ovulated follicles <12.2 mm, which was attributed to the 
change in pH of the uterine environment (Jinks et al., 2012).   
1.3.4.3. Effect on short lifespan CL 
In cattle, the first spontaneous pubertal or postpartum ovulation results in a short estrous 
cycle of 7 to 10 days (Garverick et al., 1992). Originally, it was proposed that progesterone 
before ovulation was needed for normal luteal function in cattle (Copelin et al., 1987). Similarly, 
it was proposed that only circulating estradiol levels preceding ovulation would also affect the 
lifespan of the resultant CL. Using the ovariectomized bovine model, cows were given low, 
medium, or high doses of estradiol at 8-hour intervals for 40 hours, followed by increasing 
amounts of injectable progesterone to simulate CL progesterone production. Subsequently, cows 
were given intramuscular oxytocin 6 days after the last estradiol treatment, which resulted in an 
increase in PGF metabolite in both the low and medium estradiol groups (Mann and Lamming, 
2000). It was concluded that high levels of estradiol (with or without pretreatment of 
progesterone) inhibit endometrial oxytocin receptor concentrations in a dose-dependent manner. 
Therefore, following the first postpartum or pubertal ovulation, the CL lifespan is shortened due 
to estradiol not fully inhibiting oxytocin receptors on the endometrium. Consequently, oxytocin 
can bind to the remaining oxytocin receptors, which releases PGF and leads to early luteolysis 
(Mann and Lamming, 2000). This decrease in oxytocin receptors may have been a contributing 
factor for the observed increase in P/AI in dairy cows given exogenous estradiol 2 days before 
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AI (Cerri et al., 2004). Many extensive field-trial studies do not incorporate ultrasonography or 
blood sampling 7 to 10 days after AI, so the incidences of short lifespan CL is unknown.  
1.4. Aromatase enzyme 
1.4.1. Location and classification 
The aromatase enzyme is a member of the cytochrome P450 family. It catalyzes the rate-
limiting step of estrogen biosynthesis: aromatization of testosterone and androstenedione into 
estradiol and estrone, respectively (Chumsri et al., 2011). The preferred substrate, 
androstenedione, is aromatized in three successive oxidation steps: hydroxylation of the angular 
C-19 methyl group followed by aromatization of the A ring of androstenedione and loss of the C-
19 carbon atom which in turn cleaves the C10-C19 bond (Colozza et al., 2014). The first two of 
these steps are common in all P450 cytochrome proteins, but the third step is unique to 
aromatase (Akhtar et al., 2011). Aromatase has been found in a variety of tissues, including the 
ovary, placenta, testis, skin, brain, fat and bone (Thompson and Siiteri, 1974; Valladares and 
Payne, 1979; Durham et al., 1985; Simpson et al., 1994). In breast cancer cells, aromatase has 
been shown to exhibit higher activity than non-cancer cells, and this is the impetus for breast 
cancer treatment with aromatase inhibitors (Harada, 1997). In fetal bovine ovaries, 
immunohistochemical studies have found aromatase expression between 45 to 250 days of 
gestation (Burkhart et al., 2010). In the adult bovine ovary, the presence of aromatase is most 
profound in mural granulosa cells of the follicle, but it has also been found in the CL, which has 
been hypothesized to play a role in luteolysis (Okuda et al., 2001). In cattle, although detected in 
follicles as small as 4 to 6 mm, aromatase mRNA expression continues to increase throughout 
follicle selection and is maximal during the preovulatory stage in association with follicular fluid 
estradiol concentrations (Bao et al., 1997; Bao and Garverick, 1998). The aromatase enzyme is 
 15 
encoded by the CYP19A1 gene, which has been used to understand aromatase mRNA 
expression.   
1.4.2. CYP19A1 gene 
The CYP19A1 gene is located on chromosomes 10 and 15 in cattle and humans, 
respectively (Chumsri et al., 2011; National Center for Biotechnology Information, 2019). The 
upregulation of the CYP19A1 mRNA expression is achieved mainly by FSH (Stocco, 2009). In 
an autocrine manner, estradiol acts to enhance FSH actions, and this effect is believed to play a 
role in follicle dominance in the rat (Fitzpatrick and Richards, 1991). Similarly, androgens can 
enhance FSH’s effect on CYP19A1 mRNA expression. Testosterone was more effective than 
estradiol in enhancing the effect of FSH on CYP19A1 (Hillier and Tetsuka, 1997). Therefore, it 
was hypothesized that androgens derived from theca cells are not only used as a substrate for 
estradiol synthesis, but also control the action of FSH on CYP19A1 (Fitzpatrick and Richards, 
1991).    
1.5. Aromatase inhibitors 
Aromatase inhibitors were initially investigated in the 1970s as a means of treating 
metastatic breast cancer in women (Chumsri et al., 2011). The first aromatase inhibitor, 
aminoglutethimide, inhibited multiple cytochrome P450 enzymes, including CYP19 (aromatase) 
as well as cortisol production (from CYP11). This required patients to undergo cortisol 
replacement treatment, and therefore aminoglutethimide was abandoned as a breast cancer 
treatment (Fisher et al., 1994).  
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1.5.1. Mechanism of action 
The modern age of aromatase inhibitors can be classified into two categories: steroidal 
(i.e. formestane and exemestane) or non-steroidal (i.e. anastrozole and letrozole). Steroidal 
aromatase inhibitors (Type I) irreversibly bind to the substrate-binding spot and are referred to as 
“suicide inhibition” or noncompetitive inhibition (Brodie et al., 1981; Santen et al., 2009). 
Following suicide inhibition, the aromatase enzyme initiates hydroxylation that produces a 
covalent bond between the inhibitor and enzyme that is unbreakable. Therefore, enzyme activity 
is permanently blocked and can only be restored by synthesis of new enzymes (Buzdar, 2003).  
For this reason, steroidal aromatase inhibitors are generally long-term and specific, so the long-
term presence of the drug is not needed. Non-steroidal (competitive) aromatase inhibitors (Type 
II) have higher specificity and less long-term, toxic effects (Chumsri et al., 2011). Non-steroidal 
aromatase inhibitors bind in a non-covalent manner to the heme group and saturate the binding 
sites (i.e., prevent the binding of androgens). Due to the competitive binding nature, this 
inhibition can be reversed by an increase in circulating androgens. Therefore, the effectiveness of 
non-steroidal aromatase inhibitors is based on the concentrations of the drug in the circulation 
(Buzdar, 2003). Currently, there are 3 aromatase inhibitors approved by the U.S. Food and Drug 
Administration for breast cancer treatment: anastrozole and letrozole (non-steroidal) and 
exemestane (steroidal; Chumsri et al., 2011). 
1.5.2. Use of aromatase inhibitors for breast cancer treatment 
Approximately 70% of human breast cancers are estrogen-receptor positive (Lumachi et 
al., 2013). Therefore, aromatase inhibitors are one of the first treatments chosen for 
postmenopausal women (Smith and Dowsett, 2003). Tamoxifen, a selective estrogen receptor 
modulator, is also used to block tumor growth by competitively antagonizing estrogen at its 
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receptor. Unfortunately, treatment with tamoxifen has been linked to thromboembolism and 
uterine cancer (Fisher et al., 1998). Although most aromatases are found in gonadal tissues, they 
have also been located in adipose, liver, brain, breast and breast cancer tissues (Miller et al., 
1982). Mean plasma estradiol concentrations fall from 110 to 7 pg/mL following menopause in 
women, but the levels in carcinoma tissue have been reported as 10x the concentrations in 
plasma due to aromatase activity in tumors (Thijssen and Blankenstein, 1989). Treatment with 
third-generation aromatase inhibitors (letrozole and anastrozole) reduces plasma concentrations 
of estradiol, estrone, and estrone sulfate by 81% to 98% (Geisler et al., 1996, 2002). For 
metastatic breast cancer, treatment with letrozole has been shown to be superior to tamoxifen in 
time to disease progression (42 vs 23 weeks, respectively; Mouridsen et al., 2001). In 
neoadjuvant therapy (i.e. treatment given before surgery), treatment with letrozole led to a 
significantly higher rate of tumor suppression in comparison to tamoxifen (Eiermann et al., 2001; 
Ellis et al., 2001). In premenopausal women, treatment with exemestane (steroidal aromatase 
inhibitor) was just as effective as tamoxifen but required ovarian suppression by GnRH agonist 
or ovariectomy (Francis et al., 2014). For this reason, tamoxifen is the preferred treatment for 
premenopausal breast cancer. Unfortunately, after 5 years, treatment with tamoxifen is not 
beneficial, and during this period, breast cancer relapse occurs (Fisher et al., 1996). Studies have 
shown that a 5-year regimen of letrozole following 5 years of tamoxifen significantly increased 
the survival rate compared to placebo-treated premenopausal women (Goss et al., 2003). 
 
1.5.3. Use of aromatase inhibitors for induced ovulation and stimulation in women 
The most commonly used ovulation-inducing treatment in women from the 1960s to the 
early 2000s was clomiphene citrate (CC; Casper and Mitwally, 2006). Clomiphene citrate acts as 
both an estrogen agonist and antagonist by binding to estrogen receptors throughout the body. 
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Treatment with CC can lead to depletion of estrogen receptors in the hypothalamus and an 
incorrect interpretation of estrogens in circulation. When estrogens are thought to be low, an 
increase in gonadotropins (FSH and LH) occurs, which can lead to an ovulation rate of 60% to 
80% following CC treatment (Garcia et al., 1977). Although ovulation rates are elevated, 
pregnancy rates are low, possibly due to the antiestrogen effect of CC on both the endometrium 
and cervical mucus because of its extended terminal half-life (5 days to 3 weeks; Casper and 
Mitwally, 2006). The terminal half-life of the commonly used aromatase inhibitor, letrozole is 45 
hours in women (Winer et al., 2002). Theoretically then, by decreasing circulating estrogens via 
aromatase inhibitors, the release of hypothalamic negative feedback could be achieved without 
adverse long-term effects on the uterus and cervix.  
Although aromatase inhibitors are not approved for use for any other condition than 
hormone-dependent breast cancer in postmenopausal women (Health Canada, 2005), the first 
study involving aromatase inhibitors for ovulation induction in women with polycystic ovarian 
syndrome (PCOS) was done in 2001. These women, who failed to respond to CC, had ovulation 
and pregnancy rates of 75% and 25%, respectively following aromatase inhibitor treatment 
(Mitwally and Casper, 2001). Another benefit of letrozole treatment was a significant reduction 
in the number of twin pregnancies in women undergoing infertility treatment in comparison to 
CC (Mitwally et al., 2005). Treatment with letrozole also resulted in the highest pregnancy rate 
per cycle in comparison to CC, FSH, or untreated controls (Casper and Mitwally, 2006). Due to 
the inability to perform frequent blood sampling in women, understanding the effect of letrozole 
on LH and FSH release is contradicting in the literature. Following oral letrozole administration, 
circulating estradiol begins to decrease and in several studies an increase in circulating LH 
occurred (Verpoest et al., 2006; Bedaiwy et al., 2011; Lee et al., 2011; Allaway et al., 2017), and 
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circulating FSH was reported to either increase (Allaway et al., 2017), decrease (Lee et al., 2011) 
or remain unchanged (Verpoest et al., 2006). The reasons for this discrepancy may be due to the 
menstrual day that treatment was initiated. Comparisons to the bovine model are reviewed in 
Section 1.4.4.3 below. 
Aromatase inhibitors have also been used recently to increase the ovarian stimulatory 
response in women in combination with FSH (reviewed by Garcia-Velasco, 2012). The 
reasoning behind this stems from two hypotheses: 1) release of the estradiol negative feedback 
on the hypothalamus increases FSH release from the pituitary (Requena et al., 2008), or 2) 
increased intraovarian androgens upregulating FSH-receptors in the granulosa cells requiring less 
FSH to stimulate follicular growth (Weil et al., 1998). In recent years, the latter has been mainly 
accepted due to conflicting literature regarding the first hypothesis. Also, treatment with 
aromatase inhibitors combats the adverse reactions seen with supraphysiological estrogen levels 
in the endometrium following stimulation and embryo transfer (Forman et al., 1988; Simon et al., 
1998). The original trial comparing FSH stimulation with the addition of letrozole to FSH alone 
resulted in a significant reduction in the amount of recombinant FSH required in the letrozole 
group to produce an increase in the number of mature follicles counted on the day of 
administration of human chorionic gonadotropin (Mitwally and Casper, 2002). Three years later, 
the first study showing an increase in follicular fluid and serum testosterone following 
administration of letrozole was shown to increase the number of oocytes retrieved (Garcia-
Velasco et al., 2005). As FSH constitutes one of the highest costs of ovarian stimulation, co-
treatment with letrozole may also allow assisted reproductive technologies to be an affordable 





Letrozole (Figure 1.2; molecular weight: 285.3 g/mol) is a 3rd generation, reversible, non-
steroidal aromatase inhibitor approved for the treatment of hormone-dependent breast cancer. 
Letrozole is marketed by Novartis under the trade name Femara and was approved by the U.S. 
Food and Drug Administration in 2001 (Cohen et al., 2002). In comparison to first- and second-
generation aromatase inhibitors, letrozole is highly specific to the P450arom enzyme and does not 




Figure 1. 2. Molecular structure of letrozole which contains a triazole group that selectively 
binds to the heme group of the aromatase enzyme. 
 
1.5.4.2. Pharmacokinetics and metabolism 
In women, letrozole is taken orally (0.1 to 5 mg/day) and is rapidly absorbed from the 
gastrointestinal tract. In healthy postmenopausal women, reported bioavailability of a single oral 
dosage is 99.9%, and the time to maximum plasma concentration and terminal half-life was 1 
and 42 hours, respectively. Following an intravenous bolus, letrozole plasma levels rapidly 
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decreased, suggesting a fast distribution into tissues (Sioufi et al., 1997a), although no 
differences were detected in letrozole pharmacokinetic parameters between age groups (Pfister et 
al., 2001). Letrozole suppressed estradiol, estrone and estrone sulfate by 75% to 95% within 2 to 
3 days (Cohen et al., 2002) and inhibited aromatization (as analyzed by isotopic analysis) by 98 
to > 99% (Dowsett et al., 1995; Geisler et al., 2002). Elimination of letrozole is mainly by P450 
isozymes (CYP3A4 and CYP2A6), which metabolize letrozole into the primary inactive carbinol 
metabolite, 4,4'-methanol-bisbenzonitrile (Sioufi et al., 1997b). A total of 90% of radiolabeled 
letrozole is recovered in urine consisting of 75% of the carbinol metabolite, 9% unidentifiable 
metabolites, and 6% unchanged letrozole (U.S. Food and Drug Administration, 2007).    
1.5.4.3. Use of letrozole in cattle 
The hypothesis proposed was that letrozole treatment in cattle would terminate the 
growth of the dominant follicle, and that the emergence of a new follicular wave would 
subsequently occur. On the contrary, letrozole given iv 2.5 days after wave emergence increased 
the size and period of dominance of the largest follicle in the wave, presumably due to increased 
circulating LH (Yapura et al., 2012). Further investigation revealed that regardless of the day in 
which a 3-day iv regimen of letrozole was given (Days 1 to 3, 3 to 5, or 5 to 7 post-ovulation), 
letrozole treatment extended the interwave interval in comparison to non-treated control heifers 
(Yapura et al., 2011). Although release of the inhibitory effects of estradiol on the hypothalamus 
resulted in an increase in circulating LH profiles, letrozole treatment failed to elicit increased 
FSH release (Yapura et al., 2011, 2012). Therefore, it was hypothesized that administration of 
increased concentrations of letrozole might elicit FSH release. To test this hypothesis and to 
compare the route and vehicle of administration, letrozole (1 mg/kg) was given either iv (in 
benzyl alcohol) or im (in oil) 3 days after ovulation. Following treatment, circulating estradiol 
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concentrations dropped most rapidly in the iv group, but estradiol suppression was sustained in 
the im group for up to 6 days after treatment. Plasma FSH and LH concentrations at post-
treatment wave emergence were higher in letrozole than in control heifers, but no differences in 
FSH concentrations were detected immediately following letrozole treatment. This unchanged 
plasma FSH supported the notion that the hormone responsible for the extended interwave 
interval in cattle following letrozole treatment is LH rather than FSH (Yapura et al., 2014). To 
mitigate the issue of giving letrozole im or iv at multiple intervals, an intravaginal device was 
developed in subsequent studies (Yapura et al., 2013, 2015). The first intravaginal device was 
developed with wax used in humans with a melting point of 37°C, and therefore much of the 
wax/letrozole formulation was lost through the vulvar opening (Yapura et al., 2013). This study 
showed that intravaginal letrozole administration was feasible, and that the terminal half-life of 
letrozole was approximately 33 hours in beef heifers. Three different aromatase inhibitors 
(letrozole, anastrozole and fenbendazole) were cultured with bovine granulosa cells in a 
subsequent study (Yapura et al., 2015) and letrozole was shown to be the most potent inhibitor. 
Further investigation revealed that a letrozole-containing gel covering a wax-vehicle intravaginal 
device resulted in a more rapid increase of plasma letrozole. This device yielded a prolonged 
suppression of estradiol and increased follicular growth and dominant follicle lifespan (Yapura et 
al., 2015). A study was then done to investigate the effect of a 4-day letrozole intravaginal device 
at known stages of the estrous cycle on fertility. Following ovulation (Day 0), heifers were 
assigned randomly to one of five treatment groups and a 4-day letrozole was initiated on Days 0, 
4, 8, 12, or 16. Heifers were given PGF at the time of device removal, and GnRH was given and 
AI was done 24 hours later. Ultrasonography was done daily from device insertion until 
ovulation was detected. The percentage of heifers that ovulated and ovulation synchrony 
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following letrozole treatment was greater compared to the control group, which were given PGF 
at a random stage of the estrous cycle followed by GnRH 24 hours later  (Yapura et al., 2016). 
The P/AI was 4% in the letrozole group, indicating a disruption in oocyte health or due to a 
short-lived CL from premature release of PGF from the endometrium. 
1.6. Intravaginal drug delivery 
The use of intravaginal drug delivery is a convenient and attractive method that provides 
sustained drug release to control the estrous cycle in farm animals. As early as the 1960s, 
sponges and silicones devices have been used to deliver pharmaceuticals (predominantly 
progestins) intravaginally in farm animals (Abecia et al., 2011).  
 
1.6.1. Sponges 
Following the identification of progestins that could be used to control the estrous cycle 
in sheep, the use of intravaginal sponges was first reported in 1965 (Robinson, 1965). The 
sponge was prepared from a dense polyurethane foam in which progestins (50 to 800 mg) were 
dissolved in ethanol and pipetted onto each sponge. Following evaporation of ethanol, sponges 
were inserted into the vagina of ewes for 10 to 30 days. Following treatment, 30/36 sponges were 
retained, and following removal, 29/30 ewes showed signs of  estrus within 3 days. Following 
natural breeding, 22/29 ewes became pregnant and produced lambs 151 to 157 days later. One of 
the negative aspects of intravaginal sponges was that copious discharge of cloudy mucus was 
observed, but this did not appear to affect fertility. Sponges were subsequently used for estrous 
control in cattle in the mid-1960s. In the initial study, sponges containing flugestone acetate 
(FGA) were inserted at random days of the estrous cycle for 18 or 19 days, and following 
removal, cows were observed for estrus and artificially inseminated. Neither estrus nor 
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ovulations were detected during treatment, but following removal, 20/36 cows came into estrus 
(Carrick and Shelton, 1967). The use of sponges in cattle has varied considerably due in part to 
their retention rates (~62%; Scanlon et al., 1971). In recent years, most sponges have utilized the 
potent progestins, FGA (20-40 mg/sponge; Synchropart; Ceva Santé Animale, France) and 
medroxyprogesterone acetate (MPA; Veramix; Pharmacia and Upjohn Animal Health, Canada) 
for ovarian control in ewes in Europe and Australia, but are not currently approved in North 
America (Abecia et al., 2011; Bartlewski et al., 2015; Swelum et al., 2015). To date, only 
silicone intravaginal devices impregnated with progesterone are permitted for use in ruminants in 
the USA and Canada (Eazi-Breed CIDR [sheep and cattle; USA and Canada], Zoetis Inc. and 
PRID Delta [cattle; Canada], Ceva Animal Health, Inc.) (Health Canada, 2019; U.S. Food and 
Drug Administration, 2019).  
1.6.2. Silicone  
The use of silicone-impregnated progesterone releasing intravaginal devices (PRID) for 
estrous control in cattle were first reported in the 1970s (Mauer et al., 1975). This intravaginal 
device consisted of a stainless-steel spiral that was coated with progesterone-impregnated 
silicone rubber. It showed efficacy by elevating plasma progesterone to ~6 ng/mL within 2 hours 
of insertion. Today’s intravaginal progesterone devices consist of 3 parts: the silicone portion 
homogeneously impregnated with ~10% wt/wt of progesterone, a plastic or stainless steel spine 
to sustain rigidity in the vagina, and a tail protruding from the vulva to facilitate removal 
(Rathbone and Burke, 2013). Initial intravaginal devices were formulated to quickly elevate and 
maintain plasma progesterone ≥ 2 ng/mL for a treatment period of 12 to 14 days, but were later 
manufactured to sustain release of progesterone for 5 to 8 days (de Graaff and Grimard, 2018). 
For example, the controlled intravaginal drug release (CIDR) was reengineered in the early 
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2000s to reduce the amount of progesterone from 1.9 g (CIDR-B 1900) to 1.38 g (CIDR 1380) 
per device while maintaining the same circulating progesterone concentrations. To achieve this, 
the thickness of the silicone covering the plastic spine was reduced to 1 mm, as progesterone is 
released in a surface area-dependent manner from the outermost 1 mm (Rathbone et al., 2002). 
The decreased diameter resulted in less residual progesterone after use. However, recent studies 
suggest a CIDR can be autoclaved and reused, resulting in elevated initial plasma progesterone 
(Zuluaga and Williams, 2008; Melo et al., 2018).  
1.6.2.1. Molecular structure of silicone 
Silicones, commonly referred to as polysiloxanes, are chemically stable, unreactive, and 
hydrophobic. They contain silicon and oxygen atoms as their backbone, and by varying the 
length of the polymer chain, silicones can range in consistency ranging from oil to solid plastic 
resins (Gunatillake and Adhikari, 2016). The molecular makeup of all silicone can be seen in 
Figure 1.3 below.  
 
Figure 1. 3. Molecular structure of all silicones, including the silicon and oxygen backbone. 
 
The silicone used in manufacturing the CIDR (and in this thesis) is supplied as a viscous, 
2-part liquid. One part contains a platinum portion, and when the 2 portions are combined, the 
platinum catalyzes the reaction, which initiates the curing (hardening) process (Figure 1.4) at 
room temperature (Mashak and Rahimi, 2009). 
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Figure 1. 4. The platinum addition cure reaction to form solid silicone. 
 
1.6.2.2. Characteristics of silicone 
Due to its unique structure, silicone can be incorporated into the matrix, membrane and 
coating of a drug delivery system. Prior to curing, hydrophobic molecules (i.e. steroids) may be 
homogenously incorporated into the mix due to their high solubility in silicone (Malcolm et al., 
2003). The silicone matrix can then be injection molded into any shape and subsequently heated 
to hasten the curing process. In vivo drug delivery from the silicone matrix is achieved by 
diffusion and is dependent on several factors, including molecular size, surface area, solubility in 
silicone, and thickness of tissues (Fu and Kao, 2010). The negative aspect of using silicones for 
drug delivery is that silicone rubbers are non-biodegradable, and they will not breakdown in a 
landfill setting.  
 
 
1.7. General Hypothesis 
Our working hypothesis is that a letrozole treatment protocol will be effective for controlling and 




1.8. General Objectives 
The overall objectives of the studies reported herein were: 
 
• To determine if letrozole can be impregnated into a silicone intravaginal device  
• To determine if letrozole is secreted into milk and to understand the pharmacokinetics of 
letrozole in lactating dairy cows 
• To test the hypothesis that letrozole increases the superstimulatory response in follicle-
stimulating hormone-treated cattle 
• To determine the effect of letrozole on the ovarian-oocyte environment in cattle 
• To determine the interval to estrus and ovulation following letrozole treatment in cattle 
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Previous letrozole intravaginal device formulations incorporated a wax-based delivery system 
which was difficult to manufacture and resulted in varying letrozole drug loads and drug release. 
In our first study, we determined that letrozole could be released from a silicone matrix both in 
vitro and in vivo. Further, we tested the hypothesis that plasma concentrations of letrozole 
released from the silicone matrix will have a biological effect on the ovaries in beef heifers.   
 
Authors’ Contributions 
As first author, EMZ participated in designing the experiment, manufacturing of intravaginal 
devices, collecting and analyzing data, and in writing and revising the manuscript. BMD 
contributed assistance in manufacturing intravaginal devices and collection and interpretation of 
data. As senior author, GPA provided the overall intellectual knowledge, experimental design, 







Two experiments were conducted to test the effectiveness of a silicone matrix as an 
intravaginal drug delivery device for letrozole, an aromatase inhibitor used for synchronization 
protocols in cattle. A wax dip-coat formulation of the intravaginal device used in previous 
studies was effective in releasing letrozole but was cumbersome to manufacture and deploy, 
resulting in unwanted variation in drug delivery and circulating concentrations of letrozole. In 
Experiment 1, a 3 x 3 design was used to test the release kinetics of letrozole from silicone in 
vitro. Silicone was mixed with 3 different letrozole drug loads (5%, 10%, 15%) and 3 different 
mineral oil loads (5%, 10%, 15%), and letrozole release into 62.5% ethanol was compared with 
the wax dip-coat formulation (positive control) by UV spectrophotometry. Letrozole was 
released from silicone in a dose-dependent manner, with no effect of mineral oil. Release 
kinetics were then examined in vivo (Experiment 2) in nulliparous beef heifers assigned 
randomly to six groups (n=6/group) and given a large surface area (LSA) or standard surface 
area (SSA) intravaginal silicone device impregnated with 5%, 10%, or 15% drug load, or a wax 
dip-coat device (positive control) or blank device (negative control). Devices were inserted on 
Day 3 (Day 0=ovulation) until Day 11. Blood samples were collected at 0, 30 mins, 1, 2, 3, 4, 6, 
8, 10, 12, and 24 h, and twice daily until Day 11 to determine letrozole plasma concentrations by 
LC-MS/MS. The ovaries were examined once daily from Day 3 to 13 by ultrasonography to 
determine follicular and luteal responses to treatment. Letrozole plasma concentrations were 
higher in heifers given a device with an LSA vs SSA (P<0.05) and those given a device with 
15% vs 5% or 10% drug-load (P<0.05). Plasma concentrations of estradiol decreased the most in 
heifers given the 15% LSA device (P=0.05). The interval between emergence of successive 
follicular waves was longest (P<0.05) in the positive control and the 15% LSA groups. As well, 
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the diameter profiles of the dominant follicle and the corpus luteum were largest (P<0.01) in the 
positive control and 15% LSA groups. In conclusion, letrozole was released from a silicone 
matrix in a dose-dependent manner, and the 15% LSA devices achieved target effects on ovarian 
function. Results may be used to manufacture a silicone intravaginal device for delivering 




The intravaginal drug-delivery method has become widely accepted by the cattle production 
industry. Beginning in the late 1960s, polyurethane sponges containing progesterone were used 
for synchronization of estrus in cattle, but due to low vaginal retention rates, they were not 
adopted for commercial use (Scanlon et al., 1972). Silicone technology for intravaginal drug 
release began in the early 1970s with the development of the progesterone releasing intravaginal 
device (PRID) consisting of a stainless-steel spiral coated in progesterone-impregnated silicone 
rubber (Mauer et al., 1975). 
Development of synchronization methods for fixed-time artificial insemination (FTAI) began 
with the ability to control follicular wave emergence by follicular ablation or treatment with a 
combination of estradiol and progesterone (Adams, 1994; Bo et al., 1995). Use of the steroid 
combination of estradiol and progesterone for synchronization has become commonplace 
throughout South America, but due to increasing regulation of the use of estrogens in food-
producing animals, its use is restricted in North America, Australia, New Zealand, and the 
European Union (reviewed in Yapura et al., 2018). The development of gonadotropin-releasing 
hormone (GnRH)-based synchronization protocols began in the mid 1990s (Pursley et al., 1995), 
but the efficacy was affected by a wide range in interval to ovulation (Wiltbank and Pursley, 
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2014). Many variations of steroid-based and GnRH-based protocols have been devised in the last 
20 years (Martinez et al., 2002; Fricke et al., 2003; Souza et al., 2008; Colazo and Ambrose, 
2011), and although P/AI have increased, costs of multiple hormone treatments have also 
increased. An alternative to current steroid- or GnRH-based synchronization protocols is the use 
of non-steroidal aromatase inhibitors, such as letrozole (Yapura et al., 2014). 
Letrozole, a 3rd generation non-steroidal aromatase inhibitor, prevents the body from 
synthesizing its own estrogen by actively binding to aromatase, the P450 enzyme that is solely 
responsible for converting androgens to estrogens (Buzdar, 2003). Currently, letrozole is licensed 
for use in humans for the treatment of breast cancer in post-menopausal women (Demers, 1994) 
but has been used in women experiencing infertility (Casper and Mitwally, 2012). The putative 
mechanism by which letrozole affects ovarian function was tested using the bovine model 
(Yapura et al., 2013, 2014), and the effectiveness of letrozole for controlling the estrous cycle in 
cattle has subsequently been documented in a series of recent studies (Yapura et al., 2013, 2014, 
2015, 2016). A letrozole-releasing intravaginal device was developed to enable continuous 
treatment over an extended period (Yapura et al., 2015). By effectively suppressing estradiol 
production (over a period of days), circulating LH concentrations increased, resulting in 
prolongation of the growing phase of the extant dominant follicle and delaying emergence of the 
next follicular wave (Yapura et al., 2014, 2015). Treatment with a vaginal device coated with a 
letrozole-in-wax formulation resulted in synchronous ovulation in over 90% of heifers regardless 
of the stage of the estrous cycle at which the protocol was initiated (Yapura et al., 2016). Further, 
results suggest that letrozole treatment is luteotrophic i.e., results in a corpus luteum (CL) that is 
larger and produces more progesterone (Yapura et al., 2013, 2014, 2015).  
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Coating a vaginal device with a letrozole wax formulation, however, does not lend itself to 
automated manufacture, and is subject to a lack of uniformity and consistency. Silicones can be 
effective as a drug delivery system for many reasons and are currently used in intravaginal 
steroid-releasing devices in women (NuvaRing, Merck, Kenilworth, NJ, USA) and cattle (CIDR, 
Zoetis, Kirkland, QC, Canada; PRID-Delta, Ceva Animal Health, Cambridge, ON, Canada). 
Liquid silicone can be molded into any shape and can set or cure quickly. When placed in the 
vagina, silicone will not deteriorate over time and nothing will adhere to it i.e., tissues will not 
grow on silicone. Many lipophilic drugs are soluble and stable in silicone due to their ability to 
permeate the hydrophobic matrix (Kajihara et al., 2003). 
With the intent of developing a device that will provide more uniformity in drug delivery 
compared to the wax dip-coat intravaginal devices used previously (Yapura et al., 2015) the 
objective of the present study was to determine if letrozole-impregnated silicone will provide an 
effective drug-delivery matrix for intravaginal treatment in cattle. Specifically, the release 
kinetics of letrozole-impregnated silicone in vitro (Experiment 1) and in vivo (Experiment 2) was 
characterized to determine if biologically effective drug levels can be achieved for the purposes 
of controlling ovarian function in cattle. 
2.3. Materials and methods 
2.3.1. Experiment 1 – In vitro testing of letrozole-release from silicone  
 
The silicone intravaginal devices produced for the purposes of this experiment contained 
letrozole, mineral oil, silicone thinner (Smooth-On, Macungi, PA, USA), and medical-grade 
silicone (Silastic Q7-4840, Dow Corning Corp., Auburn, MI, USA). Using a 3 x 3 design, 9 
different silicone formulations were prepared using 5, 10, or 15% (wt/wt) letrozole and 5, 10, or 
15% (wt/wt) mineral oil. Addition-cured silicones require the addition of platinum as a catalyst 
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to facilitate the curing reaction. Biomedical grade liquid silicone rubber (Silastic Q7-4840, Dow 
Corning Corp., Auburn, MI, USA) was supplied as two-component kits (Parts A and B) of 
platinum-catalyzed silicone elastomers which must be mixed in equal portions, by weight. In the 
following order, mineral oil, silicone thinner, and letrozole were weighed and added to the 
silicone mixture. The ingredients were mixed for 5 minutes with a spatula until homogeneous. 
After giving time for letrozole to permeate the hydrophobic silicone matrix (approximately 30 
minutes), the mixture was loaded into 60 mL catheter-tipped syringes and injected into a two-
part aluminum mold (RMD Engineering Inc., Saskatoon, Saskatchewan, Canada) containing a 
centrally placed nylon spine to provide rigidity. The mold was then heated to 200°C for 5 
minutes. The cured device was removed from the mold and a plastic tail was added to facilitate 
device removal (Fig. 2.1).  
An Erlenmeyer flask containing 250 mL of 62.5% ethanol and a magnetic stirrer was 
maintained at 37ºC on a multi-plate stirrer (RT 10, IKA Works, Inc., Wilmington, NC, USA). 
Sink conditions, defined as maintaining a volume of dissolution media that is 5 to 10 times 
greater than the saturation point of the drug in the drug delivery system (saturation of letrozole in 
62.5% ethanol = 6.11mg/mL), were achieved by placing 1.5 g portion of each silicone device 
and 0.248 g of the wax positive control into the volume of ethanol. Each silicone and wax 
portion was suspended centrally in the ethanol-filled flask, and a 10 µL sample was taken from 
each flask at 0, 5 min, 2, 4, 8, 12, 24, 36, 48, 60, 72, 84, and 96 hours to characterize the 
letrozole-release kinetics. Samples were placed in Eppendorf tubes and letrozole concentrations 
were determined with UV-Vis-Spectrophotometry (Nano-Drop, Thermo Scientific, Waltham, 
MA, USA). The letrozole concentration of each sample (10 µL) was measured 3 separate times.  
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2.3.2. Experiment 2 – In vivo testing of letrozole-release from silicone intravaginal 
devices 
 
Hereford-cross beef heifers, 12 to 17 months of age and weighing between 355 and 534 kg 
(422 ± 5.71 kg) were used for the study and were maintained in outdoor corrals at the University 
of Saskatchewan Goodale Research Farm (52° N and 106° W). Heifers were fed a mixture of 
barley silage and free-choice hay to gain approximately 1.1 kg/day, and water was provided ad 
libitum during the experimental period from April to July. Heifers were chosen from a group of 
42 after initial examination by transrectal ultrasonography (7.5 MHz linear array probe; MyLab 
Alpha, Esaote NA, Indianapolis, IN, USA) to detect the presence of a CL (i.e., to confirm 
puberty; Pierson and Ginther, 1987b). Animal procedures were done in accordance with the 
Canadian Council on Animal Care and were approved by the University of Saskatchewan 
Protocol Review Committee.  
2.3.2.1. Treatment and examinations 
 
Based on the results of Experiment 1, 4 formulations of the silicone intravaginal device were 
developed to compare the kinetics of letrozole release : 10% and 15% letrozole drug-load in a 
device with standard surface area (121.8 cm2, Fig. 2.1A), and 5% and 15% letrozole drug-load in 
a device with a larger surface area (490 cm2; Fig. 2.1B). Heifers in which a CL was detected 
during the initial examination were given two doses of cloprostenol intramuscularly 12 hours 
apart (500 µg; Estrumate, Merck, Kenilworth, NJ, USA) to induce luteolysis and synchronize 
ovulation (Gorewit et al., 1977). On Day 3 (Day 0 = ovulation), heifers were assigned randomly 
to one of six groups and given one of the four letrozole-releasing devices described above, or the 
original waxed-based dip-coat device (Yapura et al., 2015) positive control), or a blank (drug-
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free) silicone device (negative control). The intravaginal device was left in place for 8 days. The 
experiment was done in two replicates; n=6 heifers per group. 
The ovaries were examined daily from Day 3 to 13 by transrectal ultrasonography and a 
sketch was made during each examination to record the size, number and relative position of 
ovarian structures (CL and follicles ≥ 4 mm; Knopf et al., 1989). Ovulation was defined as the 
disappearance of a follicle ³ 10 mm between consecutive examinations and was confirmed by 
subsequent detection of a CL (Pierson and Ginther, 1987b). Follicular wave emergence was 
defined as the day of ovulation or determined retrospectively as the day when the dominant 
follicle was first identified at a diameter of 4 or 5 mm (Adams et al., 1993; Ginther et al., 1997). 
If the dominant follicle was not identified until it reached 6 or 7 mm, the previous day was 
considered day of wave emergence. The dominant follicle of a wave was defined as the largest 
follicle of the wave.  
2.3.2.2. Blood sampling and hormone assays 
 
To determine the pharmacokinetics of letrozole from the newly developed silicone devices, 
blood samples were taken 0, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, and 24 hours after device insertion, and 
twice daily until Day 11. Blood samples were collected by jugular venipuncture into 10 mL 
heparinized vacuum tubes (Becton Dickinson Vacutainer Systems, Franklin Lakes, NJ, USA). 
Blood samples were centrifuged at 1500 x g for 20 min, and plasma was separated and stored in 
polypropylene tubes at -20°C.  
Plasma estradiol concentrations were measured by radioimmunoassay from samples taken 
every 2 hours for the first 12 hours from device placement (Day 3) and then daily until Day 11 at 
Texas A&M University as previously described (Kirby et al., 1997). Assay sensitivity was 0.5 
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pg/mL and intra- and interassay coefficients of variation for estradiol were 3.6 and 12.6%, 
respectively.  
Plasma letrozole concentrations were determine by LC-MS/MS using a simple and quick 
protein precipitation method that was partially validated (Zarghi et al., 2007). Letrozole-d4 
(Toronto Research Chemicals, Toronto, ON, Canada), a derivative of letrozole, was selected to 
serve as the internal standard. A standard stock solution of letrozole was prepared by dissolving 
50 mg of letrozole in 50 mL of methanol (HPLC Grade Methanol, Fisher Chemical, Ottawa, ON, 
Canada) for a final concentration of 1 mg/mL (stock solution #1). Stock solution #1 was further 
diluted to a concentration of 51.2 µg/mL (stock solution #2). A volume of 995 µL of blank 
bovine plasma was spiked with 5 µL of stock solution #2 for a final concentration of 256 ng/mL 
(Standard #1). A total of 9 standards underwent serial dilution and ranged from 1 to 256 ng/mL. 
Quality controls were spiked independently with stock solution #2 to obtain concentrations of 3, 
10, and 100 ng/mL. A total volume of 100 µL of the standard or quality control was placed into a 
1.5 mL Eppendorf tube and 50 µL of the internal standard solution (letrozole-d4; 200 ng/mL) 
was added. The tube was vortexed for 5 seconds and 250 µL of acetonitrile were added. Each 
standard or quality control was vortexed for 5 seconds and centrifuged at 15,000 x g for 15 
minutes at 4°C. Following centrifugation, the supernatant was transferred to a 2 mL vial for auto-
injection into the LC-MS/MS. Double blank (- letrozole, - letrozole-d4) and blank (- letrozole, 
+letrozole-d4) samples were prepared in the same manner as described previously. Each lower 
limit of quantification (LLOQ) and quality control were prepared 6 times per day on 3 separate 
days; all other standards, double blanks, and blanks were prepared once per day for 3 days. LC-
MS/MS conditions are described elsewhere (Joshi et al., 2011).  
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 Bovine plasma samples were thawed at room temperature, and 100 µL of plasma was 
spiked with 50 µL of internal standard solution (200 ng/mL). A volume of 250 µL acetonitrile 
was added to each bovine plasma sample and vortexed, centrifuged, and transferred to a 2 mL 
vial, as described above. Linearity was tested by running 3 standard curves independently of 
each other. Regression coefficients were calculated and ratio counts vs. concentration were 
plotted. A regression coefficient (r2) ³ 0.99 was necessary for acceptance of the linearity curve. 
The mean (± SEM) r2 obtained was 0.9996 ± 0.0003. The acceptance criterion for each 
calculated standard concentration was 15% deviation from the actual value except for the lower 
limit of quantification, where it did not deviate by > 20%. Precision was defined as residual 
standard deviation (RSD) and calculated using the following formula: RSD = SD x 100/mean. 
Accuracy was calculated using the concentration recovered divided by the concentration added. 
The standard curve is shown in Table 2.1.  
 
2.3.3. Statistical analyses  
 
Statistical analyses were done using the Statistical Analysis System software package (SAS 
Learning Edition 9.4, 2013; SAS Institute Inc., Cary, NC, USA). Serial data (letrozole and 
hormone concentrations, follicle and CL diameter) were compared among groups by analysis of 
variance for repeated measures using the PROC MIXED procedure to determine the effects of 
device formulation, time, and their interactions. If an interaction was detected, individual 
comparisons among groups and days were made using the method of least significant difference. 
Pearson correlations between follicle and CL growth and letrozole concentrations were made by 
PROC CORR. The inter-wave interval was compared among groups by analysis of variance. 
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2.4.1. Experiment 1 – In vitro testing of letrozole-release from silicone 
 
Release rates of letrozole from impregnated silicone are sumarized in Figure 2.2. Data 
document that letrozole was released from the silicone matrix in a dose-related manner. The 
previously designed wax dip-coat formulation released letrozole at a faster rate, but was 
exhausted by 60 hours. Data were deemed sufficient, without further replication, to proceed to 
Experiment 2; hence, no statistical analyses were done. Based on the results of the in vitro study, 
the silicone matrix formulated with the lowest, medium, and highest letrozole loads (i.e., 5, 10 
and 15%) was selected for the following  study.  
2.4.2. Experiment 2 –  testing of letrozole-release from silicone intravaginal devices 
 
Following development of the LC-MS/MS assay for plasma letrozole, all points on the 
standard curve passed for precision and accuracy except for the sample at 256 ng/mL; therefore, 
128 ng/mL was considered the maximum standard (Table 2.1). All quality control samples 
passed for precision and accuracy and were accepted (Table 2.2). 
The vaginal device remained in place for the full 8 days in all heifers. Circulating 
concentrations of letrozole were higher (P<0.05) in heifers with the wax dip-coat device and 
those with 15% letrozole-impregnated silicone in the large surface area device than in the other 
groups (Fig. 2.3A). The 15% large surface area device exhibited greater release than the wax dip-
coat device through the first 12 hours (P<0.05), and maintained release throughout the 8-day 
period of deployment. Plasma letrozole concentrations continued to rise for 5 or 6 days in all 
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letrozole-treated groups, but a treatment-by-time interaction (P<0.0001) was attributed to a rapid 
drop thereafter in the wax dip-coat group, unlike the silicone groups in which high letrozole 
concentrations were maintained (Fig. 2.3A). Among groups with an impregnated silicone device, 
those with a higher drug-load and those with a larger surface area had significantly higher 
plasma letrozole concentrations than their counterpart (Fig. 2.3A).  
Follicle growth over the experimental period was positively correlated with letrozole 
concentrations (r=0.41; n=257, P<0.0001). At the time of device insertion (Day 3), there was no 
difference among groups in the diameter of the dominant follicle (Table 2.3). Similar to the 
pattern observed with plasma letrozole concentrations, the diameter of the dominant follicle was 
greatest in heifers with the wax dip-coat device and in those with 15% letrozole-impregnated 
silicone in the large surface area device than in the other groups, and smallest in the negative 
control group (Fig. 2.3B). Correspondingly, the interwave interval was greatest in the groups 
with a wax dip-coat device and 15% letrozole large surface area device (P<0.05; Table 2.3). By 
Day 13, the mean diameter of the dominant follicle had begun to decline in all groups except in 
the 15% letrozole large surface area group (Fig. 2.3B).  
The diameter of the CL was positively correlated with plasma letrozole concentrations 
(r=0.30, n=257; P<0.0001). The CL diameter profile was greatest in groups with a large surface 
area device and smallest in the negative control group (Fig. 2.3C). Heifers with a large surface 
area device (5% and 15% groups combined) had a greater CL diameter profile (P=0.05) than that 
of heifers with a standard surface area device (10% and 15% groups combined). Maximum CL 
diameter was greatest in the 15% large surface area group, and occurred on Day 7 after ovulation 
(Fig. 2.3C). 
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A treatment effect on plasma estradiol concentration was attributed to a decrease in the 15% 
large surface area group during the sampling period (P=0.05; Fig. 2.4).  
 
 
Table 2. 1. Precision and accuracy data from LC-MS/MS derived standard curve for letrozole in 




Concentration found  





1 (LLOQ) 0.99 ± 0.03 10.8% 98.6% 
2 2.2 ± 0.19 14.8% 109.5% 
4 3.91 ± 0.17 7.5% 97.7% 
8 8.05 ± 0.04 0.8% 100.6% 
16 17.2 ± 0.76 7.6% 107.5% 
32 32.4 ± 0.55 2.9% 101.4% 
64 64.6 ± 0.40 1.1% 100.9% 
128 127 ± 0.58 0.8% 99.2% 




Table 2. 2. Precision and accuracy data of the LC-MS/MS method for quality control samples of 
letrozole in bovine plasma (n=18 per quality control sample; Experiment 2).  
Concentration 
added (ng/mL) 
Concentration found  





3 2.80 ± 0.04 6.1% 93.3% 
10 9.73 ± 0.13 5.5% 97.3% 




Table 2. 3 The effects of treatment with intravaginal letrozole-releasing devices on follicular 
dominance in cattle (mean ± SEM). Devices were composed of silicone impregnated with 
varying percentages of letrozole in a standard- or large-surface area format, a previously 
designed wax dip-coat formulation, or a device containing no letrozole (control; Experiment 2).  
 
Standard surface area 
device (121 cm2) 
Large surface area device 
(490 cm2) 
Wax Control 
 10% 15% 5% 15% dip-coat device 
Number of heifers     
 6 6 6 6 6 6 
Dominant follicle diameter (mm) at device insertion (Day 3) 
 
9.3 ± 0.3 9.3 ± 0.4 10.3 ± 0.4 10.0 ± 0.5 9.8 ± 0.6 10.1 ± 0.6 
Follicular interwave interval (days) 
 
8.0 ± 0.4ab 10.0 ± 0.7bc 9.2 ± 0.4abc 10.0 ± 0.4bc 10.5 ± 0.4c 7.5 ± 0.5a 





Figure 2. 1. Intravaginal silicone letrozole releasing devices (LRD) with a standard surface area 







Figure 2. 2. In vitro release of letrozole from portions of vaginal devices composed of the 
original wax dip-coat formulation vs. impregnated silicone formulations (% letrozole : % mineral 
oil, respectively in the legend). Portions were placed in a volume 62.5% ethanol at 37°C, and 10 
µL samples were taken over a 4-day period (Experiment 1). 
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Figure 2. 3. Effects of treatment (mean ± SEM) with intravaginal letrozole-releasing devices in 
beef heifers on circulating concentrations of letrozole (A), the dominant follicle diameter profile 
(B), and the CL diameter profile (C). Devices were composed of the original wax dip-coat 
formulation, or silicone impregnated formulations with 5%, 10%, or 15% letrozole in a standard 
surface area (SSA) or large surface area (LSA) format, or a silicone device containing no 






Figure 2. 4. Effects of treatment (mean ± SEM) with intravaginal letrozole-releasing devices in 
beef heifers on circulating concentrations of estradiol. Devices were composed of the original 
wax dip-coat formulation, or silicone impregnated formulations with 5%, 10% or 15% letrozole 
in a standard surface area (SSA) or large surface area (LSA) format, or a silicone device 
containing no letrozole (control). Devices were inserted on Hour 0 and removed at Hour 192 












 The impetus for the study was the need for a device with more uniformity in drug 
delivery compared to the wax dip-coat intravaginal devices used previously. Beginning with an 
in vitro approach, we tested the drug-release from 9 silicone matrices of differing letrozole and 
mineral oil compositions. Results document that letrozole is released from a silicone matrix into 
a ethanol environment, similar to previous reports regarding the development of progesterone 
devices (Ogle, 1999). Further, release from the silicone matrix was dose-dependent; i.e., higher 
letrozole drug-loads into the device resulted in greater total release. In a study of progesterone 
release from silicone, release was positively correlated with the surface area of the device (van 
Werven et al., 2013), and was found to come from only the most superficial layer of silicone (≤1 
mm thickness; Rathbone and McDowell, 2013). Initial silicone CIDR devices were loaded with 
1.9 g of progesterone, but were later reduced to 1.38 g of progesterone by minimizing the 
thickness of silicone while maintaining the same surface area (Rathbone et al., 2002). In 
ovariectomized Holstein cows, a progesterone-releasing device with a surface area of 155 cm2 
(PRID-Delta, Ceva Animal Health Ltd, Amersham, Buckinghamshire, United Kingdom) resulted 
in significantly greater circulating progesterone concentrations during the first 4 days of insertion 
than a device with a surface area of 120 cm2 (CIDR, Zoetis, Kirkland, QC, Canada; van Werven 
et al., 2013).  
 Results of the in vitro study permitted the selection of the most effective silicone 
formulation for use in vivo. In the first replicate, however, using a silicone device with a surface 
area of 121 cm2, drug delivery was insufficient to raise circulating letrozole concentrations 
sufficiently to elicit a biological effect on the ovaries. Using past evidence that drug release from 
silicone is related to surface area, we developed a device with a surface area that was 4 times 
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greater than the original device (490 vs. 121 cm2) by adding wing-like structures on the sides of 
the silicone device with a thickness of 2 mm. In the second replicate, utilizing the larger surface 
area device, resulted in higher circulating letrozole concentrations while still maintaining 
continuous release, unlike the original wax dip-coat device. The circulating half-life of letrozole 
was estimated to be 33 hours in nulliparous beef heifers (Yapura et al., 2013). Hence, the decline 
in plasma letrozole concentrations after 3 days of deployment of the wax dip-coat device was 
indicative of drug depletion in the device.  
 Letrozole treatment in cycling beef heifers prolonged the growing phase of the dominant 
follicle resulting in a larger follicle and a prolonged interwave interval. However, the maximum 
diameter of the dominant follicle (and by association, the duration of follicular dominance) was 
not sustained throughout the experimental period using the wax dip-coat device. By comparison, 
the 15% large surface area device used in the present study extended the period of follicle 
dominance, in association with a sustained elevation of plasma letrozole and suppression of 
plasma estradiol, which contributed to increased plasma LH concentrations (Yapura et al., 2013, 
2014, 2015). On Day 13 (2 days after device removal), the 15% large surface area group yielded 
the largest dominant follicle. The wax dip-coat device provided a maximum plasma letrozole 
concentration of ~200 ng/mL in a previous study (Yapura et al., 2015), but only ~82 ng/mL in 
the present study. Correspondingly, the suppressive effect of letrozole treatment on plasma 
estradiol concentrations was apparent in the previous study using the wax dip-coat device 
(Yapura et al., 2015), but not in the present study. Higher letrozole concentrations and greater 
suppression of estradiol observed in the previous study were also reflected in the larger dominant 
follicle and a longer interwave interval than in the wax dip-coat group in the present study. The 
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differences between studies in the effect of the dip-coat device were unexpected and reflect the 
difficulty in consistent manufacture of this type of device. 
 As past trials have shown (Yapura et al., 2013, 2014, 2015) letrozole treatment was 
associated with the development of a larger CL and higher circulating concentrations of 
progesterone. In the present study, larger CL were also observed due to the luteotrophic effects 
of letrozole. Of the letrozole-treated animals, those in the 15% large surface area group had the 
largest CL diameter profile. Form and function of the CL has important implications for embryo 
development and maternal recognition of pregnancy (Mann and Lamming, 2001; Lonergan et al., 
2007). In embryo transfer, recipients with a CL > 20 mm2 6 days after ovulation had significantly 
higher circulating progesterone and significantly higher pregnancy per embryo transfer after 
transfer compared to recipients with CL <20 mm2 (Baruselli et al., 2003). Further, in a FTAI 
system, increasing progesterone during the synchronization period by using 2 CIDR vs 1 
CIDR/cow tended to increase P/AI at 32 days post-insemination in lactating dairy cows (52.6% 
vs 42.8%; Pereira et al., 2017).  
In summary, letrozole impregnated silicone provided continuous release throughout the 
experimental period. Of the differing silicone surface area devices, the larger surface area 
provided the highest circulating letrozole concentrations, the largest dominant follicle and 
longest interwave interval, and the largest CL 7 days post-ovulation. Results demonstrate that 
letrozole is released from a silicone matrix in a manner related to drug loading and device 
surface area, and provide impetus for commercialization and manufacturing of a letrozole 
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dairy cattle, the milk residues of letrozole must be understood. Using the letrozole-releasing 
device developed in Chapter 2, we tested the hypothesis that letrozole is secreted into the milk of 
lactating dairy cattle.   
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3.1. Abstract  
 
The aromatase inhibitor letrozole has been used in non-lactating cattle to control ovarian 
function. To date, letrozole has not been tested in lactating dairy cattle and due to its lipophilic 
nature, letrozole may be excreted into milk and enter the food supply. The primary objective of 
this experiment was to characterize and quantify concentrations of letrozole in blood plasma and 
milk during and after treatment with an intravaginal letrozole-releasing device (LRD) and the 
secondary objective was to compare ovarian effects in lactating dairy cattle. Non-pregnant, 
lactating Holsteins cows (n=12) at random stages of the estrous cycle were assigned and given 
either a silicone LRD or a blank (control) intravaginal device (Day 0). On Day 4, the intravaginal 
devices were removed, and cows were given a luteolytic dose of prostaglandin on Days 4 and 4.5 
followed by GnRH on Day 6.5 to induce ovulation. Milk samples were collected from the LRD-
treated cows twice daily from Day 0 to 14 to determine milk letrozole concentrations by a 
partially validated LC-MS/MS assay. Blood samples were collected twice daily from Day 0 to 14 
in both groups. Transrectal ultrasonography was done daily from Day 0 to 6, thereafter twice 
daily until ovulation was detected, and again daily for 5 days post-ovulation to characterize the 
ovarian response to treatment. Single point measurements were compared by t-test, and serial 
data were compared by analysis of variance for repeated measures. Data are presented as mean ± 
SEM. A standard curve was developed utilizing LC-MS/MS, which achieved an r2 value of 
0.999 ± 0.0001 analyzed over three independent days. The lower limit of quantification (LLOQ) 
and lower limit of detection (LLOD) for milk letrozole were 5.0 and 0.8 ng/mL, respectively. All 
points on the standard curve and quality controls were accepted, and were within 8% and 5.5% 
for accuracy and precision, respectively. Milk letrozole concentrations fell below the LLOQ 
within 2 days of LRD removal. Letrozole concentrations tended to be higher in plasma than milk 
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throughout the treatment period (P=0.09). Milk letrozole concentrations and milk production 
were negatively correlated (R= -0.46; P<0.0001). No difference was detected for the time to 
maximum concentration of letrozole (2.3 ± 0.4 vs. 2.7 ± 0.3 days; P=0.52) or elimination half-
life (14.6 ± 1.6 vs. 18.2 ± 1.4 hours) in plasma or milk, respectively. The variation in interval to 
ovulation following device insertion (residuals) was less in the LRD vs. control group (0 ± 0 vs. 
42.7 ± 9.2 hours, respectively; P<0.001). In summary, a method for quantifying letrozole in milk 
was partially validated. These data may be used for the recommendation of milk withdrawal 
periods following estrus synchronization with letrozole in lactating dairy cows.  
3.2. Introduction 
 
Understanding how a new drug is metabolized and excreted in food-producing animals is 
an essential step in the veterinary drug approval process. For a drug intended for use in lactating 
dairy cows, milk residue levels of the drug must be quantified to establish a maximum residue 
level (i.e., residue that is legally permitted in food commodities) for human consumption by 
government agencies (Canadian Animal Health Institute, 2019).  
Recent research in our laboratory has focused on the development of an aromatase 
inhibitor-based protocol for ovarian synchronization in beef cattle (reviewed in Yapura et al., 
2018). The efficacy of the protocol is attributed to release of the negative feedback of estradiol 
on the hypothalamus, resulting in increased circulating concentrations of luteinizing hormone 
(LH; Yapura et al., 2013). Increased LH release resulted in a prolonged period of dominant 
follicle growth, allowing a 4-day letrozole treatment protocol to be initiated at random stages of 
the estrous cycle. Followed by prostaglandin F2a induced luteolysis and ovulation induced by 
gonadotropin-releasing hormone (GnRH), >90% beef heifers ovulated in a synchronous fashion 
(Yapura et al., 2016). Recently, we have developed a silicone intravaginal letrozole-releasing 
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device (LRD) that continuously releases letrozole over a period of 8 days in beef heifers 
(Chapter 2). However, characterization of letrozole in plasma or milk in lactating dairy cows has 
yet to be done, which is a necessary step for the approval of a new veterinary drug. Moreover, a 
milk residue study of letrozole may provide insight for its use in lactating women undergoing 
breast cancer treatment.  
The molecular characteristics of a drug (i.e., lipophilic vs. hydrophilic) may impact its 
accumulation in milk. Hydrophilic drugs concentrate in the skim portion while lipophilic drugs 
tend to concentrate in the fat portion of milk (Ozdemir et al., 2018). Penicillin, a hydrophilic 
drug, is found in serum at concentrations approximately 6x higher than in whole milk (3.42 
IU/mL vs. 0.55 IU/mL; Dubreuil et al., 2001) in lactating dairy cows. In contrast, the highly 
lipophilic steroid, progesterone, is found in similar concentrations in serum and milk (Chenault 
et al., 2003). The use of tandem mass spectrometry (LC-MS/MS) has been employed, in recent 
years, to quantify pharmaceuticals found in milk due to its high molecular specificity and 
sensitivity. 
The primary objective of this study was to characterize and quantify concentrations of 
letrozole in blood plasma and milk during and after treatment with an LRD in lactating dairy 
cows. The study also provided an opportunity to compare the ovarian effects of LRD 
synchronization treatment in lactating dairy cows.  
3.3. Materials and methods 
 
 Procedures were approved by the University of Saskatchewan’s Animal Research Ethics 
Board in accordance with the guidelines of the Canadian Council on Animal Care.   
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3.3.1. Treatments and sampling 
 
Non-pregnant, lactating Holstein cows (n=6; weight: 680 ± 4.1 kg; body condition score: 
2.6 ± 0.1 [1 to 5 scale]; Ferguson et al., 1994) at various stages of lactation were purchased from 
local Saskatchewan dairy farmers. Cows were maintained outdoor pens at the Western College 
of Veterinary Medicine, University of Saskatchewan and fed alfalfa hay with free access to water 
during October. For comparison of ovarian effects, age-matched lactating Holsteins (n=6), 69.5 
±5.0 days in milk, housed at the Rayner Research Dairy Farm, University of Saskatchewan were 
selected to serve as controls. At random stages of the estrous cycle, test cows were given a 
silicone intravaginal device (Day 0) containing 5.6 grams letrozole (Chapter 2), and control cows 
were given a blank device (progesterone-free Cue-Mate; Bayer Australia, Pymble, NSW, 
Australia). On Day 4, the devices were removed, and prostaglandin F2a (500 µg cloprostenol; 
Estrumate; Merck, Kirkland, QC, Canada) was given im on Day 4 and 4.5 to induce luteolysis. 
An analog of GnRH (100 µg gonadorelin; Fertiline; Vetoquinol N.A.; Lavaltrie, QC, Canada) 
was given im on Day 6.5 to induce ovulation. Transrectal ultrasonography was done daily from 
Day 0 to 6 and twice daily thereafter until ovulation was detected using a 7.5 MHz linear-array 
probe (MyLab5; Esaote North America, Fischers, IN, USA). Ovulation was defined as the 
disappearance of a follicle ≥10 mm in diameter from one examination to the next. Following 
ovulation, the resultant corpus luteum (CL) was measured by transrectal ultrasonography daily 
for 5 days. Follicular and luteal structures were measured and recorded on ovarian sketch sheets 
for each individual cow (Knopf et al., 1989). 
Blood samples were collected twice daily from Day 0 to 14 via coccygeal venipuncture 
into heparinized vacutainer tubes (BD, Mississauga, ON, Canada) and centrifuged 1500 x g for 
15 minutes within 2 hours of collection. Plasma was aliquoted into polypropylene tubes and 
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stored frozen at -20 ºC until analysis was done within 1 month. Plasma letrozole taken twice 
daily from Day 0 to 6 was quantified by tandem mass spectrometry (LC-MS/MS), as previously 
described (Chapter 2).  
Letrozole-treated cows were milked twice daily at 12-hour intervals while restrained in a 
chute system using a portable milking system. Milk sampling began immediately before device 
insertion (Day 0) and continued twice daily for 14 days for letrozole analysis. Following 
complete milk-out, the milk container was weighed, and a 50 mL sample of milk was taken and 
subsequently frozen at -20°C until analysis was done within 1 month. Between each cow, the 
bucket was cleaned to prevent cross-contamination of samples. Cows selected as controls were 
milked 3x per day at 8-hour intervals at the Rayner Research Dairy Farm and produced 43.1 ± 
3.2 kg of milk daily. 
 
3.3.2. LC-MS/MS for letrozole milk residue 
 
Whole milk (Dairyland, Saskatoon, SK, Canada) was purchased from the grocery store 
and brought to room temperature and briefly vortexed for homogeneity. A working solution of 1 
mg/mL letrozole in methanol was created by dissolving 50 mg of letrozole in 50 mL of 
methanol. A total of 100 µL of the 1 mg/mL solution was diluted in 900 µL of methanol for a 
final concentration of 100 µg/mL. The 100 ug/mL solution was further diluted to make eight 
working solutions ranging from 500 to 10,000 ng/mL in methanol. A total of 4.950 mL of whole 
blank milk was added to a 15 mL Falcon tube and 50 µL of each working solution was added to 
the respective tube to yield true concentrations ranging from 5 (lower limit of quantification; 
LLOQ) to 100 ng/mL (n=8 total standards; Table 2.1). Each standard was spiked with 250 µL of 
the internal standard, letrozole-d4 (200 ng/mL in methanol; Toronto Research Company, 
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Toronto, ON, Canada) to quantify against peak analyte area and gently inverted to mix. A 
volume of 5 mL of acetonitrile was added to each tube, and 2 g of MgSO4 and 0.5 g of NaCl was 
subsequently added within 10 seconds. The tube was vigorously shaken by hand for 1 minute to 
prevent coagulation followed by centrifugation at 3700 x g for 5 minutes. A volume of 1 mL of 
the organic layer (top layer) was added to a 2 mL QuEChERS tube containing 25 mg C18 sorbent 
and 150 mg MgSO4 (QuEChERS Dispersive Kit for Meat Residues; Agilent Technologies, Santa 
Clara, CA, USA). The tube was vortexed for 1 minute, centrifuged at 3000 x g for 3 minutes, and 
500 µL of the organic layer was added to a 2 mL vial for auto-injection into the LC-MS/MS. 
Quality control (QC) samples were spiked independently from the standards in a similar manner 
at concentrations of 15, 25, and 80 ng/mL. Double blank (- letrozole, - letrozole-d4) and blank (- 
letrozole, + letrozole-d4) were prepared in the same manner. Standards, quality controls, and 
blanks were prepared once per day on three separate days. 
Previously frozen milk samples derived from letrozole-treated cows were thawed at room 
temperature. For homogeneity, samples were vortexed and inverted for 1 minute. A total of 5 mL 
of milk was pipetted into a 15 mL tube, and 250 µL of letrozole-d4 (200 ng/mL) was added to 
each sample. Thereafter, samples were prepared in the same manner as the standards and quality 
controls as described above. 
Separation by high-pressure liquid chromatography (HPLC; Agilent 1200; Agilent 
Technologies, Santa Clara, CA, USA) was done with an analytical column (50 x 2.1 mm, 3 µm 
particle size, Thermo Scientific Betasil C18; Thermo Scientific, Waltham, MA, USA) at 35°C. 
The HPLC flow rate, solvent conditions and LC-MS/MS conditions were done as previously 
described (Joshi et al., 2011). 
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Linearity was tested by running three standard curves independently of each other on 
separate days. Regression coefficients were calculated, and ratio counts vs. concentration were 
plotted. To accept the linear curve, a regression coefficient (r2) ≥0.99 was required. The mean 
(±SEM) r2 obtained was 0.999 ± 0.0001. The acceptance criterion for each calculated standard 
concentration was 15% deviation from the expected value except for the LLOQ (5 ng/mL) where 
it did not deviate by >20%. The following formula was used for precision: RSD= Standard 
deviation x 100/mean. Accuracy was calculated by using the concentration found (from the 
standard curve) divided by the expected concentration. All points on the standard curve and 
quality control samples were accepted (Table 3.1 and 3.2). The limit of detection for letrozole in 
milk was 0.8 ng/mL, based on a signal of the analyte to background noise ratio of 3:1. 
The terminal elimination half-life (t1/2), maximum concentration (Cmax), time to 
maximum concentration (Tmax) and  area under the curve (AUClast) were determined for plasma 
and milk letrozole concentrations using a commercial pharmacokinetic software program 
(WinNonlin, Version 2.1; Pharsight Corporation, Mountain View, CA, USA). The terminal 
elimination half-life (t1/2) was extrapolated using the formula: ln2/l, where λ was derived based 
on the quantifiable concentrations taken after the LRD was removed on Day 4. 
3.3.3. Radioimmunoassay 
 
 Plasma progesterone concentrations were measured by a solid-phase radioimmunoassay 
(Coat-a-Count; Diagnostic Products Corp., Los Angeles, CA, USA). The minimum detection 
limit was 0.1 ng/mL and the intra-assay coefficients of variations for low and high samples were 
14.0 and 8.6%, respectively.  
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3.3.4. Statistical analyses 
 
 Data were analyzed using SAS Enterprise Guide (Version 4.2; Statistical Analysis 
System Institute Inc., Cary, NC, USA). Serial data (concentration profiles in plasma and milk, 
dominant follicle and CL diameters) were compared by analysis of variance for repeated 
measures. Single-point measurements (interval to ovulation following device removal, ovulation 
synchrony (residuals) and ovulatory follicle diameter) were compared by t-test. The proportion 
of ovulations before GnRH on Day 6.5 was analyzed by chi-square. Correlation between milk 
letrozole concentrations and daily milk production was done by PROC CORR. Data are 
presented as mean ± SEM unless otherwise stated, and significance was defined as P≤0.05.   
3.4. Results 
 
Average milk production, fat and protein percentages, and letrozole milk concentrations 
from letrozole treated cows are shown in Table 3.3. The concentration of letrozole in milk fell 
below the LLOQ (5 ng/mL) within two days following LRD removal (Fig. 3.1). The 
concentration of letrozole in plasma tended (P=0.09) to be higher than in milk during treatment 
(Fig. 3.1). There was a negative correlation (r= -0.46; P<0.0001) between total milk produced 
and concentration of letrozole in milk. Plasma exhibited a higher maximum concentration (Cmax) 
compared to milk (37.3 ± 1.9 vs. 27.3 ± 2.9 ng/mL, respectively; P=0.02; Table 3.4). There was 
no difference in time to maximum letrozole concentrations (Tmax) between plasma and milk (2.3 
± 0.4 vs. 2.7 ± 0.3 days, respectively; P=0.52; Table 3.4). There was no difference in the 
elimination half-life (t1/2) for letrozole between plasma and milk 14.6 ± 1.6 vs. 18.2 ± 1.4 hours, 
respectively; P=0.12; Table 3.4). There was no effect of treatment (P=0.23) or interactions 
(P=0.32) for the ovulatory follicle diameter during treatment between LRD and control cows 
(Fig. 3.2A). A treatment-by-day interaction in CL diameter during treatment was attributed to a 
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larger average CL diameter in the control group at the time of device insertion (P<0.01; Fig. 
3.2B). The mean interval from device insertion to ovulation was not different between LRD and 
Control groups (mean 176 ± 11 hours; P=0.16), but the interval was less variable in the LRD 
group (residuals: 0 ± 0 vs. 42.7 ± 9.2 hours; P<0.001; Table 3.5). No effect of treatment or 
interactions were detected in post-ovulation CL diameter or plasma progesterone (Fig. 3.3) 
Table 3. 1. Precision and accuracy data from LC-MS/MS derived standard curve for letrozole in 
bovine milk.  
Concentration added 
(ng/mL) 






5 (LLOQ) 5.16 ± 0.20 4.0% 103.2% 
7.5 7.99 ± 0.06 0.7% 106.6% 
10 10.50 ± 0.2 1.9% 105.0% 
20 19.40 ± 0.17 0.9% 97.0% 
35 33.83 ± 0.42 1.2% 96.7% 
50 49.77 ± 0.75 1.5% 99.5% 
75 76.20 ± 1.32 1.7% 101.6% 
100 93.90 ± 5.05 5.4% 93.9% 
n=3 bovine milk samples per concentrations were used, except for the lower limit of 
quantification (LLOQ, n=5) 
 
Table 3. 2. Precision and accuracy data of the LC-MS/MS method for quality control samples of 
letrozole in bovine milk (n=5 per sample).  
Concentration added 
(ng/mL) 






15 13.82 ± 0.47 3.4% 92.1% 
25 24.10 ± 1.09 4.5% 96.4% 













Table 3. 3. Total milk production, component percentage and concentration of letrozole 
determined in the milk by tandem mass spectrometry (mean ± SEM). Cows were given a 
letrozole releasing device immediately following milking on Day 0 for 4 days (n=6 cows).  
Day Milk produced (kg) Fat % Protein % Letrozole in milk (ng/mL) 
0 6.12 ± 0.91 8.10 ±0.83 4.27 ± 0.24 - 
0.5 5.52 ± 0.76 7.76 ± 0.94 4.40 ± 0.30 15.98 ± 1.20 
1 4.84 ± 0.61 7.42 ± 1.04 4.34 ± 0.31 19.90 ± 0.99 
1.5 4.84 ± 0.85 8.10 ± 1.28 4.50 ± 0.39 24.18 ± 1.26 
2 4.76 ± 0.66 7.62 ± 1.13 4.49 ± 0.47 25.55 ± 1.17 
2.5 4.69 ± 0.64 7.87 ± 1.29 4.54 ± 0.44 25.32 ± 1.17 
3 4.76 ± 0.70 8.23 ± 1.55 4.61 ± 0.55 25.83 ± 1.27 
3.5 5.07 ± 0.62 8.07 ± 1.29 4.53 ± 0.47 22.83 ± 1.00 
4 5.22 ± 0.62 7.31 ± 1.18 4.40 ± 0.45 19.43 ± 1.15 
4.5 4.76 ± 0.56 6.92 ± 0.98 4.40 ± 0.41 12.39 ± 0.54 
5 4.99 ± 0.51 6.36 ± 0.56 4.18 ± 0.31 8.24 ± 0.30 
5.5 5.14 ± 0.51 6.25 ± 0.77 4.18 ± 0.33 6.08 ± 0.28 
6 5.22 ± 0.53 6.23 ± 0.50 4.15 ± 0.31 Below lower limit of quantification 
 
 
Figure 3. 1. Concentrations of letrozole (mean ± SEM) in milk and plasma in lactating Holstein 
cows treated for 4 days with an intravaginal letrozole releasing device (n=6/sample). Letrozole 
concentrations were quantified by a tandem mass spectrometry with a lower limit of 























Days from device insertion
Milk Plasma
Intravaginal letrozole releasing device
Effect P-Value
Milk vs. Plasma 0.0952
Day <0.0001
Matrix x Day 0.2475
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Table 3. 4. Pharmacokinetic data (mean ± SEM) from lactating Holstein cows treated for 4 days 
with an intravaginal letrozole releasing device. Elimination half-life (t1/2) was determined from 
letrozole concentrations after the device was removed on Day 4.  
Endpoint Plasma Milk P-Value 
Tmax (days) 2.3 ± 0.4 2.7 ± 0.3 0.52 
Cmax (ng/mL) 37.3 ± 1.9 27.3 ± 2.9 0.02 
T1/2 (hours) 14.6 ± 1.6 18.2 ± 1.4 0.12 





Figure 3. 2. Mean (± SEM) ovulatory follicle diameter (A) and CL diameter (B) in lactating 
Holsteins given either a letrozole releasing device (LRD) or a blank intravaginal device (Control) 
for 4 days (n=6/group). Cows were given 500 µg cloprostenol im on Day 4 and 4.5 followed by 
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Table 3. 5. Ovulation data (mean ± SEM) from cows treated with either an intravaginal letrozole 
releasing device (LRD) or a blank intravaginal device for 4 days (n=6/group). The device was 
removed on Day 4 and 500 µg cloprostenol was given on Day 4 and 4.5 followed by 100 µg 
gonadorelin (GnRH) im on Day 6.5. 
Endpoint LRD Control P-value 
Time of ovulation (hours after device insertion) 192 ± 0 160 ± 21 0.16 
Ovulation synchrony (residuals; hours) 0 ± 0 42.7 ± 9.2 <0.001 
Ovulated before GnRH (Day 6.5) 0/6 (0%) 2/6 (33.3%) 0.97 
Ovulatory follicle diameter (mm) 16.2 ± 1.5 19.5 ± 1.6 0.16 
 
 
Figure 3. 3. Mean (± SEM) CL diameter (A) and plasma progesterone concentration (B) 
following post-treatment ovulation (mean ± SEM) in cows treated for 4 days with either an 


























































 Evidence that letrozole is secreted into milk following vaginal delivery is an important 
consideration for the continued development of its use for synchronization in dairy cattle. Our 
quantitative analysis showed that milk letrozole fell below the LLOQ (5 ng/mL) within two days 
following LRD removal, and this rapid elimination provides optimism for its future use in 
lactating dairy cattle. Limited data on aromatase inhibitors for use in food-producing species 
makes it difficult to speculate on the tolerance (maximum residue level) for letrozole. However, 
an acceptable daily intake could be established from toxicity studies done in rodents. If a 
maximum residue limit of 5 ppb (ng/mL) for letrozole was established, results of the present 
study suggest that a 4-day LRD regimen would result in a total withdrawal period of 6 days (12 
milking sessions). At current Canadian milk prices (August 2019; Dairy Farmers of Ontario, 
2019), a cow producing 40 kg of milk per day at 3.5%, 3.0%, and 5.65% fat, protein and other 
solids, respectively would result in a loss of $28.95 CAD per day or $173.71 CAD for a 6-day 
withdrawal period. Caution should be exercised when evaluating elimination time of letrozole as 
low producing, cull cows were used in the present study (average 9-11 kg/day), and there was a 
strong negative correlation between milk production and milk letrozole concentration. For the 
endogenous steroid progesterone, metabolic clearance rate is highly correlated to liver blood 
flow (R=0.92) and liver blood flow was positively correlated to dry matter feed intake 
(Sangsritavong et al., 2002). Similarly, in pasture-based cows treated with a intravaginal 
progesterone device, progesterone concentrations were lower in cows fed ad libitum compared to 
feed-restricted cows (Rabiee et al., 2001a), although no effect of circulating progesterone was 
observed between differing milk yields (Rabiee et al., 2001b). From these studies, it was 
hypothesized that elimination of steroids (predominantly progesterone) in dairy cows was 
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attributed to liver metabolism (from increased feed intake) rather than excretion into milk 
(Sangsritavong et al., 2002). As progesterone exhibits similar size and properties to letrozole 
(i.e., 314 vs. 283 g/mol; lipophilic), this method of elimination may also exist for letrozole. 
Future studies on the pharmacokinetics of letrozole in high producing dairy cows are warranted 
to test this hypothesis.  
 Feeding non-saleable milk following letrozole treatment to calves may be a viable option; 
however, an understanding of the potential effects of lowering circulating estrogen 
concentrations in calves will be important. If calves were fed 6-8 L of milk daily from the period 
of maximum letrozole concentration found in the present study (~25 ng/mL), they would 
consume approximately 150 to 200 µg of letrozole per day. In post-menopausal women, the 
daily oral dose of letrozole is 2.5 mg, but 100 µg /day resulted in a 95% suppression of plasma 
estradiol and estrone from baseline within two weeks of treatment (Demers, 1994). Secretion of 
LH is regulated in part by the negative feedback of estradiol in calves. In one study, plasma LH 
concentrations were measured in bull calves that were either castrated, castrated plus given an 
estradiol implant, or left intact at 6 weeks of age. The castrated plus estradiol group exhibited the 
lowest mean LH concentration from 1 to 7 weeks following castration (Wise et al., 1987). In a 
study examining the effect of GnRH treatment in 4- to 6-week-old bull calves, it was concluded 
that LH (and subsequent androgen production) was necessary for initiating testicular 
development and sperm production following puberty (Chandolia et al., 1997). Similarly, heifer 
calves treated twice daily from 4- to 6-weeks of age with GnRH had a reduced age at puberty of 
six weeks compared to control heifers (Madgwick et al., 2005). Therefore, suppression of 
estradiol by giving letrozole may lead to an increase in circulating LH concentrations in 
prepubertal calves which may shorten the interval to puberty. 
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 In comparison to our previous studies (Yapura et al., 2012, 2013, 2015), letrozole failed 
to produce a larger preovulatory follicle in the present study. This may have been due to the 
difference in milk production between the LRD and control groups, or due to lower plasma 
letrozole concentrations compared to previous studies (Yapura et al., 2015). Previous studies 
indicated a positive correlation between the size of the preovulatory follicle and milk production 
(r=0.55; Lopez et al., 2005). This may result from the reduced plasma concentrations of 
progesterone seen in high producing cows (Lopez et al., 2005), which has been associated with 
increased LH pulsatility (Adams et al., 1992a). This may have confounded the comparison in the 
present study since LRD-treated cows produced approximately 25% of total milk compared to 
controls (i.e., 11 kg vs. 43 kg/day).  
 The plasma elimination half-life of lactating Holsteins in the present study was 
approximately half of that reported for nulliparous beef heifers (i.e., 15 vs. 33 hours; Yapura et 
al., 2014). A similar increase in clearance rate for lactating dairy cows has been observed with 
the use of the antibacterial agent, enrofloxacin (fluoroquinolones; Idowu et al., 2010). When 
treated at 5 mg/kg body weight iv, dairy cows have a shorter elimination half-life than beef steers 
(i.e., 3.7 vs. 5.2 hours). In humans, approximately 60% of letrozole is protein bound to albumin 
(Requena et al., 2008), thus, protein binding may explain the shorter elimination half-life in 
lactating cows. The 40% of letrozole unbound to albumin may be transferable in milk in lactating 
cows. The degree of drug transfer into breast milk in women is indirectly influenced by the 
drug’s protein binding ability (i.e., ibuprofen is 99% protein-bound in plasma, with limited 
diffusion into breast milk; Hotham and Hotham, 2015; Hale and Rowe, 2017). Conversely, lipid-
soluble drugs may dissolute into the fat droplets of milk as seen with citalopram in women 
(Rampono et al., 2000). In humans, metabolism of letrozole has been shown to occur in the liver 
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by the CYP-450 isoenzymes, CYP3A4 and CYP2A6, into inactive carbinol metabolites 
(Bhatnagar, 2007). Letrozole and its metabolites are excreted mainly via urine (~90%; U.S. Food 
and Drug Administration, 2007). Additional studies are needed to better understand elimination 
and metabolism mechanisms of letrozole and its metabolites in milk, plasma, and urine in high-
producing lactating dairy cows.  
 In summary, results of the present study document the letrozole milk residue profile after 
treatment of lactating dairy cows with an intravaginal letrozole-releasing device using LC-
MS/MS. Maximum letrozole concentrations were greater in plasma than in milk, but no 
difference in elimination half-life was observed. This study confirmed that letrozole is excreted 
into milk and can be used for future studies in the veterinary approval process of letrozole as a 
novel estrous synchronization strategy in cattle.   
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The aromatase inhibitor, letrozole, has been used in the treatment of infertility in women by 
inducing mild ovarian superstimulation or augmenting the ovarian response to FSH treatment. 
The effect has been attributed to an apparent upregulation of FSH-receptors on granulosa cells as 
a result of increased androgen concentrations. The objective of the study was to determine if 
treatment with the aromatase inhibitor, letrozole, will increase the number of antral follicles 
present at wave emergence, and if letrozole will potentiate the superovulatory response during 
gonadotropin treatment using a bovine model. In Experiment 1, sexually mature beef heifers 
(n=8) at random stages of the estrous cycle underwent ultrasound-guided transvaginal ablation of 
all follicles ≥5 mm to synchronize emergence of a new follicular wave. On Day 0 (wave 
emergence), the number of antral follicles ≥2 mm were counted, and an intravaginal letrozole-
releasing device (LRD) was placed intravaginally. On Day 5, the LRD was removed, and 
transvaginal follicle ablation was done to permit antral follicle count at the subsequent wave 
emergence (Day 6.5). In Experiment 2, non-lactating Holstein cows (n=30) were given two 
luteolytic doses of prostaglandin 12 hours apart and scanned daily by transrectal ultrasonography 
to detect ovulation. Transvaginal follicle ablation was done 5 to 8 days after ovulation to 
synchronize wave emergence, and either an LRD or a blank device was placed for 5 days 
(n=15/group). On the expected day of wave emergence (Day 0), cows in both groups were given 
8 doses of 50 mg pFSH im at 12-hour intervals, and prostaglandin on Days 3 and 3.5. The 
vaginal devices were removed at the time of the second prostaglandin treatment, and paint was 
applied to the tailhead to facilitate the detection of estrus. On Day 5, cows were given GnRH 
(100 µg gonadorelin) im and artificially inseminated 12 and 24 hours later. The ovaries were 
examined by ultrasonography to record the follicular and luteal response, and ova/embryos were 
 68 
collected transcervically on Day 12. In Experiment 1, there was no difference in the number of 
follicles at wave emergence before vs after letrozole treatment (23.2 ± 3.2 vs. 23.5 ± 3.8 follicles; 
P=0.67). In Experiment 2, there was no treatment effect or treatment-by-day-interaction on the 
number of follicles >8 mm on Days 3.5, 5 and 6.5. Plasma estradiol concentrations on Day 3.5 
were lower and estrus was exhibited later (50.3 ± 1.1 vs 40.7 ± 2.0 hours after first 
prostaglandin; P<0.001) and with less variance (residuals, 3.1 ± 0.5 vs 6.7 ± 0.9 hours; P<0.01) 
in the LRD than the sham group, respectively. The number of corpora lutea (CL) on Day 6.5 was 
lower in the letrozole vs sham group (9.1 ± 1.1 vs 12.3 ± 1.1; P=0.05). The total number of 
ova/embryos collected per cow did not differ (5.0 ± 1.9 vs 5.4 ± 1.8; P=0.75), but the proportion 
of transferable embryos tended to be lower (18/30 [60.0%] vs 43/54 [79.6%]; P=0.06) in the 
letrozole versus sham group, respectively. In summary, LRD treatment did not increase the 
number of antral follicles at wave emergence and did not improve the superovulatory response or 
numbers of ova/embryos recovered in the bovine model. Letrozole treatment resulted in more 
synchronous estrus which may be used in the design of a fixed-time artificial insemination 
protocol following superstimulatory treatment in cattle. 
 
 
4.2. Introduction  
 
Letrozole is a third-generation non-steroidal aromatase inhibitor that specifically and 
reversibly inhibits the enzyme P450aromatase in a dose-dependent manner (Hong and Chen, 2006). 
The aromatase enzyme is essential for the conversion of androstenedione and testosterone into 
estrone and estradiol, respectively. Commercially available letrozole (FEMARA®) is labeled for 
use in hormone-dependent breast cancer in post-menopausal women (Health Canada, 2005); 
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however, several reports have been published on the use of letrozole in women undergoing 
ovarian superstimulation for the treatment of subfertility (Mitwally and Casper, 2002; Garcia-
Velasco et al., 2005).  
Although not critically examined, the putative effect of letrozole in the treatment of 
subfertility in women is based on the concept that estradiol suppresses gonadotropin release 
through negative feedback effects on the hypothalamo-pituitary axis. The reduction of circulating 
estradiol by means of aromatase inhibition is thought to relieve the suppressive effects on 
follicle-stimulating hormone (FSH) release, thus stimulating the development of more than one 
ovarian follicle to a pre-ovulatory size (Requena et al., 2008). While this hypothesis remains to 
be tested in women, a second mechanism has been proposed for the apparent superovulatory 
effect of aromatase inhibitor treatment based on an increase in intrafollicular concentrations of 
testosterone and androstenedione as a result of reduced conversion of androgens to estrogens 
(Garcia-Velasco et al., 2005). In addition, 3-10 days of androgen exposure resulted in increased 
FSH-receptor expression in granulosa cells (Weil et al., 1998, 1999) of non-human primates, and 
in knock-out mice, androgens attenuated follicular atresia and enhanced FSH-receptor 
expression, which then augmented FSH-mediated follicle growth (Sen et al., 2014). Long-term 
androgen priming has also been found to improve in vitro fertilization (IVF) outcome in poor-
responder human patients (Moawad and Shaeer, 2012), and daily co-administration of letrozole 
and FSH during ovarian stimulation improved the IVF outcome compared to gonadotropin 
treatment alone (Haas et al., 2017).  
 The bovine model has been used to characterize ovarian follicular dynamics in women 
and to test mechanistic hypotheses related to the control of follicular growth and ovulation 
(Adams et al., 2012; Baerwald et al., 2012). In a series of studies using the bovine model to 
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examine the effects of aromatase inhibitors, there was no support for the hypothesis that 
treatment results in an increase in circulating FSH; however, through an elevation in circulating 
LH, treatment altered follicular wave dynamics in a fashion that may be useful for ovulation 
synchronization in programmed breeding programs (Yapura et al., 2018). To-date, the effects of 
aromatase inhibitor treatment as an adjunct to gonadotropin treatment for ovarian 
superstimulation have not been reported. 
 Using the bovine model, the objectives of the present study were to determine if 
treatment with the aromatase inhibitor, letrozole, will increase the number of follicles present at 
wave emergence (Experiment 1) and if letrozole will potentiate the superovulatory response 
following FSH treatment (Experiment 2).  
 
4.3. Materials and Methods 
Experimental protocols were approved by the University of Saskatchewan’s Animal 
Research Ethics Board and were conducted in accordance with the guidelines of the Canadian 
Council on Animal Care (Animal Use Protocol: #20150076). 
 
4.3.1. Experiment 1 
 
Sexually mature, Hereford-cross heifers (n=8) maintained at the University of 
Saskatchewan’s Livestock & Forage Centre of Excellence were used during April. Heifers 
weighed 398 ± 24 kg (mean ± SEM) and were allowed free access to water and fed a 
combination of barley silage and dry alfalfa hay to maintain a body condition score of 3.0 (Scale 
1-5, Richards et al., 1986). Prior to enrolment in the study, the ovaries were examined by 
transrectal ultrasonography to confirm the presence of a corpus luteum (CL; i.e., post-pubertal). 
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At random stages of the estrous cycle, transvaginal ultrasound-guided follicle ablation was done 
by aspiration of follicles ³5 mm in diameter in both ovaries (Bergfelt et al., 1994) using a 5-8 
MHz convex-array transvaginal probe (MyLab Alpha, Esaote North America, Fishers, IN, USA) 
equipped with a disposable 18-ga needle (BD, Mississauga, Ontario, Canada) attached to a 6 mL 
syringe by silicone tubing (60 cm long x 1.14 mm internal diameter; Cole-Palmer, Montreal, 
Quebec, Canada). Based on previous studies (Bergfelt et al., 1994), 36 hours after ablation was 
expected to be the day of new follicular wave emergence (Day 0) and was the day on which a 
silicone intravaginal letrozole-releasing device (LRD) was inserted (Chapter 2). On Day 5, the 
LRD was removed, and heifers underwent follicular ablation in the same manner as previously 
described. The ovaries were examined by transrectal ultrasonography on Day 0 (pre-treatment 
wave emergence) and Day 6.5 (post-treatment wave emergence) using a 7.5 MHz linear-array 
probe (MyLab Alpha, Esaote North America, Fishers, IN, USA). The size and relative position 
of follicles ³2 mm in diameter were recorded on an ovary sketch sheet. Blood samples were 
collected daily from Day 0 to 5 and on Day 6.5 by jugular venipuncture into heparinized 
vacutainer tubes (BD, Mississauga, ON, Canada), and centrifuged at 1500 x g for 15 minutes; the 
plasma was aliquoted and stored frozen at -20ºC. The experimental timeline is displayed in 
Figure 4.1.  
 Plasma was analyzed for concentrations of letrozole using LC-MS/MS, as previously 
described (Chapter 2). Briefly, plasma samples were thawed at ambient temperature and, 100 µL 
were transferred to a 1.5 mL microcentrifuge tube; the samples were spiked with 50 µL internal 
standard (200 ng/mL letrozole-d4), and 250 µL of acetonitrile was added, and samples were 
centrifuged at 15000 x g at 4°C for 15 mins. A total of 200 µL of the supernatant layer was then 
transferred to a 2 mL autosampler vial and loaded into the LC-MS/MS apparatus for analysis.  
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4.3.2. Experiment 2 
 
Mature non-lactating, Holstein cows (n=30; age 3 to 10 years) were maintained in 
outdoor pens at the Western College of Veterinary Medicine, University of Saskatchewan in 
May. Cows were fed alfalfa hay with free access to water and weighed 763.3 ± 0.7 kg with a 
body condition score of 2.6 ± 0.1 (Scale 1-5; (Ferguson et al., 1994)). At random stages of the 
estrous cycle, cows were given two luteolytic doses of prostaglandin (PGF; 500 µg cloprostenol; 
Vetoquinol N.A., Lavaltrie, QC, Canada) im 12 hours apart and examined daily by transrectal 
ultrasonography to detect ovulation. On the day of ovulation, antral follicles ≥3 mm were 
counted and recorded on an ovarian sketch sheet, and cows were ranked numerically by the 
number of antral follicles ≥3 mm counted on the day of ovulation (Singh et al., 2004). The 
ranking was used to distribute cows of similar rank evenly (by lottery) between two treatment 
groups (n=15 per group). At 5 to 8 days post-ovulation, cows underwent ultrasound-guided 
transvaginal ablation of follicles ³5 mm and given either an intravaginal LRD or a blank sham 
device (progesterone-free Cue-Mate device, Bayer Australia, Pymble, NSW, Australia).  
Beginning on Day 0 (wave emergence), cows in both groups were given 8 doses of 50 
mg pFSH (Folltropin; Vetoquinol N.A.; Lavaltrie, QC, Canada) im at 12-hour intervals. A 
luteolytic dose of PGF (500 µg cloprostenol im; Bioestrovet; Vetoquinol N.A.; Lavaltrie, QC, 
Canada) was given on Days 3 and 3.5. The vaginal device was removed, and paint was applied to 
the tail-head to facilitate estrus detection (Reveal; Cooperative Resources International, 
Shawano, WI, USA) on Day 3. On Day 5, gonadotropin-releasing hormone (GnRH; 100 µg 
gonadorelin im; Fertiline, Vetoquinol N.A., Lavaltrie, QC, Canada) was given and artificial 
insemination was done using proven fertile semen (Semex; Guelph, ON, Canada) 12 and 24 
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hours later. Estrous behavior was monitored at 8-hour intervals from Day 3.5 to Day 6. Cows 
were considered in estrus if observed standing to be mounted or if the tail paint was missing at 
subsequent observation. The ovaries were examined by transrectal ultrasonography on Days 0, 
3.5, 5, 6.5, and 12 to record the follicular and luteal response. Ova/embryos were recovered by a 
nonsurgical transcervical technique by inexperienced embryo transfer course participants by 
transcervical uterine flush on Day 12 and evaluated for quality (1 to 3: transferable; 4: 
degenerate; infertile) by IETS standards (Robertson and Nelson, 2010). The experimental 
timeline is depicted in Figure 4.2.  
 Blood samples were collected by jugular venipuncture into heparinized 10 mL vacutainer 
tubes (BD, Mississauga, ON, Canada) on Day -1.5, 0, 3, 5, and 6.5, centrifuged at 1500 x g for 
15 minutes and the plasma was aliquoted and frozen at -20°C. Plasma estradiol concentrations 
were measured by radioimmunoassay at Texas A&M University, as previously described (Kirby 
et al., 1997). The minimum detection limit was 0.5 pg/mL and the intra- and inter-assay 
coefficients of variation were 1.6 and 1.5%, respectively. 
 
4.3.3. Statistical analyses 
 
Data were analyzed using SAS Enterprise Guide (Version 4.2; Statistical Analysis System 
Institute Inc., Cary, NC, USA). Nominal data were compared between groups by paired t-test 
and by analysis of variance for repeated measures. Binomial data were compared by chi-square 
test or GLIMMIX. Data are presented as mean±SEM unless stated otherwise, with significance 






4.4.1. Experiment 1 
 
There was no difference in the number of follicles ≥2 mm at the time of wave emergence 
before vs after letrozole treatment (23.2 ± 3.2 vs. 23.5 ± 3.8 follicles; P=0.67). Mean plasma 
letrozole concentrations are shown in Figure 4.1.  
 
4.4.2. Experiment 2 
 
The number of follicles detected at post-ablation wave emergence did not differ between 
letrozole- and sham-treated groups (P=0.68, Table 4.1). The proportion of letrozole-treated cows 
that exhibited estrus tended to be lower than sham-treated cows (P=0.07; Table 4.1). However, 
letrozole-treated cows exhibited estrus later following PGF treatment than sham-treated cows 
(P<0.001; Table 4.1) and the interval to estrus was less variable (residuals; P<0.01; Table 4.1). 
The proportion of ovulations (number of CL on Day 12 over the number of follicles ≥3 mm per 
cow on Day 0) was not different between groups (P=0.15; Table 4.1). The number of ovulations 
by Day 6.5 was lower in the letrozole than the sham group (P=0.05; Table 4.1), although the 
number of CL on the day of embryo recovery did not differ (P=0.32; Table 4.1). The total 
number of ova/embryos collected (P=0.75) and the number of transferable embryos (P=0.56) per 
cow did not differ between letrozole and sham groups (Table 4.1). There was a tendency for a 
treatment-by-day interaction for the number of follicles >8 mm due to an increase on Day 5 in 
the sham group (P=0.08; Figure 4.3A). There was no treatment effect or treatment-by-day-
interaction for the number of follicles ≤8 mm on Day 3.5, 5, and 6.5 (Figure 4.3B). A treatment-
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by-day-interaction was observed for plasma estradiol during treatment (P=0.04), which was 
attributed to lower estradiol on Day 3 in the LRD group (Figure 4.4).  
No ova/embryos were recovered from 9 cows in the LRD group and 5 cows in the sham 
group, so comparisons were made based on n=6 and n=10 in the respective groups (Table 4.2). 
The number of quality 1 embryos was proportionally lower in the letrozole than the sham group 
(P=0.02). The proportion of transferable embryos tended to be lower (P=0.06), and the 
proportion of degenerate embryos tended to be higher (P=0.08) in the letrozole vs. sham group. 
No differences were detected between groups in the proportion of Quality 2 or 3 embryos or 




Figure 4. 1. Mean (± SEM) plasma letrozole concentrations in beef heifers (n=8) treated with a 
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Figure 4. 2. Experimental timeline for Experiment 2 in which Holstein cows were given either a 
letrozole releasing device (LRD) or a sham device and were superstimulated with follicle 
stimulating hormone (FSH). PGF: 500 µg cloprostenol; BS: blood sample; US: transrectal 




Figure 4. 3. Mean (± SEM) number of follicles >8 mm (A) and ≤8 mm (B) in which Holstein 
cows were given either a letrozole releasing device (LRD) or a sham device and were 



































































































Figure 4. 4. Mean (± SEM) plasma estradiol concentrations in which Holstein cows were given 
either a letrozole releasing device (LRD) or a sham device and were superstimulated with follicle 
stimulating hormone (FSH; Experiment 2). PGF: 500 ug cloprostenol; GnRH: 100 ug 














































Intravaginal LRD or Sham
8x FSH (50mg/treatment)
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Table 4. 1. Follicular, luteal, estrus, and embryo responses (mean ± SEM) in which Holstein 
cows were given either a letrozole releasing device (LRD) or a sham device and were 
superstimulated with follicle stimulating hormone (FSH; Experiment 2). 
 
LRD Sham P-value 
Cows (n) 15 15 - 
Follicles ≥3 mm at wave emergence (Day 0)  24.6 ± 3.1 26.5 ± 3.3 0.68 
Proportion of cows exhibited estrus 12/15 (80%) 15/15 (100%) 0.07 
Interval to estrus from 1st PGF (hrs) 50.3 ± 1.1 40.7 ± 2.0 <0.001 
Variance in interval to estrus (hrs)  3.1 ± 0.5 6.7 ± 0.9 <0.01 
Proportions of ovulations x 0.65 ± 0.02 0.70 ± 0.02 0.15 
Ovulations by Day 6.5 9.1 ± 1.1 12.3 ± 1.1 0.05 
Number CL day of collection 15.9 ± 2.5 19.0 ± 2.0 0.32 
Transferable embryos recovered y 3.0 ± 1.2 4.3 ± 1.5 0.56 
Infertile ova/degenerate embryos y 2.0 ± 0.8 1.1 ± 0.4 0.29 
Total structures recovered y 5.0 ± 1.9 5.4 ± 1.8 0.75 
xTotal number of corpora lutea (CL) on day of embryo collection over the total number of follicles 
≥3 mm at wave emergence (Day 0)  
yData derived from cows in which structures were successfully recovered following transcervical 
uterine flush (n=6 LRD and n=10 Sham) 
 
Table 4. 2. Ova/embryo recovery results following superovulation and transcervical recovery in 
cows treated with an intravaginal letrozole-releasing device (LRD) or a sham device (Experiment 
2).  
 
LRD Sham P-value 
Number of cows 6 10 - 
Total structures recovered 30 54 - 
Quality 1 13/30 (43.3%) 38/54 (70.3%) 0.02 
Quality 2 3/30 (10.0%) 3/54 (5.6%) 0.46 
Quality 3 2/30 (6.7%) 2/54 (3.7%) 0.55 
Total transferable embryos 18/30 (60.0%) 43/54 (79.6%) 0.06 
Unfertilized ova 4/30 (13.3%) 5/54 (9.3%) 0.57 





The bovine model has been used extensively for the study of follicular dynamics in 
women (Adams and Pierson, 1995). It is difficult to compare the ova/embryo production rates 
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following stimulation between cattle and women, due to the fact that an increased number of 
follicles leads to a greater chance of ovarian hyperstimulation syndrome (OHSS) which can be 
life-threatening in women (Rova et al., 2012). Incidences of OHSS have been reported to 
increase significantly when more than 18 oocytes were recovered (Magnusson et al., 2018). 
Therefore, care is taken during superstimulation in women and maximizing the number of 
oocytes and embryos is not the only goal for the use of advanced reproductive technologies in 
women. In cattle, the main goal for the use of advanced reproductive programs is to maximize 
the quantity of transferable or freezable embryos from high-valued genetic donors. 
Gonadotropins (i.e., FSH) given for ovarian superstimulation to maximize embryo production 
results in substantial expenses for cattle producers. Most recent data show that 94,000 in vivo 
embryo collections and 112,000 oocyte aspirations for in vitro fertilization (IVF) were done 
worldwide in 2016 in cattle (Perry, 2017). A conservative estimate of $100 per superstimulatory 
treatment (Hasler, 2014) corresponds to over $20.6 million spent annually on superstimulation 
treatments in cattle. Therefore, cost-effective alternatives for gonadotropins are sought while still 
maintaining the production of high-quality embryos. 
The use of letrozole in the present study did not increase the number of ova/embryos 
following superstimulation in cattle. In women with low antral follicle counts, letrozole 
treatment was associated with an increased in the number of oocytes retrieved, perhaps as a 
result of increased FSH receptor gene expression induced by an increase in intrafollicular 
androgens (Garcia-Velasco et al., 2005). In women, treatment with 1.25 mg/day of testosterone 
for 21 days decreased the dosage of FSH needed while increasing the number of oocytes 
retrieved following aspiration (Kim et al., 2011). Follicular fluid was not sampled in the present 
study, but the transient drop in plasma estradiol concentrations in letrozole-treated cows may not 
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have been sufficient to alter intraovarian androgen concentrations sufficiently to affect FSH 
receptor expression. The role of androgens in ovarian follicular dynamics is not well understood. 
Early research with monkeys revealed that short-term treatment with testosterone increased the 
number of preantral follicles (Vendola et al., 1998). Recent studies in mice indicated that 
testosterone decreased the expression of anti-Müllerian hormone (AMH) as well as increased the 
size of preantral follicles (Laird et al., 2017). Due to the inhibitory effect of on preantral follicle 
recruitment, as well as their responsiveness to FSH (Visser et al., 2006), it may be hypothesized 
that androgens control follicular development through a paracrine manner. 
A shortcoming of the present study is the lack of frequent blood sampling (every 15 
minutes for 8 hours) during superstimulation to quantify luteinizing hormone (LH) pulse-
frequency. To the best of our knowledge, the low estradiol environment model during 
superstimulation on LH pulse frequency and its subsequent role in embryo quality has not been 
tested. As shown in a previous study (Yapura et al., 2011), letrozole treatment increased plasma 
LH concentrations due to the release of hypothalamic estradiol feedback. Therefore, in the 
present study, it may be hypothesized that LH profiles differed between groups. When pulses of 
LH were induced (with a small dosage of exogenous GnRH: i.e., 0.25 to 1 pulse per hour) during 
superstimulation with FSH, no difference was detected in the number of large follicles present at 
the time of induced LH surge. Following a bolus of GnRH given to induce a preovulatory LH 
surge, only 1 out of 5 cows ovulated and this was attributed to a decreased LH surge. The 
inhibition of the LH surge was unexpected and was hypothesized to be due to a desensitization of 
the pituitary gland by estradiol, GnRH or LH itself (Price et al., 1999). Although not investigated 
in the present study, the expected increase in LH in the letrozole group may have led to 
desensitization of the pituitary and thus, decreased numbers of ovulations. Pulse amplitude and 
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frequency of LH has been reported to be lower in superstimulated vs. unstimulated which was 
attributed to increased estradiol in superstimulated animals (Roberge et al., 1995). Individual 
follicles in superstimulated cattle exhibit lower levels of estradiol (although systemic estradiol 
was higher) present in the follicular fluid compared to unstimulated follicles (Assey et al., 1994). 
This difference of estradiol may contribute to the reduced developmental competence of 
superovulated oocytes. Therefore, as letrozole-treated cows in the present study were 
hypothesized to have lower follicular fluid levels of estradiol, this may explain the lower 
transferable embryo rate observed in this group. Although this conclusion should be exercised 
with caution, due to the low recovery rate of embryos by inexperienced practitioners in the 
present study.  
For a superovulatory protocol to be successful in cattle, correct timing of artificial 
insemination (before ovulation) and subsequent in vivo fertilization must be achieved to 
maximize embryo numbers. In the present study, the onset of estrus following PGF was 
lengthened by approximately 10 hours but was more synchronous in the letrozole-treated group 
due to delayed estradiol release following LRD removal. No letrozole-treated cows exhibited 
estrus before 48 hours following PGF (range 48-56 hours) and three cows failed to exhibit estrus, 
even though superstimulation was achieved (i.e., ³ 6 CL present on Day 12). Plasma estradiol 
was higher on Day 5 (i.e., 12 hours before insemination) in the letrozole group, which may 
benefit sperm transport following insemination (Hawk and Cooper, 1975). The interval to estrus 
(i.e., at the time of peak estradiol) has been shown to be variable among superstimulated cattle 
(D’Occhio et al., 1997), and ovulation has been reported to occur earlier in donors with ≥4 vs. <4 
CL at the time of ova/embryo collection (Bo et al., 2006). Therefore, the timing of the 
endogenous LH surge and subsequent ovulations are also variable among superstimulated cattle. 
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Unlike for ovarian stimulation protocols in women, protocols for cattle do not generally involve 
the use of a GnRH antagonist or agonist (Depalo et al., 2012), although these substances have 
been shown to be efficacious in preventing the endogenous LH surge (D’Occhio et al., 1997). 
Therefore, without the use of GnRH-antagonists, AI before ovulation is essential for in vivo 
fertilization and subsequent embryo production in cattle.    
With the knowledge attained from this study, future studies should investigate the effect 
of letrozole at a later stage during superstimulation. By increasing LH pulsatility, letrozole 
treatment immediately after follicular ablation may have affected early follicular growth. A 
regimen in which letrozole treatment is initiated when follicles are approximately 7 to 8 mm in 
diameter (i.e., LH-dependent follicles; Ginther et al., 2001) might increase superstimulation and 
subsequent ovulatory response. Due to the competition of multiple dominant follicles for LH, a 
higher number of follicles may continue to grow and eventually ovulate (Mapletoft et al., 2002). 
Due to its short half-life, FSH must be given once or twice per day to women and cattle, 
respectively (Mapletoft et al., 2002). Therefore, a superstimulation protocol could be developed 
with FSH given as a single dosage at the onset of wave emergence, followed by letrozole 
treatment 2 days later. The FSH may allow for simulation until the follicles reach the 7 to 8 mm 
size, then letrozole treatment would increase endogenous LH concentrations and continue to 
increase the size and ovulatory potential of the follicles.       
In conclusion, the results of the present study involving the bovine model did not support 
the hypothesis that letrozole treatment potentiates the superovulatory effects of FSH treatment. 
Letrozole treatment was not associated with either an increase in the number of antral follicles at 
the time of wave emergence or in the ovarian superstimulatory response and ova/embryo 
production in cattle. However, letrozole treatment resulted in more synchronous estrus, which 
 83 
may be useful in the design of a fixed-time artificial insemination protocol following 
superstimulatory treatment in cattle.  
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Relationship of this study to the dissertation 
In this chapter, we used an intravaginal letrozole-releasing device developed in Chapter 2 to test 
the effect of letrozole on the local ovarian environment and the ability of the cumulus-oocyte 
complexes to undergo in vitro maturation and in vitro fertilization. The hypothesis was that 
letrozole treatment would result in a lower proportion of cumulus-oocyte complexes that would 
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5.1. Abstract  
 
The use of the aromatase inhibitor, letrozole has allowed for a new approach for ovarian  
follicular control in cattle. To date, little has been published on the effects of letrozole on the 
local ovarian environment and the cumulus-oocyte complex (COC). The objectives of this study 
were to characterize the local effect of letrozole on the ovary (Experiment 1), in vitro maturation 
of COC (Experiment 2), and in vitro embryo production (Experiment 3) in beef heifers. Three to 
four days after ovulation, ultrasound guided transvaginal follicle ablation was done to induce 
emergence of a new follicular wave 1 day later (wave emergence = Day 0) and heifers were 
given an intravaginal letrozole-releasing device (LRD) or a sham device for 4 days immediately 
after ablation. In Experiment 1, heifers were given a 4-day LRD or sham device and underwent 
follicle sampling either before the LH surge (i.e., immediately after device removal on Day 3) or 
after the LH surge on Day 5.5 (i.e., PGF on Day 3 followed by GnRH on Day 5) in a 2x2 
factorial design. Follicular fluid was analyzed for letrozole concentrations by tandem mass 
spectrometry (LC-MS/MS), which was partially validated as a secondary objective of the study. 
Granulosa cell mRNA from dominant and subordinate follicles was analyzed for expression of 
HSD3B, LHCGR, STAR, INHBA, FSHR, CYP11A1, CCND2, NPR2, and CYP19A1 by 
polymerase chain reaction (PCR). In Experiment 2, a 2x2 crossover experimental design was 
used to compare a 4-day LRD or sham device followed by COC aspiration done on Day 4 and in 
vitro maturation of COC for 0 or 24 hours. The COC were then fixed and oocytes were examined 
for nuclear maturation. A subset of heifers underwent frequent blood collections to determine 
plasma LH secretion on Day 3 (i.e., device removal). In Experiment 3, heifers were given either 
a 4-day LRD or sham device followed by COC aspiration 1 day after device removal. The COC 
underwent in vitro maturation, fertilization, and culture and were evaluated for embryo 
 86 
development. Continuous data were analyzed by t-test or ANOVA and proportional data were 
analyzed by chi-square. In Experiment 1, no effect of treatment was observed for gene 
expression from granulosa cells derived on Day 3. Follicular fluid concentrations of letrozole did 
not differ (P=0.37) between dominant and subordinate follicles, but a day effect was observed 
(P<0.001). A significant positive correlation was shown between plasma and follicular 
concentrations of letrozole at the time of sampling (R=0.9889, P<0.0001). In Experiment 2, the 
mean LH area under the curve (AUC) was greater in LRD vs sham device (148.2 ± 22.4 vs 74.2 
± 11.8 mins x ng/mL, respectively; P<0.01). A higher proportion of oocytes undergoing 
maturation for 24 hours in the LRD group continued to the MII stage compared to the other 
groups (P<0.05). In Experiment 3, the proportion of blastocysts over the total COC was greater 
in the LRD vs sham group (17/160 [10.6%] vs 9/209 [4.3%], respectively, P=0.02) but no 
difference was detected in embryo quality 7 days after fertilization. When follicular aspiration 
data were combined from Experiments 2 and 3, a lower number of total follicles (12.7 ± 0.7 vs 
16.1 ± 1.0; P<0.01)  and COC (6.3 ± 0.6 vs 8.8 ± 0.9; P=0.02) were collected in the LRD vs 
sham group, respectively. In summary, letrozole was detected in follicular fluid but did not affect 
granulosa cell function. Letrozole treatment increased the LH AUC and resulted in a greater 
proportion of oocytes in the MII stage following 24 hours of maturation. Finally, letrozole did 
not affect in vitro fertilization nor embryo quality, and thus, should not adversely affect fertility 




Aromatase inhibitors have been used off-label for infertility treatment in women during 
the past 20 years (Mitwally and Casper, 2002). The non-steroidal aromatase inhibitor, letrozole, 
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acts by competitively binding to the heme group of the aromatase enzyme inhibiting the 
conversion of androgens to estrogens throughout the body (Chumsri et al., 2011). By lowering 
circulating estrogen concentrations, the hypothalamus is released from its negative feedback 
permitting a subsequent rise in gonadotropin release. Due to the pulsatile secretory pattern, 
gonadotropins are challenging to assess in women due to the requirement of frequent sampling. 
Utilizing non-human models to test the effects of letrozole has allowed for a better 
understanding of the physiological role of letrozole in women experiencing infertility. In a 
mouse model, letrozole induced an ovarian response similar to polycystic ovarian syndrome 
(PCOS) in women (Kauffman et al., 2015). Treatment with the aromatase inhibitor, letrozole, 
reduced estrogen in follicular fluid (Haas et al., 2018) and serum (Pereira et al., 2016) and 
reduced the negative feedback of estrogens on the hypothalamus. As in women experiencing 
PCOS, treatment with letrozole in monkeys led to hypersecretion of luteinizing hormone (LH) 
followed by an overproduction of androgens from the theca cells (Kraynak et al., 2017). We have 
used the bovine model to study the effect of letrozole on ovarian function (reviewed in Yapura et 
al., 2018). To date, experiments in cattle have examined the effects of letrozole on follicular and 
luteal function (Yapura et al., 2013, 2014), synchronization of ovulation (Yapura et al., 2016), 
co-superstimulation with exogenous FSH ((Zwiefelhofer et al., 2019); Chapter 4), and 
development of a novel letrozole-impregnated silicone intravaginal device (Chapter 2). Reduced 
plasma estradiol concentrations following letrozole treatment in cattle have resulted in increased 
plasma LH concentrations (Yapura et al., 2011, 2012) which have resulted in an increase in 
dominant follicle diameter, lengthened interwave intervals, and increased progesterone 
concentrations following ovulation. To date, no studies have assessed the pulsatile secretory 
pattern of LH in response to letrozole treatment. 
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If hypersecretion of LH does occur following letrozole treatment, as has been shown in 
women with PCOS, early intrafollicular maturation or atresia of the cumulus-oocyte complex 
(COC) may also occur as seen persistent cystic follicles in dairy cows and buffalo (Hamilton et 
al., 1995; Raghu et al., 2002). In cattle, superstimulation with porcine FSH containing low 
concentrations of LH increased the ovulation rate and the number of recovered and transferable 
embryos compared to products with high LH content (Chupin et al., 1984). Chronic exposure of 
preantral follicles to LH has been shown to decrease expression of FSH-receptors which has led 
to reduced follicular growth in the rat (Orisaka et al., 2013). Whether LH is beneficial or 
detrimental to early follicular development is still not understood.  
Studies on whether hypothalamic release from estradiol negative feedback (from 
letrozole) elicits follicle-stimulating hormone (FSH) release from the pituitary have varied. 
Sources claim an increase in FSH (Requena et al., 2008), a decrease in FSH (Kauffman et al., 
2015) or increased mRNA expression in FSH-receptors in the ovaries (from increased 
intraovarian androgens; (Weil et al., 1999; Kauffman et al., 2015) following letrozole treatment. 
It has been hypothesized that LH secretion from the pituitary is favored over FSH secretion 
following letrozole treatment (Burt Solorzano et al., 2012).  
 Studies on local ovarian effect of letrozole has focused on steroid release into follicular 
fluid (Haas et al., 2018) and blood circulation (Schoolcraft et al., 2008). Intravaginal treatment 
with our novel silicone intravaginal letrozole releasing device (LRD; Chapter 2), may have a 
more profound local effect on the ovary due to arterio-venous anastomosis networks (i.e., 
bypassing systemic circulation). Therefore, letrozole concentrations may be increased in 
follicular fluid compared to circulation, because of passage (similar to prostaglandin F2a (PGF)) 
through the utero-ovarian venoarterial pathway in ruminants (Lee et al., 2010). To our 
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knowledge, no studies have quantified letrozole in follicular fluid following treatment in any 
species.  
The objectives of this study were to use the bovine model to investigate the effect of 
letrozole treatment in cattle on 1) the local ovarian environment using follicular fluid analyses 
and granulosa cell gene expression, 2) LH release and nuclear maturation of oocytes following 
follicular aspiration, and 3) in vitro embryo production following follicular aspiration and in 
vitro maturation, fertilization, and culture. We hypothesized that intravaginal treatment with 
letrozole would result in increased letrozole concentrations in follicular fluid compared to 
plasma, an increase in FSH-receptor mRNA in granulosa cells, increased LH release and 
premature maturation of the COC leading to a reduced capacity for embryo developmental. 
 
5.3. Materials and Methods 
 
Experiments were approved by the University of Saskatchewan’s Animal Research 
Ethics Board following the guidelines of the Canadian Council on Animal Care. Sexually 
mature, Hereford-cross heifers used for the study were maintained at the University of 
Saskatchewan’s Livestock and Forage Centre of Excellence Goodale Farm. Heifers were kept in 
outdoor pens and fed barley silage with ad libitum access to alfalfa hay and water during the 
experimental period of April to July. 
 
5.3.1. Experiment 1-Effects of letrozole on the local ovarian environment in cattle 
 
5.3.1.1. Animals and treatments 
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Hereford-cross heifers (n=31), 11 to 16 months of age were chosen from a herd of 70 
based on the detection of a corpus luteum (CL) ≥20 mm diameter by transrectal ultrasonography 
(7.5 MHz linear array probe, MyLab Alpha, Esaote North America, Fishers, IN, USA). The 
heifers were given two luteolytic doses of PGF (500 µg cloprostenol im, Bioestrovet, Vetoquinol 
N.A., Lavaltrie, QC, Canada) 12 hours apart and gonadotrophin-releasing hormone (GnRH; 100 
µg gonadorelin im, Fertiline, Vetoquinol N.A., Lavaltrie, QC) 3 days later. The ovaries were 
examined by transrectal ultrasonography once per day for the following 2 days after 
administration of GnRH, and the heifers that ovulated were included in the experiment (n=31). 
Transvaginal ultrasound-guided ablation of follicles ³5 mm was done 3 to 4 days after ovulation 
to synchronize follicular wave emergence; the day after ablation was considered the day of wave 
emergence (Day 0). Heifers were assigned randomly to one of four groups (n=7-8 heifers per 
group) in a 2x2 factorial design to compare the effects of treatment (LRD vs. sham device) and 
follicle stage (pre- vs. post-LH surge) on the follicular environment. An intravaginal device 
(LRD or sham) was inserted immediately after follicle ablation (Day -1), and was removed on 
Day 3, followed immediately by ultrasound-guided follicle sampling in pre-LH surge groups. 
Heifers in the post-LH surge groups were given PGF at the time of vaginal device removal (Day 
3), GnRH on Day 5, and follicular sampling was done on Day 5.5. (Supplementary Fig. 5.1). 
Ovarian follicular and luteal dynamics were monitored by transrectal ultrasonography on Days -
1, 3, 4, 5, and 5.5. 
 
5.3.1.2. Follicle sampling 
 
Follicle sampling was done following caudal epidural anesthesia was induced (5 mL of 
2% lidocaine; Lurocaine, Vetoquinol N.A., Lavaltrie, QC) and the perineum was disinfected 
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using an iodine-based detergent and solution. The vagina was lavaged by 5 alternating infusions 
of 60 mL saline and disinfectant solution (1% wt/vol; Virkon; Vetoquinol N.A., Lavaltrie, QC) 
to remove mucopurulent vaginal discharge due to the presence of the intravaginal device. 
Aspiration of the follicular contents of the dominant and subordinate follicles was done by 
transvaginal ultrasound-guided puncture (5-8MHz convex-array probe; MyLab Alpha, Esaote 
North America Inc, Fishers, IN, USA) with an 18-ga short-beveled inverted needle (Watanabe 
Tecnologia Aplcada Ltda, Cravinhos, SP, Brazil) connected to a 6 mL syringe via silastic tubing. 
The dominant follicle was aspirated first and individually; care was taken to relieve the vacuum 
in the syringe after follicle collapse and before the needle was withdrawn back into the vaginal 
cavity to minimize the possibility of aspirating any vaginal residue. The follicular aspirate was 
expelled into a 35 mm Petri dish, and a new needle and tubing were installed before aspiration of 
pooled subordinate follicles (n=2-3) in a similar manner to minimize contamination. The aspirate 
was searched by stereomicroscope (10x magnification) to locate and discard the cumulus-oocyte 
complexes (COC). The granulosa cells and follicular fluid were placed in RNase-free 2 mL 
micro-centrifuge tubes, and centrifuged (1500 x g for 15 minutes) to form a pellet. The follicular 
fluid portion was removed and aliquoted into 1.5 mL RNase-free micro-centrifuge tubes and 
frozen at -20°C. The pellet was resuspended in 0.5-1 mL of RNA Later (Life Technologies, 
Carlsbad, California, USA) at 4°C overnight, and then stored frozen at -80°C. 
 
5.3.1.3. RNA extraction and cDNA Synthesis 
 
Total RNA extraction from the granulosa cell isolate was done using the Rneasy micro 
kit (Qiagen, Venlo, Netherlands) in accordance with the manufacturer’s instructions. Extracted 
RNA was analyzed using spectrophotometry (NanoDrop; Thermo Scientific, Waltham, 
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Massachusetts, USA) for concentration and quality. Samples with a 260/280 ratio below 1.55 
were excluded (n=1), and samples of a concentration below 15 ng/µL (n=8) were concentrated 
with an RNA Clean and Concentrator 5 Kit (Zymo Research, Irvine, California, USA) in 
accordance with manufacturer’s instructions to reach a concentration suitable for the reverse 
transcription procedure. 
From each sample, an aliquot containing 200 ng RNA was utilized for reverse 
transcription to complement DNA with the iScript Advanced cDNA synthesis kit (Bio-Rad 
Laboratories, Hercules, California, USA) to produce a cDNA sample for qPCR. This synthesis 
was done in accordance with the manufacturer’s protocol. 
 
5.3.1.4. Reference Genes and Normalization 
 
Eight reference genes (GAPDH, RPL19, RPLPO, EIF2B2, H2AFZ, B2M, SF3A1, and 
RFN20) were considered for normalization based on previous studies for the cell type being 
examined (Khan et al., 2016). Primers were verified using NCBI BLAST as well as qPCR melt 
curves from previously prepared bovine granulosa cell cDNA. Following primer verification, 
qPCR was done for each of the potential reference genes using SYBR Green Supermix (Wisent 
Bio Products, St-Bruno, Quebec, Canada) for the 27 samples (LRD dominant follicle n=6, LRD 
subordinate follicle n=6, Sham dominant follicle n=7, Sham subordinate follicle n=8). A 2 µL 
aliquot of cDNA from each sample was combined with 5 µL of SYBR Green Supermix, 2 µL 
Rnase free H2O, and 1 µL primer in a well of a 384 well white PCR plate (Diamed Lab Supplies 
Inc., Mississauga, Ontario, Canada) kept on ice. Once complete, the plate was sealed with an 
adhesive cover and centrifuged at 2000 x g for 2 minutes, then analyzed with a CFX384 Touch™ 
Real-Time PCR Detection System (Bio-Rad Laboratories). Final reference gene selection was 
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determined using geNorm analytic software (Qbase+, Biogazelle, Gent, Belgium), with the 
geometric mean of RPL19, RPLPO, EIF2B2, & H2AFZ producing the lowest level of variance 
(geNormV=0.22). Additional confirmation of reference genes was done through independent 
geNorm analysis of results from dominant and subordinate follicles, each of which included 
these reference genes in their normalization recommendation. 
 
5.3.1.5. qPCR Analysis of Genes of Interest 
 
Details of the primers for the four reference and nine genes of interest are provided in 
Supplementary Tables 3 and 4. Primers for nine genes of interest (HSD3B, LHCGR, STAR, 
INHBA, FSHR, CYP11A1, CCND2, NPR2, and CYP19A1) were verified in the manner 
described above. A 2 µL aliquot of cDNA from each sample was combined with 5 µL of SYBR 
Green, 2 µL Rnase free H2O, and 1 µL primer in a well of a 384 well PCR plate kept on ice. 
Once complete, the plate was centrifuged at 2000 x g for 2 minutes, then analyzed with a 
CFX384 Touch™ Real-Time PCR Detection System (Bio-Rad Industries). 
 
5.3.1.6. Follicular fluid LC-MS/MS and radioimmunoassay analysis 
 
Follicular fluid was analyzed for concentrations of letrozole by tandem mass 
spectrometry (LC-MS/MS) with a method that was partially validated as part of this study. 
Follicular fluid from abattoir-derived ovaries was aspirated, centrifuged (3200 x g for 15 minutes 
at 4°C), aliquoted, and stored frozen at -20°C until use. A stock solution of 1 mg/mL of letrozole 
was prepared by dissolving 50 mg of letrozole in 50 mL of 100% methanol. A standard curve 
consisting of concentrations of 1, 2, 4, 8, 16, 32, 64, 128, and 256 ng/mL was prepared by serial 
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dilution in pooled follicular fluid (i.e., removing half of higher concentration and diluting by half 
using blank follicular fluid). A total of 100 µL of each standard was pipetted into a 1500 µL 
plastic microcentrifuge tube. Standards were then spiked with 50 µL letrozole-D4 (200 ng/mL in 
100% acetonitrile, letrozole-D4, Toronto Research Company, Toronto, ON) to serve as an 
internal standard for quantifying peak height and area against letrozole, vortexed for 3 seconds, 
and 250 µL of high-pressure liquid chromatography (HPLC) grade acetonitrile was added. 
Standards were vortexed for 5 seconds and centrifuged (15,000 x g for 15 min. at 4°C). 
Following centrifugation, 200 µL of supernatant was transferred to an HPLC autosampler vial 
and loaded into the HPLC/LC-MS/MS machine (QTRAP 4000; SCIEX; Framingham, 
Massachusetts, USA) autosampler for analysis. Partial validation parameters included linearity, 
accuracy, and precision.  
Separation by HPLC (Agilent 1200; Agilent Technologies, Santa Clara, CA, USA) was 
done with an analytical column (50 x 2.1 mm, 3 um particle size, Thermo Scientific Betasil C18; 
Thermo Scientific, Waltham, MA, USA) at 35°C. HPLC flow rate, solvent conditions, and LC-
MS/MS conditions were done as previously described (Joshi et al., 2011).  
Linearity was tested by running three standard curves independently of each other. Ratio 
counts vs. actual concentration were plotted and the r2 values were calculated. The mean (± 
SEM) r2 value was 0.998 ± 0.002. The calibration curve required a correlation coefficient of r2 ≥ 
0.99. The acceptance criteria for each calculated standard was 15% difference from the nominal 
value of the non-zero calibrators (2, 4, 8, 16, 32, 64, 128, and 256 ng/mL) except the lower limit 
of quantification (LLOQ) which was set at 20%. Accuracy and precision were calculated by 
running three independently spiked quality control (QC) samples (3, 10, and 100 ng/mL) 18 
times (6 samples per day on 3 separate days). Accuracy was calculated by the percentage of true 
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concentration of letrozole recovered by the assay. Precision was expressed as the relative 
standard deviation using the following formula: %RSD=(SD x 100)/mean. The acceptance 
criteria for precision were <20% LLOQ and <15% for the remaining concentrations. The 
acceptance criteria for accuracy was 100 ± <20% for LLOQ and 100 ± <15% or higher for the 
remaining concentrations.  
Follicular fluid concentrations of estradiol were analyzed by radioimmunoassay as 
previously described (Dias et al., 2013). Intra-assay coefficients of variation (CV) for low (15 
ng/mL) and high (40 ng/mL) samples were 10 and 12%, respectively.  
 
5.3.2. Experiment 2 –Frequent blood sampling for gonadotropin release and 
maturation status of COC following letrozole treatment 
 
 
5.3.2.1. Animals and treatments 
 
Hereford-cross heifers in which a CL was detected by transrectal ultrasonography (n=24) 
were given PGF 12 hours apart followed by GnRH 3 days later as described in Experiment 1. 
The ovaries were examined by transrectal ultrasonography once daily for 3 days following 
GnRH to confirm ovulation. Three days after ovulation, heifers underwent transvaginal 
ultrasound-guided ablation of all follicles ³5 mm to synchronize follicular wave emergence (Day 
0). Heifers were randomly distributed by the lottery system and given a 4-day intravaginal device 
(LRD or sham device) immediately following ablation. On Day 3. devices were removed and 
transrectal ultrasonography was done on Days 3 and 4 for analysis of ovarian structures. On Day 





5.3.2.2. COC Collection 
 
Collection of COC was done by transvaginal ultrasound-guided aspiration of all follicles 
≥ 3 mm in diameter using an 18-ga short, and inverted beveled needle (Watanabe Tecnologia 
Aplcada Ltda, Cravinhos, SP, Brazil) connected to a 50 mL conical Falcon tube by silastic 
tubing. Before aspiration, caudal epidural anesthesia was induced by 5 mL of 2% lidocaine 
(Lurocaine, Vetoquinol N.A., Lavaltrie, QC) and the perineum was washed by betadine 
detergent and 70% alcohol. Follicular contents were aspirated by a vacuum pump (BV 003i 
Digital Vaccum Pump, Watanabe Tecnologia Aplcada Ltda) at a flow rate of 16 mL/min and the 
collection medium consisted of Dulbecco’s phosphate-buffered saline (DPBS), 0.15% ET 
surfactant (Vetoquinol N.A., Lavaltrie, QC, Canada), and 200 IU/L heparin. Follicular aspirates 
were poured from the Falcon tube into an ova/embryo filter (Emcon filter, Agtech, Manhattan, 
KS, USA) and rinsed with collection medium without surfactant. Once rinsed, all contents were 
poured into a 90 mm petri dish and searched by stereo microscopy at 10x magnification. Groups 
were facilitated for a maximum of 12 heifers per COC collection day (6 letrozole, 6 control). 
Each animal was collected twice in a crossover design, with a washout period of 12 days 
following letrozole treatment (Supplementary Fig. 5.2). 
At the time of recovery, COC were classified according to the appearance of the cumulus 
cell layers and the ooplasm. The cumulus layer was classified as compact good (>3 layers of 
granulosa cells tightly surrounding the oocyte), compact regular (1-3 layers of granulosa cells 
surrounding the oocyte), expanded (cumulus cells expanded or partially dissociated), denuded 
(oocyte without cumulus cells), or degenerate. Degenerate oocytes were excluded from further 
processing. Oocytes were pooled into four treatments, coinciding with their treatment and 
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maturation times (LRD 0-hour, LRD 24-hour, Control 0-hour, Control-24 hour); oocytes in the 
0-hour group were denuded immediately and fixed as described below, and oocytes in the 24-
hour group were placed in maturation medium for 24 hours before denuding and fixation. 
 
5.3.3. In vitro maturation (IVM) and COC nuclear maturation status 
 
The medium used for the maturation of oocytes in the 24-hour group was BO-HEPES-
IVM (IVF Bioscience, Falmouth, Cornwall, UK). The COC were washed 3 times in IVM 
medium before being placed into a portable incubator (LabMix; Watanabe Tecnologia Aplcada 
Ltda, Cravinhos, SP, Brazil) for transport to the laboratory and were maintained at 38.8°C for 24 
hours. Oocytes were denuded (at 0 or 24 hours after collection) by repeated pipetting in 0.3% 
hyaluronidase (wt/vol) in Ca++ and Mg+ -free DPBS, washed in 0.1% (wt/vol) polyvinyl alcohol 
(PVA) PBS 3x, and fixed in 4% (vol/vol) paraformaldehyde/PBS for 15 minutes. Following 
fixation, oocytes were washed in 0.1% PVA PBS 3x and stored in 4°C until staining. Staining 
was done as previously reported (Cervantes et al., 2016) and examined under an epifluorescence 
laser microscope (Zeiss Axioskop 5 Carl Zeiss Ltd., Toronto, ON, Canada). Nuclear maturation 
stage was classified as germinal vesicle (GV), germinal vesicle breakdown (GVBD), metaphase I 
(MI), or metaphase II (MII) as shown in Figure 5.1. 
 
5.3.4. Experiment 3 –In vitro fertilization following letrozole treatment 
 
5.3.4.1. Animals and treatments 
 
Using the same synchronization protocol as Experiment 2 (Supplementary Fig. 5.2), 
Hereford-cross beef heifers (n=33) selected from a larger group of heifers were used in a 
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crossover design to facilitate treatment with both an LRD and a sham device. As in Experiment 
2, COC were collected by transvaginal follicular aspiration, degenerate COC were discarded, and  
the remaining COC underwent in vitro maturation for 24 hours followed by in vitro fertilization.  
 
5.3.4.2. In vitro maturation, fertilization, and culture 
 
The COC were washed twice in 0.5 mL BO-WASH (IVF Bioscience) and once in 0.25 
mL BO-HEPES-IVM (IVF Bioscience). The grades of COC were pooled by treatment and 
placed in 0.5 mL tubes (Sarstedt, Germany) containing BO-HEPES-IVM (IVF Bioscience) and 
placed in a portable incubator (LabMix; Watanabe Tecnologia Aplcada Ltda, Cravinhos, SP, 
Brazil) at 38.8°C and transported to the laboratory for a maturation time of 21-24 hours.  
After 21-24 hours of in vitro maturation in the incubator, COC were removed from the 
maturation tubes and washed once in a preheated and equilibrated 500 µL well of BO-IVF (IVF 
Bioscience, United Kingdom). The group of oocytes was transferred into a preheated and 
equilibrated 90 µL drop of BO-IVF with 0.5 mL overlaying mineral oil in a four well plate. The 
dish was placed in an incubator (Miri® Benchtop Multi-room Incubator, Esco Medical ApS, 
Denmark) at 38.8°C 5% CO2. A volume of 2 mL of BO-SemenPrep (IVF Bioscience) was 
warmed in two separate 15 mL tubes at 37.0°C. Two 0.25 mL Holstein semen straws (Semex, 
Guelph, ON, Canada) were thawed in 37.0°C water for 1 minute. The straws were dried, and 
each emptied into one of the 15 mL tubes containing the BO-SemenPrep. Tubes containing the 
semen were then centrifuged for 5 minutes at 328 x g. The supernatants were removed until 300 
µL of SemenPrep/sperm solution remained, in which 2 mL of preheated SemenPrep was added; 
the sperm pellet was resuspended and centrifuged for 5 minutes at 328 x g. The supernatant of 
SemenPrep was removed until 300 µL remained, and the 2 sperm solutions were combined and 
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mixed with a pipette. Each 90 µL drop of BO-IVF with COC was fertilized with the prepared 
sperm to attain a final concentration of 2 x 106 sperm/mL. Oocytes and sperm were co-incubated 
at 38.8°C in 5% CO2 for 18 hours. 
Following 18 hours after fertilization, presumptive zygotes were denuded in BO-WASH 
(IVF Bioscience) and washed in one 500 µL well of preheated and equilibrated BO-IVC (IVF 
Bioscience) at 38.8°C in 6% O2, 6% CO2 and 88% N2. Each set of presumptive zygotes were 
placed in a preheated and equilibrated 90 µL drop of BO-IVC with 0.5 mL overlaying mineral oil 
in a four well plate and incubated at 38.8°C in 6% O2, 6% CO2 and 88% N2. Presumptive zygotes 
were evaluated 56 hours after fertilization and classified as 1 cell (unfertilized ova) or cleaved (≥2 
cells). On Day 7, (Day 0=IVF) embryos were evaluated and classified by quality and grade under 
the IETS grading system (Stringfellow and Givens, 2010). 
 
5.3.5. Blood sampling, LC-MS/MS, and radioimmunoassays  
 
Blood samples were taken by jugular venipuncture into heparinized tubes (Vacutainer; 
Becton Dickinson and Co., Franklin Lakes, NJ), subsequently centrifuged (<2 hours after 
collection; 1,500 x g) and plasma was aliquoted into polypropylene tubes and frozen at  -20°C 
until assay. In Experiment 1, blood samples were taken on Day 3 in all groups and twice daily 
from Day 4 to Day 5.5 in the post-LH group. In Experiments 2 and 3, blood samples were taken 
at the time of follicular aspiration. On a subset of heifers (n=6/group) in Experiment 2, frequent 
blood samples were taken for analysis of serum LH and FSH concentrations. Samples were 
collected via indwelling jugular catheters (Bergfelt et al., 1997) taken every 15 minutes for 8 
hours starting immediately following device removal on Day 3. Blood samples were taken by a 
12-mL syringe and placed into 12 x 75 mm Borosilicate glass tubes (Fisher Scientific; Hampton, 
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New Hampshire, USA), allowed to clot, centrifuged (1500 x g, 15 minutes) within 45 minutes of 
collection and serum was placed in polypropylene tubes and frozen at -20°C until analysis. 
Collections were done in two replicates to facilitate use of time. 
Plasma concentrations of letrozole were analyzed by LC-MS/MS using a method that was 
partially validated in Chapter 2. The lower limit of quantification was 1 ng/mL.  
Plasma concentrations of estradiol were determined by radioimmunoassay as previously 
described (Kirby et al., 1997) at Texas A&M University. The intra-assay coefficient of variation 
(CV) was 1.5%, and the minimum detection limit was 0.5 pg/mL.  
Plasma concentrations of progesterone were determined by a solid-phase 
radioimmunoassay (Coat-a-Count; Diagnostic Products Corp., Los Angeles, CA, USA) with a 
minimum detection limit of 0.1 ng/mL. Intra-assay CV for low, medium, and high samples were 
11.9, 6.0, and 5.8%, respectively. Inter-assay CV for low, medium, and high samples were 8.4, 
6.8, and 1.7%, respectively. 
Serum concentrations of LH were analyzed by radioimmunoassay as previously 
described (Honaramooz et al., 2000) with a minimum detection limit of 0.1 ng/mL, and intra-
assay CV for low and high samples were 7.4 and 4.9%, respectively. Serum concentrations of 
FSH were analyzed by radioimmunoassay as previously described (Rawlings et al., 1984) with a 
minimum detection limit of 0.13 ng/mL, and intra-assay CV of 5.6%. 
 
5.3.6. Analysis of LH and FSH 
 
The area under the concentration-time curve until the final serum sample (AUClast) was 
determined using the linear trapezoidal rule for both LH and FSH. Luteinizing hormone pulses 
were identified using the previously described criteria (Goodman and Karsch, 1980): 1) the peak 
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occurred within two samples of the previous nadir, 2) pulse amplitude exceeded assay sensitivity 
(i.e., ≥0.1 ng/mL), and 3) the peak was 2 standard deviations (assay variability) above the 
preceding and following nadirs. Pulse amplitude was defined as the peak concentration 
subtracted from the previous nadir concentration occurring within 2 sample time points.  
 
5.3.7. Statistical analyses 
 
Data were analyzed using SAS Enterprise Guide (Version 4.2; Statistical Analysis 
System Institute Inc., Cary, NC, USA). Continuous data were compared by t-test or 2x2 analysis 
of variance using the PROC MIXED procedure. Analysis of variance for repeated measures was 
used for profile data, and correlations between letrozole in follicular fluid and plasma was done 
with PROC CORR. Proportional data were compared by Chi-square. Data are presented as 
mean±SEM, and significance was defined as P≤0.05.  
5.4. Results  
 
5.4.1. Experiment 1 – Effects of letrozole on the local ovarian environment in cattle 
 
Partial validation for determining the concentration of letrozole in follicular fluid, the 
standard curve and quality control samples all passed and the accuracy and precision for the 
standard curve and quality control samples are shown in Supplementary Tables 5.1 and 5.2. No 
interactions were found between the daily dominant follicle and CL diameter. A tendency 
(P=0.09) for CL treatment was due to slower luteolysis following PGF in the LRD group (Fig. 
5.2). An increase in plasma progesterone concentrations on Day 3, 4, and 4.5 in the LRD group 
led to a treatment (P=0.04) and treatment by day interaction (P=0.003; Fig. 5.3). A treatment 
effect for plasma estradiol concentrations following PGF was attributed to lower (P=0.001) 
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concentrations in the LRD group and no effect of treatment (P=0.22) or interactions (P=0.15) 
were detected between groups for plasma LH concentrations following PGF between groups. On 
Day 3, the LRD group tended (P=0.07) to have higher progesterone than the sham group (Table 
5.1). Plasma estradiol concentrations were increased (P<0.05) on Day 5.5 (post-LH) vs. Day 3 
(pre-LH), and the LRD group had lower (P<0.05) estradiol concentrations on Day 5.5 (Table 
5.1). Similarly, plasma estradiol concentrations in the dominant follicle was greater on Day 5.5 
than 3 and tended (P=0.07) to be lower in the LRD group on Day 3. Follicular fluid 
concentrations of letrozole did not differ (P=0.37) between dominant and subordinate follicles, 
but a pre- vs. post-LH treatment difference was observed (P<0.001; Table 1, Fig. 5.4). There was 
a highly significant positive correlation between plasma and follicular concentrations of letrozole 
at the time of sampling (R=0.9889, P<0.0001).  
Granulosa cells from the post-LH group had low-quality RNA, and we were unable to do 
PCR; therefore, only gene expression data from Day 3 was only assayed (i.e., pre-LH dominant 
and subordinate follicles). No treatment or treatment by follicle interactions was detected for any 
gene expression data. No follicle effects for gene expression from granulosa cells were shown 
for HSD3B, LHCGR, INHBA, FSH, or STAR (Table 2). A follicle effect for gene expression 
was shown for Cyp11A1 (P<0.001), CCND2 (P<0.01), NPR2 (P=0.05), and Cyp19A1 
(P<0.0001; Table 5.2).  
 
5.4.2. Experiment 2 - Frequent blood sampling for gonadotropin release and 
maturation status of COC following letrozole treatment 
 
The serum LH concentration profiles from frequent blood samples from four individual 
heifers given both LRD and sham treatments are shown in Figure 5.5. The LH AUClast was 
greater in LRD vs sham (P<0.01; Table 5.3). Number of LH pulses per 8-hour interval did not 
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differ (P=0.56) between groups, but overall pulse amplitude (P<0.001), LH pulse amplitude >0.5 
ng/mL (P=0.03), and LH pulse amplitude >1 ng/mL (P=0.02) were all greater in the LRD group 
(Table 5.3). Plasma estradiol concentrations were lower on Day 3 in the LRD vs. sham group 
(P=0.03; Table 5.3).  
The total number of follicles aspirated tended (P=0.07) to be fewer in the LRD group, 
and the LRD group tended (P=0.10) to have a greater number of degenerate COC (Table 5.4).  
A total of 35 oocytes (3-12 per group) out of 238 oocytes that were collected were lost 
during the fixing and staining procedure, and data from the remaining oocytes were used for 
statistical comparison of nuclear maturation among groups (Table 5.5). There were more oocytes 
in the MI stage in the sham 24-hour group compared to the other groups (P<0.05). The LRD 24 
hour group yielded a higher proportion of oocytes that were in MII compared to the other groups 
(P<0.05; Table 5.5) and the sham 24-hour group had a higher proportion of oocytes in the MII 
stage compared to both 0-hour groups (P<0.05; Table 5.5).  
 
5.4.3. Experiment 3 - In vitro fertilization following letrozole treatment 
 
One heifer was excluded from the LRD group because the vaginal device was lost during 
treatment. There was a greater number of follicles aspirated (P=0.02), compact regular- (P=0.01) 
and total-COC per heifer (P=0.03) in the sham group (Table 5.6). The COC collection rate was 
higher in the sham vs. LRD group (61.6% vs. 51.7%, respectively; P<0.01; Table 5.6).  
The proportion of cleaved zygotes from total COC submitted to IVF tended to be higher 
in the sham vs. LRD group (P=0.07; Table 5.7). The proportion of blastocysts from total COC 
submitted to IVF was higher in the LRD vs. sham group (P=0.02; Table 5.7). The proportion of 
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embryos from compact COC tended to be higher in LRD vs. sham (P=0.06; Table 5.7). The 
proportion of embryos from cleaved COC was greater in LRD vs. sham (P=0.02; Table 5.7).  
When follicular aspiration data from Experiment 2 and 3 were combined, the mean 
number of compact regular COC (P=0.02), total compact COC (P=0.01) and total COC collected 



















Figure 5. 1. Cattle oocytes at different stages of nuclear maturation: germinal vesicle (GV), 
germinal vesicle break-down (GVBD), metaphase I (MI), metaphase II (MII). Oocytes were 
stained with anti-Lamin AC/DAPI (Experiment 2). Seen visually by green fluorescence 
following Anti-Lamin AC staining is the nuclear envelope (only visible in GV and GVBD) while 
DNA appears with blue fluorescence (DAPI; Diminophenylindole). 













Figure 5. 2. Dominant follicle and corpus luteum (CL) diameter profiles from Experiment 1. 
Ultrasound guided follicular ablation of all follicles ≥ 5mm was done on Day -1 and heifers were 
given a letrozole releasing device (LRD) or a sham device (n=15 and 16/group, respectively). 
Mean ± SEM  
 
  
Figure 5. 3. Plasma progesterone concentrations in heifers (n=7 or 8/group) following device 
removal and 500 µg cloprostenol (PGF) on Day 3 and 100 µg gonadorelin (GnRH) on Day 5 
(Experiment 1). Heifers were given either a 4-day letrozole releasing device (LRD) or a sham 


















































Treatment         0.0882
Day                  <0.001
Trt x Day          0.5845
Dominant follicle diameter
Effect P-value
Treatment         0.2592
Day                  <0.001
Trt x Day          0.5983
































†Among days, values tended to be different (P=0.08); *Among days, values were different 





Figure 5. 4. Follicular fluid concentrations of letrozole assessed by tandem mass spectrometry 
(LC-MS/MS). Follicular fluid was collected by ultrasound-guided follicular aspiration from 
dominant and subordinate follicles on Day 3 or Day 5.5 following ultrasound-guided follicular 



































Figure 5. 5. Individual serum luteinizing hormone (LH; ng/mL) from four heifers that underwent 
frequent blood sampling done every 15 mins for 8 hours beginning immediately after a 4-day 
treatment with either a letrozole-releasing device (LRD) or a sham device. Total area under the 
curve (AUClast) is indicated for each heifer while under each treatment (Experiment 2).  
 
Table 5. 1. Ovarian and endocrine endpoints between heifers given either a 4-day letrozole 
releasing device (LRD) or a sham device in Experiment 1. Mean ± SEM  
 
Day of Sampling  
 Day 3     Day 5.5   
LRD Sham LRD Sham 
Heifers 7 8 8 8 
Dominant follicle diameter (mm) 9.3 ± 0.6 a, x 9.2 ± 0.5 a, x 13.8 ± 1.2 a, y 11.5 ± 0.7 a, y 
CL diameter (mm) 21.0 ± 0.6 a, x 23.0 ± 1.0 a, x 14.7 ± 0.6 a, y 11.4 ± 1.2 b, y 
Plasma progesterone (ng/mL) 4.1 ± 0.9 a, x * 3.0 ± 0.4 a, x * 0.02 ±0.02 a, y 0.00 ± 0.00 a, y 
Plasma estradiol (pg/mL) 1.7 ± 0.3 a, x 2.1 ± 0.4 a, x 1.9 ± 0.3 a. y 3.9 ± 0.6 b, y 
Dominant follicle estradiol (ng/mL) 36.6 ± 14.8 a, x* 107 ± 27.7 a, x* 171 ± 30.4 a, y 190 ± 39.5 a, y 
Subordinate follicle estradiol (ng/mL) 4.1 ± 1.8 a, x * 21.2 ± 6.2 a, x * 20.1 ± 12.9 a, x 11.1 ± 9.1 a, x 
Plasma letrozole (ng/mL) 70.4 ± 3.9 x - 22.9 ± 2.2 y - 
Dominant follicle letrozole (ng/mL) 57.3 ± 3.3 x - 13.6 ± 2.7 y - 
Subordinate follicle letrozole (ng/mL) 52.5 ± 2.1 x - 15.6 ± 1.5 y - 
Heifers underwent ultrasound-guided transvaginal ablation on Day -1 followed immediately by 
insertion of either an LRD or a sham device for 4 days. Heifers either had follicles sampled 



















































#1       AUClast
LRD: 131.6
Sham: 39.4
#2       AUClast
LRD: 229.6
Sham: 87.0
#3       AUClast
LRD: 200.9
Sham: 101.5




device removal on Day 3, followed by GnRH on Day 5, and follicle sampling on Day 5.5 (post-
LH surge). 
Within rows, values with different superscripts between treatments ab or between days xy indicate 





Table 5. 2. Relative gene expression from granulosa cells derived from heifers treated for 4 days 
with either a letrozole releasing device (LRD) or a sham (n=8/group) in Experiment 1. Mean ± 
SEM 
 LRD  Sham  
Gene Dominant Subordinate  Dominant Subordinate  
HSD3B 1.3 ± 0.5 2.3 ± 1.1  1.8 ± 0.6 2.7 ± 1.1  
LHCGR 0.9 ± 0.3 1.0 ± 0.5  2.2 ± 1.2 1.6 ± 0.7  
STAR* 1.5 ± 1.1 5.9 ± 3.0  2.2 ± 1.8 7.7 ± 3.5  
INHBA 0.8 ± 0.2 0.3 ± 0.1  1.1 ± 0.2 0.7 ± 0.5  
FSHR 1.2 ± 0.2 1.8 ± 0.8  1.5 ± 0.7 3.4 ± 1.6  
Cyp11A1 1.2 ± 0.2a 0.3 ± 0.1b  1.4 ± 0.3a 0.6 ± 0.2b  
CCND2 1.3 ± 0.5a 0.2 ± 0.1b  0.9 ± 0.1a 0.3 ± 0.1b  
NPR2 1.3 ± 0.6a 6.0 ± 3.0b  2.1 ± 1.5a 7.4 ± 3.4b  
Cyp19A1 1.2 ± 0.2a 0.3 ± 0.1b  1.4 ± 0.3a 0.6 ± 0.2b  
Genes were normalized to geometric mean of reference genes (Experiment 1). 
abWithin rows, values with no common superscript are different between follicle groups (P≤0.05) 




Table 5. 3. Serum endpoints from frequent blood sampling in heifers (n=6/group) that received 
an intravaginal letrozole releasing device (LRD) or sham device in Experiment 2. Mean ± SEM 
 LRD Sham P-value 
LH AUClast (mins x ng/mL ) 148.2 ± 22.4 74.2 ± 11.8 0.01 
LH pulse amplitude (ng/mL) 0.9 ± 0.1 0.3 ± 0.1 <0.001 
LH pulses per 8 hours  3.3 ± 0.4 3.0 ± 0.3 0.56 
LH pulses >0.5 ng/mL  2.5 ± 1.4 0.8 ± 0.8 0.03 
LH pulses >1 ng/mL  1.5 ± 0.6 0 ± 0 0.02 
FSH AUClast (mins x ng/mL) 136.7 ± 7.6 143.2 ± 14.7 0.70 
CL diameter (mm) 19.7 ± 1.0 20.1 ± 1.1 0.78 
Serum progesterone (ng/mL) 4.8 ± 0.7 4.1 ± 0.3 0.34 
Serum estradiol (pg/mL) 2.5 ± 0.3 4.1 ± 0.5 0.03 
Serum letrozole (ng/mL) 69.3 ± 4.2 - - 
AUClast: cumulative area under the curve; LH: luteinizing hormone; FSH: follicle-stimulating 




Table 5. 4. Mean (± SEM) plasma steroids, follicular and cumulus-oocyte complex (COC) 
endpoints in heifers treated with either a letrozole releasing device (LRD) or a sham vaginal 
device in Experiment 2.  
  LRD Sham P-Value 
Heifers (n) 24 24 - 
Plasma progesterone (ng/mL) 3.7 ± 0.7 3.8 ± 0.3 0.91 
Plasma estradiol (pg/mL) 3.4 ± 0.3 3.5 ± 0.3 0.91 
Dominant follicle size at aspiration (mm) 10.3 ± 0.3 10.1 ± 0.3 0.50 
Total follicles aspirated 10.2 ± 0.9 13.7 ± 1.6 0.07 
Compact good COC 0.5 ± 0.2 1.0 ± 0.3 0.18 
Compact regular COC 2.4 ± 0.6 3.3 ± 0.6 0.28 
Compact COC Total 2.9 ± 0.6 4.3 ± 0.7 0.15 
Expanded COC 0.4 ± 0.2 0.5 ± 0.1 0.52 
Denuded COC 0.7 ± 0.2 1.0 ± 0.3 0.42 
Degenerate COC 0.6 ± 0.3 0.2 ± 0.1 0.10 
COC collected per heifer 4.1 ± 0.8 5.9 ± 0.8 0.24 
COC collection rate (COC/follicles 





Table 5. 5. Nuclear status of oocytes from heifers (n=12 heifers/group) treated with either a 
letrozole releasing device (LRD) or sham device for 4 days in Experiment 2.  
 LRD 0 hours LRD 24 hours Sham 0 hours Sham 24 hours 
GV 25/38 (65.8%)a 1/49 (2%)b 33/52 (63.5%)a 0/64 (0%)b 
GVBD 11/38 (29.9%)a 0/49 (0%)b 16/52 (30.8%)a 2/64 (3.1%)b 
MI 1/38 (2.6%)a 6/49 (12.2%)a 2/52 (3.8%)a 27/64 (42.2%)b 
MII 1/38 (2.6%)a 42/49 (85.7%)b 1/52 (1.9%)a 35/64 (54.7%)c 
Following collection, cumulus-oocyte complexes (COC) in the 0-hour group were immediately 
denuded and fixed with 4% paraformaldehyde. COC in the 24-hour group were placed into 
maturation medium for 24 hours prior to fixation. 
A total of 35 oocytes were lost during the fixing/staining procedure (n=3-12/group); GV: 
germinal vesicle; GVBD: germinal vesicle breakdown; MI: metaphase I; MII: metaphase II 
abc







Table 5. 6. Mean (± SEM) plasma steroids, follicular and cumulus oocyte complex (COC) 
endpoints in heifers treated with either a letrozole releasing device (LRD) or a sham vaginal 
device in Experiment 3. 
  LRD Sham P-Value 
Heifers (n) 32 33 - 
Plasma progesterone (ng/mL ± SEM) 5.0 ± 0.5 4.2 ± 0.3 0.12 
Plasma estradiol (pg/mL ± SEM) 6.4 ± 0.8 6.6 ± 0.6 0.83 
Dominant follicle size at aspiration (mm) 10.1 ± 0.2 10.1 ± 0.2 0.84 
Total follicles aspirated 14.6 ± 0.8 17.9 ± 1.0 0.02 
Compact good COC 1.2 ± 0.2 1.6 ± 0.3 0.28 
Compact regular COC 3.7 ± 0.6 6.3 ± 1.0 0.03 
Compact COC Total 4.9 ± 0.7 7.9 ± 1.0 0.01 
Expanded COC 0.3 ± 0.1 0.5 ± 0.2 0.39 
Denuded COC 2.1 ± 0.3 2.3 ± 0.4 0.72 
Degenerate COC 0.3 ± 0.1 0.3 ± 0.1 0.75 
COC collected per heifer 7.5 ± 0.9 11.0 ± 1.3 0.03 
COC collection rate (COC/follicles 









Table 5. 7. Cleavage and embryo rates following in vitro fertilization on Day 0 in heifers treated 
with a letrozole releasing device (LRD) or a sham vaginal device in Experiment 3.  
 LRD Sham P-value 
Cleavage/total COC 109/177 (61.6%) 167/238 (70.2%) 0.07 
Cleavage/compact COC 109/128 (85.2%) 167/186 (89.8%) 0.22 
Morulae/total COC 28/160 (17.5%) 39/209 (18.7%) 0.77 
Blastocysts/total COC 17/160 (10.6%) 9/209 (4.3%) 0.02 
Embryos/total COC 45/160 (28.1%) 48/209 (23.0%) 0.26 
Embryos/compact COC 45/118 (38.1%) 48/173 (27.7%) 0.06 
Embryos/cleaved COC 45/97 (46.4%) 48/150 (30%) 0.02 
Cleavage was assessed 56 hours after co-culture with sperm and embryo evaluation was done on 
Day 7. 





Table 5. 8. Mean (± SEM) plasma steroids, follicular and cumulus oocyte complex (COC) 
endpoints in heifers treated with either a letrozole releasing device (LRD) or a sham vaginal 
device in Experiment 2 and 3 combined. 
  LRD Sham P-Value 
Heifers (n) 56 57 - 
Plasma progesterone (ng/mL) 4.5 ± 0.4 4.0 ± 0.2 0.34 
Plasma estradiol (pg/mL) 5.2 ± 0.5 5.3 ± 0.4 0.80 
Dominant follicle size at aspiration (mm) 10.2 ± 0.2 10.1 ± 0.2 0.54 
Total follicles aspirated 12.7 ± 0.7 16.1 ± 1.0 <0.01 
Compact good COC 0.9 ± 0.2 1.4 ± 0.2 0.10 
Compact regular COC 3.1 ± 0.4 5.0 ± 0.6 0.02 
Compact COC total 4.0 ± 0.5 6.4 ± 0.7 0.01 
Expanded COC 0.3 ± 0.1 0.5 ± 0.1 0.28 
Denuded COC 1.5 ± 0.2 1.7 ± 0.3 0.51 
Degenerate COC 0.4 ± 0.1 0.3 ± 0.1 0.27 
COC collected per heifer 6.3 ± 0.6 8.8 ± 0.9 0.02 
COC collection rate (COC/follicles 

















Supplementary Figures and Tables 
 
 
Supplementary Figure 5.1. Experimental treatment and sampling timeline (Day 0 = day of 
ovarian follicular wave emergence). At the time of ultrasound-guided transvaginal ablation, 
heifers were given either a 4-day letrozole releasing device (LRD) or a sham device. Follicle 
sampling was done on Day 3 (pre-luteinizing hormone [LH] surge) or Day 5.5 (post-LH surge) 
in Experiment 1 (4 groups; n=7 to 8/group). PGF: 500 µg cloprostenol; GnRH: 100 µg 
gonadorelin; Ov: Ovulation 
 
 
Supplementary Figure 5.2. Experiment timeline for Experiments 2 and 3. On Day -1, heifers 
underwent ultrasound-guided transvaginal ablation of follicles ≥5 mm to induce wave emergence 
and were given either a 4-day letrozole releasing device or a sham device. Devices were removed 
on Day 3 and on Day 4 heifers underwent ultrasound-guided transvaginal oocyte aspiration. Both 
experiments utilized a crossover design to facilitate individual heifers (n=24 to 33) receiving 
both treatments at different times.  
PGF: 500 µg cloprostenol; GnRH: 100 µg gonadorelin 
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Supplementary Table 5.1. Precision and accuracy data from LC-MS/MS derived standard curve 
for letrozole in bovine follicular fluid.  
Concentration added (ng/mL) Concentration found (mean ± SD; ng/mL) Precision (%) Accuracy (%) 
1 (LLQ) 0.96 ± 0.14 14.3% 96.5% 
2 2.01 ± 0.26 13.0% 100.5% 
4 4.25 ± 0.24 5.6% 106.3% 
8 7.78 ± 0.61 7.9% 97.3% 
16 16.37 ± 1.71 10.5% 102.3% 
32 31.13 ± 1.40 4.5% 97.3% 
64 62.27 ± 4.97 8.0% 97.3% 
128 126.67 ± 2.08 1.6% 99.0% 
256 260.33 ± 7.77 3.0% 101.7% 
Each standard curve was independently run on 3 separate days (n=3/sample; lower limit of 
quantification (LLQ) n=18). 
 
Supplementary Table 5.2. Precision and accuracy data from LC-MS/MS method for quality 
control samples of letrozole in bovine follicular fluid.  
Concentration added (ng/mL) Concentration found (mean ± SD; ng/mL) Precision (%) Accuracy (%) 
3 2.94 ± 0.55 18.6% 98.3% 
12 10.87 ± 1.57 14.3% 90.6% 
120 114.47 ± 17.93 15.7% 95.4% 
Each standard curve was independently run on 3 separate days (n=18/sample). 
 
 
Supplementary Table 5.3. Reference genes, primer sequences and polymerase-chain reaction 
efficiency. 
Gene Accession no. Oligo Primer sequence (5’ to 3’) Amplicon size (BP) 
Efficiency 
(%) 
GAPDH NM_001034034.2 Forward Reverse 
ACCCAGAAGACTGTGGATGG 
CAACAGACACGTTGGGAGTG 178 73.2 
RPL19 NM_001040516.2 Forward Reverse 
GCCAACTCCCGTCAGCAGA 
TGGCTGTACCCTTCCGCTT 154 100.3 
RPLPO NM_001012682.1 Forward Reverse 
GGCGACCTGGAAGTCCAACT 
CCATCAGCACCACAGCCTTC 149 97.0 
EIF2B2 NM_001015593 Forward Reverse 
CATGAGATGGCAGTCAATTTGT 
CTTGAACATAGGAGCACAGACG 219 95.3 
H2AFZ NM_174809.2 Forward Reverse 
GGTAAGGCTGGGAAGGACTC 
CGGTGAGGTACTCCAGGATG 181 99.7 
B2M XM_002691119.4 Forward Reverse 
GCGTCCTCCAAAGATTCAAG 
CAGGTCTGACTGCTCCGA 154 95.8 
SF3A1 NM_001081510 Forward Reverse 
TGTGTCCCTCTTGCTGAGTTT 
ATTCCTGGTTTCACGTCTCCTA 194 116.4 
RFN20 NM_001081587 Forward Reverse 
TCCAGGTTCTCCTCGCTAATAC 
GAGCCTGAAGAAGAGGTTCAAA 153 95.8 
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Supplementary Table 5.4. Genes of interest, primer sequences and polymerase-chain reaction 
efficiency.  
Gene Accession no. Oligo Primer sequence (5’ to 3’) Amplicon size (BP) 
Efficiency 
(%) 
HSD3B XM_010803103.3 Forward Reverse 
GCTAATGGGTGGGCTCTGAA 
TGATTGGTCAGGATGCCGTT 140 101 
LHCGR XM_015473421 Forward Reverse 
GCTAATGCCTTTGACAACCTCC 
TTGTAAACGCTCCAGCCTCA 91 98.2 
STAR NM_174189.3 Forward Reverse 
GAGATGGCTGGAAGAAGGTG 
GCCAGATAACCCCATCTCAA 101 91.4 
INHBA NM_174094.4 Forward Reverse 
CTTCAGCTGCTCCTCTTGCT 
TGACTCCAGGATCTCCACCT 157 92.8 
FSHR XM_024998263.1 Forward Reverse 
GCCAAAGGATTTGACGTGAT 
GTGATGGCCAGGATGCTAAT 167 100 
Cyp11a1 NM_176644.2 Forward Reverse 
CAGTGTCCCTCTGCTCAACCTCC 
TTATTGAAAATTGTGTCCCATGCG 99 96.8 
Cyp19a1 NM_174305.1 Forward Reverse 
GTGTCCGAAGTTGTGCCTATT 
GGAACCTGCAGTGGGAAATGA 148 91.1 
NPR2 XM_024995444.1 Forward Reverse 
CTGCTCCTAAGCTGGGTGAGT 
GGTCATCTGTGCGAGCAT 99 95.2 
CCND2 XM_024992177.1 Forward Reverse 
TGAGGAGCAGAAGTGCGAAG 






In Experiment 1, letrozole treatment affected luteolysis as evinced by the larger CL and 
higher plasma progesterone concentrations following PGF treatment and device removal. As the 
terminal half-life of plasma letrozole in heifers has been reported to be 33 hours (Yapura et al., 
2013) letrozole would be expected to be present in the circulation inhibiting estradiol production 
for at least that long after LRD removal. The low concentrations of plasma estradiol may explain 
the reduced rate of luteolysis in the LRD group. In cattle undergoing natural luteolysis (i.e., 
approximately 15 to 18 days after ovulation), exogenously administered estradiol has been 
shown to be associated with decreased plasma progesterone and increased plasma prostaglandin 
metabolite concentrations (Araujo et al., 2009). The estradiol receptor in the endometrium is 
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stimulated by endogenous estradiol, which in turn stimulates oxytocin receptor synthesis in the 
endometrium (Robinson et al., 2001). Oxytocin releases from the posterior pituitary and CL 
binds to the oxytocin receptor and PGF is released from the endometrium leading to the 
luteolytic cascade (Silvia et al., 1991; Mann et al., 2001). In the present study, luteolysis was 
induced with the prostaglandin F2a analog, cloprostenol, which has a half-life of approximately 3 
hours in cattle (Reeves, 1978). It may be hypothesized that the exogenously administered 
cloprostenol induced oxytocin release from the CL, but a lack of oxytocin receptors in the 
endometrium, because of the reduced estradiol environment, prevented the endogenous release 
of PGF. As estradiol began to increase slowly after removal of the LRD, oxytocin receptors were 
likely synthesized in the endometrium leading to the production of endogenous PGF and 
eventual luteolysis. Frequent blood sampling for plasma progesterone and prostaglandin 
metabolite following PGF in LRD-treated heifers is needed to test this hypothesis. 
Interestingly, in the present study, letrozole concentrations were highly correlated in 
plasma and follicular fluid, although letrozole concentrations were lower in the follicular fluid 
portion. To our knowledge, this is the first study reporting letrozole concentrations in follicular 
fluid. Exogenous drugs or metabolites such as cotinine (a metabolite of nicotine) in women have 
been shown to be highly correlated between follicular fluid and serum. (Younglai et al., 2002). 
Serum and follicular fluid concentrations of steroids do not correlate in women, regardless of age 
(Smitz et al., 2007; von Wolff et al., 2017), although in the present study, plasma and follicular 
fluid concentrations of estradiol were correlated (r=0.51; P<0.01).  
In the present study, there were no differences between treatments in expression of any of 
the genes analyzed in granulosa cells. Previous studies in letrozole-treated mice showed an 
upregulation of Cyp19 and FSHR, but no differences in LHR expression (Kauffman et al., 2015). 
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The idea that concentrations of androgens positively correlate to FSHR expression in granulosa 
cells (Weil et al., 1999), has been used to improve ovarian stimulation in women combining 
letrozole and FSH (Garcia-Velasco et al., 2005). The use of letrozole in combination with FSH 
did not increase the superovulatory response in cattle (Chapter 4), which is consistent with a lack 
of difference in mRNA expression in FSHR in the present study. It may be argued that the dose 
of letrozole given did not affect gene expression and an increased dosage may be expected to 
elicit an effect. It has been reported that a single 2.5 mg letrozole tablet taken orally resulted in 
peak circulating concentrations of letrozole of approximately 40 ng/mL in healthy 
postmenopausal women (Vanol et al., 2016). Circulating concentrations of letrozole in women 
who took repeated 2.5 mg per day for 6 months ranged from 57 to 290 ng/mL (Precht et al., 
2012). Therefore, the plasma letrozole concentrations (mean 70 ng/mL) obtained in heifers 
during this study fall within range used to reduce estrogen levels for breast cancer treatment and 
ovarian stimulation in women (Mitwally and Casper, 2004); a prolonged elevation of 
intraovarian androgens may be needed to elicit a change in FSHR gene expression.  
Treatment with letrozole decreased estradiol and increased LH pulsatility during the 
frequent 8-hour sampling period, although no changes were observed in serum FSH 
concentrations. This lack of difference in serum FSH concentrations following letrozole 
treatment confirms that inhibin may be the primary regulator of FSH secretion and FSH secretion 
does not differ following release of the negative feedback on the hypothalamus, but LH secretion 
is regulated by both estradiol and progesterone (Bergfeld et al., 1996; Gregory and Kaiser, 2004). 
In the present study, plasma progesterone concentrations were increased in the LRD group, and 
the concentrations of progesterone did not result in a decreased LH AUC. Therefore, it may be 
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hypothesized that estradiol may play a more inhibitive role on the LH secretory pattern than 
progesterone in cattle (reviewed in Price et al., 1999).  
The high amplitude of LH pulsatility did not cause premature maturation in the LRD 0-
hour maturation group, which did not support our hypothesis in Experiment 2. On the contrary, 
following 24 hours of maturation, the LRD group had the highest proportion of oocytes in the 
MII stage (Table 5.5). Similarly in women, co-stimulation with LH and FSH led to a higher 
number of metaphase II stage oocytes following in vivo induced maturation compared to FSH 
alone (De Placido et al., 2005). Although the increased LH amplitude may have increased oocyte 
maturation, it could be detrimental in early follicle development. At the time of oocyte 
aspiration, the number of follicles aspirated, and total number of oocytes recovered was lower in 
the LRD group. Our experimental protocol utilized transvaginal ablation of all ovarian follicles 
³5 mm in diameter to induce wave emergence approximately 1 day later (Bergfelt et al., 1997). 
Immediately following ablation of follicles (removal of inhibin and estradiol), FSH is expected 
to surge, but in our protocol, an LRD was inserted, and LH pulse amplitude may have increased. 
The dependency of follicles ≤7 mm on FSH is well characterized (Adams et al., 1992b), but the 
pulse frequency of LH during early follicular growth in cattle is not well defined. In cattle, 
maximal concentrations of FSH and LH in the circulation have been reported to occur 8- and 24 
to 32-hours, respectively after follicle wave emergence (Ginther et al., 1998). Therefore, this lag 
in maximal LH concentrations may play a role in early follicular development, and high LH 
during this period may cause atresia in small follicles. Frequent blood samples would need to be 
taken at the time of device insertion to better understand whether this FSH to LH relationship 
exists during early follicle development.  
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In summary, despite estradiol concentrations that were decreased following treatment 
with an intravaginal LRD, no differences were detected in granulosa cell gene expression 
(Experiment 1). Treatment with an LRD increased pulse amplitude of plasma LH, but not FSH, 
and resulted in the highest proportion of COC reaching the metaphase II stage following 24 
hours of in vitro maturation compared to all other groups (Experiment 2). Finally, letrozole 
treatment did not impact in vitro fertilization rates in heifers (Experiment 3). Future studies 
assessing the impact of LH on early follicle development should be done.  
 
5.6. Acknowledgements  
 
We thank Laurence Boligon de Araujo and David Moore for assistance in COC 
collections. CJ was supported through the Western College of Veterinary Medicine’s 
Interprovincial Undergraduate Student Research program and Boehringer Ingleheim. Special 
thanks to Ky Pohler, Sydney Reese and Gessica Franco from Texas A&M University for and 
Susan Cook, Kim Tran, and Danielle Carriere at the University of Saskatchewan for assistance in 
running radioimmunoassays. The study was supported by grants from Alberta Agriculture and 
Forestry, Venco Animal Health (a subsidiary of Dechra Pharmaceuticals PLC), and the Natural 
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Relationship of this study to the dissertation 
In Chapter 5, we revealed that there was no deleterious effect of letrozole treatment on the ability 
of the oocyte to undergo in vitro maturation, fertilization, and culture. We investigated the 
interval to ovulation and developed a fixed-time artificial insemination protocol following 
treatment with a letrozole releasing device developed in Chapter 2. We hypothesized that 
ovulation and P/AI would be higher following letrozole treatment compared to two other fixed-
time artificial insemination protocols. 
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Experiments were done to determine the interval to ovulation following a 4-day letrozole 
treatment (Experiment 1), pregnancy per AI (P/AI) following letrozole treatment and fixed-time 
artificial insemination (FTAI) in a field trial (Experiment 2), and the effect of presynchronization 
with prostaglandin F2a (PGF) prior to letrozole treatment with two different letrozole releasing 
devices (LRD; Experiment 3) on P/AI. In Experiment 1, nulliparous heifers and lactating beef 
cows (n=30/parity) at random stages of the estrous cycle were given an intravaginal LRD on Day 
0 and PGF on Day 4. Cattle were then assigned randomly and given 100 μg GnRH at 48- or 60-
hours after PGF, or no GnRH (n=10/parity/treatment). Transrectal ultrasonography was done 
every 8 hours from Day 6 until ovulation. In Experiment 2, nulliparous heifers (n=71) and 
lactating beef cows (n=126) at random stages of the estrous cycle were assigned randomly to one 
of three FTAI protocols, 1) a 4-day LRD, followed by PGF at LRD removal and GnRH 
concurrently with FTAI at 48 hours after PGF, 2) 2.5 mg estradiol-17b plus 50 mg progesterone 
(E2P4) in oil and a progesterone releasing intravaginal device (PRID) for 7 days, PGF at device 
removal and GnRH concurrently with FTAI at 60 hours after PGF or 3) a modified 5-day 
Cosynch plus PRID, with PGF given at device removal and GnRH concurrently with FTAI at 72 
hours after PGF. All cattle were inseminated with frozen-thawed semen and had their ovaries 
examined by transrectal ultrasonography from FTAI until ovulation. In Experiment 3, 
nulliparous heifers (n=26) at random stages of the estrous cycle were assigned randomly to either 
PGF on Day -8 (Presynchronization) or no PGF (Control). On Day 0, heifers were again 
assigned randomly and given either a newly designed X-LRD or a T-LRD for three days. 
Devices were removed and PGF was given on Day 3 followed by GnRH and FTAI on Day 5 (48 
hours later). On Days 0 and 3 vaginal irritation was assessed visually and assigned to a 5-point 
 121 
scale where 1 was no irritation and 5 was widespread hyperemia with mucosal erosions. Blood 
sampling was done at 0, 2, 4, 6, 8, 10, 12 hours, and daily until Day 5 following device 
placement on a subset of heifers (n=10/group) to determine plasma letrozole concentrations. 
Binary data were compared by GLIMMIX and continuous data by ANOVA or t-test. In 
Experiment 1, there was no difference in the proportion of cattle that ovulated following 
letrozole treatment (overall 54/60 [90%]). Cattle in the GnRH 48-hour group ovulated earlier 
(P=0.03) than either the GnRH 60-hour or no-GnRH groups. Cows in the GnRH 48-hour group 
ovulated more synchronously (P<0.05) than either the Cow 60-hour or Heifer 48-hour groups. In 
Experiment 2, the dominant follicle was larger (P<0.001) and the P/AI was lower in the LRD 
group compared to both the E2P4 and PRID groups (14/69 [20.3%] vs. 35/58 [60.3%] and 31/69 
[44.9%], respectively; P<0.001). In Experiment 3, the X-LRD resulted in higher (P<0.0001) 
plasma letrozole concentrations during treatment and decreased (P=0.14) vaginal irritation score 
numerically on Day 3 compared to the T-LRD. The P/AI did not differ (P=1.0) for 
synchronization treatment protocol or between devices. In summary, although ovulation 
synchrony was achieved following letrozole treatment, the LRD group had the lowest P/AI 
compared to other estrus synchronization protocols. The X-LRD improved letrozole release and 
was considered appropriate for future studies for understanding the interval to estrus and 









The aromatase inhibitor, letrozole, was initially developed for the suppression of tumor 
growth during breast cancer treatment because it prevented estrogen synthesis (Iveson et al., 
1993). Letrozole reversibly binds to the P450 heme group of the aromatase enzyme. In addition, 
letrozole was found to be more effective in inducing ovulation in women with polycystic ovarian 
syndrome (PCOS) than the selective estrogen receptor modulator, clomiphene citrate (Mitwally 
and Casper, 2001). Letrozole is used in combination with human menopausal gonadotropin 
(hMG) for controlled ovarian stimulation in women with PCOS. An increase in fertility with 
letrozole and hMG co-treatment compared to hMG alone was attributed to lower estradiol levels 
and increased receptivity of the endometrium (D’Amato et al., 2018).  
Currently, two synchronization strategies are employed worldwide for fixed-time 
artificial insemination (FTAI) in cattle; gonadotropin releasing hormone(GnRH)- and steroid-
based protocols (Bo et al., 1993; Pursley et al., 1995). The efficacy of GnRH-based protocols is 
dependent on the ability of the first administration of GnRH to induce ovulation of a dominant 
follicle and synchronize the emergence of a new follicular wave. When GnRH is given at 
random stages of the estrous cycle, 44 to 54% of dairy cows ovulated, resulting in a failure to 
synchronize follicle wave emergence in half of the cows (Bello et al., 2006; Colazo et al., 2009). 
To increase the proportion of ovulation in response to the first GnRH administration, 
presynchronization with prostaglandin (PGF) has been used before initiating the GnRH-based 
protocol (Presynch; Moreira et al., 2001) and successive GnRH-based protocols (Double 
Ovsynch; Souza et al., 2008). Steroid-based protocols involve giving estradiol and progesterone 
to induce follicle wave emergence approximately 4 days later (Bo et al., 1993), followed by 
luteolysis induced by PGF and FTAI. Steroid-based protocol are short in duration and effective; 
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>11 million FTAI treatments were administered in Brazil in 2016 utilizing this technology 
(Mapletoft et al., 2018). With increasing consumer concern over steroid use in food-producing 
animals, estradiol is prohibited for use in estrus synchronization protocols in food producing 
animals in the United States, Europe, and in milk-producing animals in Australia and New 
Zealand, but can still be obtained by veterinarian prescription in Canada (Lane et al., 2008; 
AETA, 2019). 
To fill this void in commercially approved protocols, letrozole has been investigated in 
our laboratory for ovarian synchronization in cattle (Yapura et al., 2018). Letrozole is delivered 
through a novel intravaginal device ((Yapura et al., 2015); Chapter 2) that has been used for 
ovulation induction (Yapura et al., 2016) and co-superstimulation with follicle-stimulating 
hormone ((Zwiefelhofer et al., 2019); Chapter 4). We have characterized follicular fluid 
concentrations of letrozole in cattle treated with an intravaginal letrozole releasing device (LRD) 
and the subsequent decline of estradiol production in both dominant and subordinate follicles 
(Chapter 5). Letrozole-treatment in cattle has been shown to have no deleterious effects on 
granulosa cell function, nuclear maturation of the oocyte, the ability of oocyte to undergo in vitro 
fertilization (Chapter 5). In an early estrus synchronization study (Yapura et al., 2016), 92% of 
heifers ovulated following a 4-day regimen of letrozole treatment, with PGF at device removal 
and GnRH concurrently with FTAI 24 hours later. However, only 3 of 43 became pregnant 
following FTAI (Yapura, 2015). The reason behind the low P/AI may have been due to the short 
interval from PGF to GnRH (24 hours) resulting in short-lived corpora lutea (CL) following  
ovulation as previously described (Rantala et al., 2009).  
Intravaginal administration of letrozole was found to be effective because of continuous 
prolonged drug release and ease of delivery ((Yapura et al., 2015); Chapter 2). Giving a drug 
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over multiple days by im or iv administration is labor intensive and can be avoided by utilization 
of intravaginal drug delivery. However, mucopurulent discharge is commonly observed at the 
time of intravaginal device removal in cattle (Walsh et al., 2008; Yapura et al., 2015). No 
differences in P/AI have been reported in cattle with or without evidence of mucopurulent 
discharge following removal of an intravaginal progesterone device (Villarroel et al., 2004), but 
intravaginal devices have been associated with increased vaginal pH and decreased fertility 
following natural breeding in sheep (Martinez-Ros et al., 2018). As cattle producers may 
perceive vaginal discharge following device removal as undesirable in estrus synchronization 
protocols, minimizing vaginitis may make an intravaginal device more attractive for commercial 
use.   
We hypothesized that letrozole-based synchronization protocols for FTAI will result in a 
higher P/AI compared to commonly used protocols, and a newly developed LRD will increase 
letrozole release and decrease vaginitis. The objectives of these studies were to 1) determine the 
interval to ovulation following letrozole treatment, 2) compare P/AI following letrozole 
treatment compared to other commonly used estrus synchronization protocols and 3) develop a 
new intravaginal letrozole-releasing device to maximize letrozole release and minimize vaginitis. 
 
6.3. Materials and Methods 
 
 Procedures were approved by the University of Saskatchewan’s Animal Research Ethics 
Board in accordance with the guidelines of the Canadian Council on Animal Care. Cattle were 
housed at the University of Saskatchewan’s Livestock and Forage Centre of Excellence Goodale 
Farm in outdoor pens. Cattle were fed a mixed ration consisting mainly of barley silage and had 
ad libitum access to alfalfa hay and water. Experiments 1 utilized nulliparous Hereford-cross 
 125 
heifers (n=30; weight: 395 ± 8 kg; BCS: 3.3 ± 0.06 on 1-5 scale (Richards et al., 1986) and 
lactating beef cows (n=30; weight: 640 ± 15 kg; BCS: 2.9 ±0.08) >42 days postpartum during the 
month of May. In Experiment 2, sexually mature, nulliparous, Hereford-cross heifers (n=71; 
weight: 438 ± 6 kg; BSC: 3.2 ± 0.2) and lactating beef cows (>42 days postpartum; n=126; 
weight: 666 ± 9 kg; BCS: 3.2 ± 0.03) were used during the months of June and July. Experiment 
3 was conducted during the months of August and September and utilized non-pregnant, 
nulliparous heifers (n=26) previously used in Experiment 2. 
 
6.3.1. Experiment 1 – Interval to ovulation following letrozole treatment in beef 
heifers and cows 
 
 Cattle were given an LRD at random stages of the estrous cycle (Day 0) for 4 days 
followed by a luteolytic dose of PGF (500 µg cloprostenol im; Estrumate, Merck, Kirkland, QC) 
on Day 4. Following PGF, cattle were assigned randomly to one of three groups and given 
GnRH (100 µg gonadorelin im; Fertiline, Vetoquinol N.A., Lavaltrie, QC) at 48- (Day 6) or 60-
hours after device removal and PGF (Day 6.5) or no GnRH (n=10 cows and 10 heifers per group; 
Figure 6.1). Beginning on Day 6, transrectal ultrasonography (7.5 MHz linear array transrectal 
probe; MyLab Alpha; Esaote North America, Fishers, IN) was done at 8-hour intervals for 4 
days or until ovulation was detected to measure the diameter of the ovulatory follicle and 
determine ovulation. Daily ultrasonography was done for 8 days following ovulation to assess 




6.3.2. Experiment 2 - Fixed-time artificial insemination concurrently with GnRH at 
48 hours after LRD removal 
 
 At random stages of the estrous cycle cattle were assigned randomly to one of the 
following three groups (Figure 6.2): 1) a 4-day LRD, followed by PGF at LRD removal and 
GnRH concurrently with FTAI at 48 hours after PGF (n=46 cows, 23 heifers), 2) 2.5 mg 
estradiol-17b plus 50 mg progesterone (E2P4) in oil (Bo et al., 1994) and a progesterone 
releasing intravaginal device (PRID; Vetoquinol N.A., Lavaltrie, QC, Canada) for 7 days, PGF at 
device removal and GnRH concurrently with FTAI at 60 hours after PGF (n=40 cows, 18 
heifers) or 3) a modified 5-day Cosynch plus PRID with no GnRH given at PRID insertion, PGF 
given at device removal and GnRH concurrently with FTAI at 72 hours after PGF (n=39 cows, 
30 heifers). Cattle were FTAI with frozen-thawed semen as part of another experiment (Yang et 
al., unpublished). The ovaries were examined for ovulatory follicle diameter by transrectal 
ultrasonography on the day of PGF and AI, and daily for two days following AI until ovulation 
was detected (Day 0). A subgroup of cows (n=20/group) underwent transrectal ultrasonography 
for CL diameter on Day 10 and 20. Pregnancy diagnosis was done 28 days after ovulation by 
transrectal ultrasonography to confirm the presence of an embryo proper with a heartbeat.    
 
6.3.3. Experiment 3. Development of a new intravaginal LRD  
 
 At random stages of the estrous cycle, heifers were assigned randomly and given PGF on 
Day -8 (Presynchronization; Day 0=device insertion) or no presynchronization (Control) and one 
of two letrozole releasing devices (a newly designed LRD (X-LRD; Figure 6.3A) or the LRD 
designed in Chapter 2 (T-LRD; Figure 6.3B) on Day 0. Heifers in the presynchronization group 
were given a luteolytic dose of PGF im on Day -8. In all groups, the LRD were inserted on Day 0 
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and removed on Day 3 (Figure 6.4). At that time, heifers were given PGF and fitted with an 
electronic estrus detection sensor (Heatwatch, Cow Chips, Manalapan, NJ, USA) attached to the 
tailhead to record the interval to estrus. On Day 5 (i.e., 48 hours after PGF), heifers were given 
GnRH (100 µg gonadorelin im; Fertiline, Vetoquinol N.A., Lavaltrie, QC, Canada) concurrently 
with FTAI with frozen-thawed semen (Semex, Guelph, ON, Canada). The ovaries were 
examined daily by transrectal ultrasonography to monitor follicular and luteal dynamics from 
Day 0 to 5 and twice daily from Day 5 until ovulation was detected. Vaginoscopy was done on a 
subgroup of heifers (n=5 per treatment group/4 total groups) on Day 0 and Day 3 to record the 
appearance of the vaginal wall, the nature of the vaginal secretions, and to collect a vaginal 
fornix swab sample for cytology. The cytological samples were taken from around the cervical 
os using a sterile, double-guarded culture swab and a disposable vaginal speculum. The culture 
swab was then smeared onto a microscope slide that was air-dried, stained with hematoxylin and 
eosin and examined by wide-field microscopy (20x magnification) for the number of neutrophils 
per 100 cells. The gross appearance of the vaginal wall was scored on a 5-point scale where 1 
was no irritation and 5 was widespread hyperemia with mucosal erosions. The vaginal discharge 
was also scored on a 5-point scale where 1 was clear mucus, 2-3 mucopurulent, and 5 was frank 
purulent material. The interval to onset of estrus (hours from PGF to onset of estrus) was derived 
from HeatWatch software. The return to estrus rate was determined by the number of heifers that 
returned to estrus within 10 days of FTAI. Pregnancy diagnosis was done 28 days after ovulation 




6.3.4. Blood sampling, radioimmunoassays, and LC-MS/MS  
 
 In all experiments, blood samples were taken by jugular venipuncture into heparinized 
tubes (Vacutainer; Becton Dickinson and Co., Franklin Lakes, NJ) which were centrifuged in <2 
hours of collection at 1,500 x g, and plasma was aliquoted into polypropylene tubes and frozen at 
-20°C until assay. In Experiment 1, blood samples were taken on Days 0, 3, 4, 5, 6, and 3x per 
day from Days 6 to 7.3. Blood samples were then taken 2, 4, 6, and 8 days following post-
treatment ovulation. In Experiment 2, blood samples were taken from a subset of cows 
(n=20/group) at the time FTAI, ovulation, and 10 and 20 days post-ovulation. In Experiment 3, 
blood samples were taken daily from Day 0 to 5. On a subset of heifers (n=5/group) frequent 
blood samples were taken for plasma letrozole at 0, 2, 4, 6, 8, 10, 12 hours after device 
placement.  
 Plasma concentrations of estradiol were determined by radioimmunoassay as previously 
described (Kirby et al., 1997) at Texas A&M University. The minimum detection limit was 0.5 
pg/mL, and the intra- and inter-assay coefficients of variation (CV) were 2.4 and 3.9%, 
respectively.  
 Plasma concentrations of luteinizing hormone (LH) were determined by 
radioimmunoassay as previously described (Rawlings et al., 1984). The minimum detection limit 
was 0.1 ng/mL and intra-assay CV for low and high samples were 7.3 and 6.0%, respectively.  
 Plasma concentrations of progesterone (P4) were determined using a solid-phase 
radioimmunoassay (Coat-a-Count; Diagnostic Products Corp., Los Angeles, CA, USA) with a 
minimum detection limit of 0.1 ng/mL. Intra- assay CV for low, medium, and high samples were 
9.0, 6.8, and 3.2%, respectively. Inter-assay CV for low, medium and high samples were 14.3, 
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8.4 and 17.4%, respectively. Plasma concentrations of letrozole were analyzed by LC-MS/MS as 
previously described (Chapter 2). 
6.3.5. Statistical Analyses: 
 
Data were analyzed using SAS Enterprise Guide (Version 4.2; Statistical Analysis 
System Institute Inc., Cary, NC, USA). Numerical data (interval to ovulation and estrus, 
residuals, CL or dominant follicle diameter and steroid levels at defined timepoints, neutrophil 
counts, and vaginal discharge/irritation scores) were analyzed by 2x3 (Experiment 1 and 2) or 
2x2 (Experiment 3) ANOVA. Serial data (CL or dominant follicle diameter profiles and steroid, 
hormone and letrozole profiles) were analyzed by analysis of variance for repeated measures 
using the MIXXED procedure. Binary data (ovulation and return to estrus rate, and P/AI) were 
analyzed by the GLIMMIX procedure using binary distribution and link logit function. If an 
interaction was detected, post hoc analyses were done using least significant difference. 





6.4.1. Experiment 1 – Interval to ovulation following letrozole treatment in beef 
heifers and cows 
 
 There was no difference between parity or GnRH treatment for ovulation rate within 120 
hours after PGF (total 54/60 [90%]; Table 6.1). An effect of GnRH on the interval from PGF to 
ovulation was attributed to a shorter interval in the 48-hour group compared to the 60-hour and 
no GnRH groups (P=0.03; Table 6.1). A tendency (P=0.08) for variation in the interval to 
ovulation was due to decreased variation in the cow GnRH 48-hour GnRH group compared to 
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both the cow 60-hour GnRH and heifer 48-hour GnRH groups (P<0.05; Table 6.1). Cattle in the 
no GnRH group ovulated a larger (P<0.01) follicle than either the 48- and 60-hour GnRH groups 
(Table 6.1). An effect of GnRH treatment (P<0.001) on plasma estradiol concentrations was due 
to lower plasma estradiol during treatment in the heifer 60-hour GnRH group (Fig. 6.5). An 
interaction (P<0.001) for GnRH treatment by day for plasma estradiol in heifers was detected, 
and individual day comparisons are shown in Fig. 6.5. No differences were detected for plasma 
estradiol concentrations in cows (Fig. 6.6), plasma LH in heifers or cows, plasma progesterone 
following post-treatment ovulation in heifers (Fig. 6.7a), or CL diameter following post-
treatment ovulation in cows (Fig. 6.8b). A GnRH treatment-by-day interaction (P=0.001) was 
detected for the CL diameter following post-treatment ovulation in heifers attributed to a 
decreased diameter in the 60-hour GnRH group 8 days after ovulation (Fig. 6.7b). A GnRH 
treatment-by-day interaction (P<0.01) was detected for plasma progesterone following post-
treatment ovulation in cows. The interaction was due to increased plasma progesterone 4-days 
following ovulation in the 60-hour GnRH group vs. the 48-hour GnRH group (P<0.05; Fig. 
6.8a).  
 
6.4.2. Experiment 2 - Fixed-time artificial insemination concurrently with GnRH at 
48 hours after LRD removal 
 
 The dominant follicle at device removal was larger (P<0.001) in the LRD vs. E2P4 and 
PRID groups (Table 6.2) as well as larger (P<0.001) in the cow vs. heifer groups (Table 6.2). 
The ovulatory follicle on the day of FTAI was larger (P<0.001) in the LRD and E2P4 groups 
compared to PRID groups (Table 6.2) and the heifer LRD group had the largest ovulatory follicle 
which led to a significant interaction of parity by FTAI protocol (P=0.05). No differences were 
detected between FTAI protocols for plasma progesterone (P=0.91) or estradiol (P=0.97) on the 
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day of AI (Table 6.2). Similarly, no differences for parity (P=0.99) or FTAI protocol (P=0.93) 
were detected for the proportion of cattle that ovulated following FTAI (Table 6.2). A tendency 
(P=0.08) for a greater proportion of animals ovulated before FTAI in the LRD and PRID group 
than the E2P4 group (Table 6.2). A greater (P=0.02) proportion of animals ovulated by 24 hours 
after FTAI in the E2P4 group than the LRD and PRID group (Table 6.2). The E2P4 group 
resulted in a longer (P=0.04) interval to ovulation compared to the LRD and PRID groups (Table 
6.2). The interval from FTAI to ovulation was also more synchronous (P<0.01) in the E2P4 
group compared to both the LRD and PRID groups (Table 6.2) and in heifers compared to cows 
(P=0.04; Table 6.2). Cattle in the LRD group had a lower (P<0.001) P/AI compared to the E2P4 
and PRID groups (Table 6.2). No difference between FTAI protocols or interactions for plasma 
progesterone or CL diameter following post-treatment ovulation (Fig. 6.9) were observed in 
cows.   
 
6.4.3. Experiment 3 - Development of a new intravaginal LRD 
 
 No differences or interactions were detected between FTAI protocols or devices for the 
number of neutrophils per 100 cells on Day 0 and 3, vaginal irritation score on Day 3, proportion 
of heifers that displayed estrus, or the interval from PGF to estrus  (Table 6.3). There were no 
differences between FTAI protocols or devices for ovulation within 48 hours after GnRH, 
plasma progesterone 10 days following post-treatment ovulation, proportion of heifers that 
returned to estrus within 10 days of ovulation, or P/AI (Table 6.3). The presynchronization group 
resulted in a reduced (P=0.001) vaginal discharge score on Day 3 than the control group (Table 
6.3). There were no differences in plasma letrozole concentrations among FTAI protocol groups; 
therefore, their data were combined. The X-LRD resulted in increased (P<0.001) plasma 
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letrozole compared to the T-LRD throughout treatment (Fig. 6.10a). A device by day interaction 
(P<0.0001) for plasma letrozole was detected and post-hoc analysis revealed that the X-LRD 
resulted in increased (P<0.05) plasma letrozole from 12 hours- to 5 days-following device 
insertion (Fig. 6.10a). There was no effect of FTAI protocol (P=0.83) or device (P=0.13) for 
plasma estradiol concentrations during treatment. The CL diameter during treatment was greater 
(P=0.05) in the presynchronization group and a FTAI protocol-by-device-by-day-interaction 
(P=0.03) was detected for CL diameter and comparisons are shown in Figure 6.11a. A FTAI 
protocol-by-device-by-day interaction (P<0.01) for plasma progesterone was due to a higher 
concentration of progesterone on Day 0 in the X-LRD Random group (Fig. 6.11b). A FTAI 
protocol-by-day interaction (P<0.01) for dominant follicle diameter was due to an increased 
diameter on Day 2 and 4 in the presynchronization group (Fig. 6.12). 
 
Figure 6. 1. Experimental timeline for heifers and cows (n=10/parity/group) treated with a 
letrozole releasing device (LRD) for 4 days at random stages of the estrous cycle (Experiment 1). 
On Day 4, cattle were given 500 µg cloprostenol (PGF) and assigned randomly to one of three 
groups and given 100 µg gonadorelin (GnRH) at 48 or 60 hours after PGF, or no GnRH. 
Transrectal ultrasonography (US) was done 3x per day until ovulation was detected. BS: blood 
sampling  
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Figure 6. 2. Experimental timeline for cattle synchronized for fixed-time artificial insemination. 
At random stages of the estrous cycle, cattle were assigned randomly to one of three treatment: 
1) a 4-day LRD, followed by 500 µg cloprostenol (PGF) at LRD removal and 500 µg 
gonadorelin (GnRH) concurrently with FTAI at 48 hours after PGF, 2) 2.5 mg estradiol-17b plus 
50 mg progesterone (E2P4) in oil and a progesterone releasing intravaginal device (PRID) for 7 
days, PGF at device removal and GnRH concurrently with FTAI at 60 hours after PGF or 3) a 
modified 5-day Cosynch plus PRID with no GnRH given at PRID insertion, PGF given at device 
removal and GnRH concurrently with FTAI at 72 hours after PGF (Experiment 2) E2: estradiol; 
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Figure 6. 3. A newly designed X-letrozole releasing device (X-LRD; A) compared to the T-LRD 
(B). The T-LRD was used in Experiment 1, 2 and 3. The X-LRD was developed in Experiment 3 
to minimize strain on the vaginal wall while maintaining identical surface areas. The X-LRD 




Figure 6. 4.  Experimental timeline in Experiment 3 for heifers either 1) presynchronized on Day 
-8 (Presynch) with 500 µg cloprostenol (PGF) or not (Control) prior to insertion of a letrozole 
releasing device (LRD). On Day 0, heifers were assigned randomly and given either a X-LRD or 
T-LRD (4 total groups; n=5 to 8 heifers/group) for 3 days. On Day 3, the device was removed 
and PGF was given followed by 100 µg gonadorelin (GnRH) concurrently with artificial 
insemination (AI) 48 hours after PGF. Twice daily transrectal ultrasonography (US) was done 
until ovulation. BS: blood sampling 
5 cm
A B
X or T LRD - 3 Days
Insert LRD
BS at 0, 2, 4, 6, 



















2x per day US
until ovulation
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Table 6. 1. Endpoints (Mean ± SEM) for Experiment 1 from cows and heifers given a 4-day 
treatment of letrozole prior to FTAI.  
 Cows Heifers P-value 
Endpoint 48 hrs 60 hrs No GnRH 48 hrs 60 hrs No GnRH Parity GnRH Parity x GnRH 
Animals (n) 10 10 10 10 10 10 - - - 
Ovulation rate1 10/10 10/10 9/10 8/10 9/10 8/10 0.97 0.99 0.99 
Interval to 
ovulation (hrs)2 77.6±2.4 83.8±7.5
 87.8±5.3 70.0±4.4 82.9±4.7 86.0±4.3 0.41 0.03 0.77 
Residuals of 
ovulation (hrs)3 5.6±2.5




16.4±0.6 16.3±0.9 18.4±0.5 14.3±0.7 14.6±1.0 16.3±0.9 <0.01 0.03 0.69 
Cattle were given PGF at the timing of device removal and then given GnRH at 48-, 60-hours 
after PGF, or no GnRH.  
abWithin rows, values with no common superscript are different (P<0.05) 
1Proportion of animals that ovulated within 120 hours after PGF 
2Hours from PGF to ovulation 
3Variation in ovulation timing 
 
 
Figure 6. 5. Mean (± SEM) plasma concentrations of estradiol in heifers given a letrozole 
releasing device (LRD) for 4 days. On Day 4, heifers were given 500 µg cloprostenol (PGF) and 
assigned randomly to one of three groups and given 100 µg gonadorelin (GnRH) at 48 or 60 
hours after PGF, or no GnRH in Experiment 1. abcWithin days, values with no common 

























































Figure 6. 6. Mean (± SEM) plasma concentrations of estradiol in cows given a letrozole releasing 
device (LRD) for 4 days. On Day 4, cows were given 500 µg cloprostenol (PGF) and assigned 
randomly to one of three groups and given 100 µg gonadorelin (GnRH) at 48 or 60 hours after 










































Figure 6. 7. Mean (± SEM) plasma progesterone concentration (a) and CL diameter (b) in heifers 
given a letrozole releasing device (LRD) for 4 days in Experiment 1. Heifers were assigned 
randomly and given GnRH at 48- or 60-hours after PGF, or no GnRH. Transrectal 
ultrasonography was done 3x per day to determine ovulation. abWithin days, values with no 
common superscripts are different (P<0.05).  
 
Figure 6. 8. Mean (± SEM) plasma progesterone (a) and CL diameter (b) in cows given a 
letrozole releasing device (LRD) for 4 days in Experiment 1 Cows were assigned randomly and 


























































































































3x per day to determine ovulation. abWithin days, values with no common superscripts are 





Table 6. 2. Endpoints from heifers and cows given either a 4-day letrozole releasing device 
(LRD), 2.5 mg estradiol plus 50 mg progesterone and a progesterone releasing intravaginal 
device (E2P4) for 7 days, or a modified Cosynch plus a progesterone releasing intravaginal 
device (PRID) for 5 days in Experiment 2. Mean ± SEM  
 Cows Heifers P-value 
Endpoint LRD E2P4 5-day Cosynch LRD E2P4 
5-day 
Cosynch Parity Protocol 
Parity x 
Protocol 
Animals (n) 46 40 39 23 18 30 - - - 
OF at device removal 
(mm) 13.9±0.5 12.6±0.4 11.9±0.6 12.9±0.5 10.2±0.4 11.0±0.4 <0.001 <0.001 0.34 
OF at FTAI (mm) 14.7±0.4ab 14.7±0.3ab 14.0±0.3b 15.4±0.5a 13.9±0.4bc 12.9±0.4c 0.19 <0.001 0.05 
Plasma P4 at FTAI 
(ng/mL)* 0.11±0.05
 0.08±0.04 0.08±0.05 - - - - 0.91 - 
Plasma E2 at FTAI 
(pg/mL)* 7.6±1.2 7.3±0.9 7.6±0.9 - - - - 0.97 - 
Ovulated by FTAI 8/46 (17%) 1/40 (3%) 6/39 (15%) 3/23 (13%) 0/18 (0%) 
3/30 
(10%) 0.36 0.08 0.99 













(67%) 0.17 0.02 0.39 
Ovulated by 48 hrs 
after FTAI 5/46 (11%) 6/40 (15%) 4/39 (10%) 0/23 (0%) 0/18 (0%) 
4/30 
(13%) 0.14 0.61 0.99 
Interval to ovulation 
(hrs)2 26.2±2.3 32.2±1.4 27.1±2.2 26.0±2.4 30.4±0.4 25.3±2.2 0.48 0.04 0.92 
Ovulation synchrony 
(hrs)3 39.0±6.1
 17.1±3.6 31.8±6.4 28.6±6.7 4.4±0.7 23.4±7.2 0.04 <0.01 0.94 








(53%) 0.22 <0.001 0.33 
          
LRD: letrozole releasing device; E2P4: 2.5 mg estradiol + 50 mg progesterone in oil; PRID: 
progesterone releasing intravaginal device; OF: ovulatory follicle; P4: progesterone; E2: 
estradiol; AI: Artificial insemination;*n=20/synch 1within 48 hours after FTAI; 2Timing to 
ovulation from FTAI; 3Residual variation of interval to ovulation  






Figure 6. 9. Mean (± SEM) plasma progesterone (a) and CL diameter (b) following post 
treatment ovulation in cows given either: a 4-day letrozole-releasing device (LRD), estradiol plus 
progesterone (E2P4), or a modified Cosynch plus progesterone releasing intravaginal device 
(PRID) for 5 days protocol (n=20/protocol). Following FTAI, ultrasonography was done daily 
for ovulation in Experiment 2.  
 
Table 6. 3. Endpoints from Experiment 3 in which heifers were either presynchronized or not 
with PGF and given either a 3-day X- or T-LRD. Mean ± SEM 
 Presynchronization  Control  
Endpoint X-LRD T-LRD  X-LRD T-LRD  
Heifers (n) 8 5  5 8  
Neutrophils per 100 cells Day 0* 24.6±12.8 38.2±17.8  23.0±10.2 18.4±17.4  
Neutrophils per 100 cells Day 3* 43.4±14.8 35.2±11.1  19.0±9.5 17.8±15.4  
Vaginal discharge score Day 3* 2.2±0.2a 2.2±0.2a  2.8±0.2b 3.2±0.2b  
Vaginal irritation score Day 3* 0.8±0.2 1.6±0.4  1.4±0.2 1.8±0.6  
Displayed estrus 3/8 (38%) 3/5 (60%)  2/5 (40%) 2/8 (25%)  
Onset of estrus (hrs)1 48.0±2.9 50.7±2.9  56.0±3.6 54.0±3.6  
Interval to ovulation (hrs)1 82.5±1.5 84.0±0  72.0±12.0 46.5±18.5  
Ovulated within 48 hrs of GnRH 8/8 (100% 4/5 (80%)  4/5 (80%) 6/8 (75%)  
P4 10 days after ovulation2 2.4±0.8 2.7±1.1  2.5±1.1 4.2±1.4  
Early return to estrus3  3/8 (38%) 1/5 (20%)  3/5 (60%) 2/8 (25%)  
Pregnancy per AI 2/8 (25%) 2/5 (40%)  2/5 (40%) 2/8 (25%)  
Heifers were either Presynchronized with 500 µg cloprostenol (PGF) on Day -8 or not (control). 

























































Day 0, followed by device removal and PGF on Day 3. Following PGF, GnRH was given 
concurrently with fixed-time artificial insemination on Day 5.  
*n=5/group; 1Hours from PGF to estrus or ovulation; 2Plasma progesterone (P4); 3Estrus 
detected by Heatwatch within 10 days from post-treatment ovulation 






Figure 6. 10. Mean ± SEM plasma concentrations of letrozole (a; n=10/device and estradiol (b; 
n=13/device) between heifers given a newly developed X-letrozole releasing device (LRD) or a 
T-LRD for 3 days in Experiment 3. Frequent blood samples were taken every two hours from 
device insertion until 12 hours and then every day until Day 5 for plasma letrozole 
concentrations. Blood samples were taken daily for plasma estradiol concentrations. On Day 3, 
500 µg cloprostenol (PGF) was given and 100 µg gonadorelin (GnRH) was given concurrently 






























































Figure 6. 11. Mean (± SEM) CL diameter (a) and plasma progesterone concentrations (b) in 
heifers either presynchronized with 500 µg cloprostenol (PGF) on Day -8 (Presynch) or not 
(Control). Heifers were either given a 3-day X- or T-letrozole releasing device (LRD) on Day 0. 
On Day 3, 500 µg cloprostenol (PGF) was given and 100 µg gonadorelin (GnRH) was given 
concurrently with artificial insemination (AI) on Day 5 in Experiment 3. abWithin days, values 
with no common superscripts are different (P<0.05).  
 
  
Figure 6. 12. Mean (± SEM) ovulatory follicle diameter in heifers either presynchronized with 
500 µg cloprostenol (PGF) on Day -8 (Presynch) or not (Control). Heifers in both groups were 



































































Protocol*Device         0.1861
Day <0.0001






Protocol*Device         0.3352
Day <0.0001














































Protocol*Device         0.269
Day <0.0001






cloprostenol (PGF) was given and 100 µg gonadorelin (GnRH) was given concurrently with 
artificial insemination (AI) on Day 5 in Experiment 3. abWithin days, values with no common 




 Following results of Experiment 1 showing a high ovulation rate (>90%) following 
letrozole treatment, the 48-hour interval from PGF to GnRH was chosen for Experiment 2 due to 
the synchrony, as well as the increased CL diameter following post-treatment ovulation. 
However, the lower P/AI observed in LRD-treated cattle in Experiment 2 was unexpected. A low 
P/AI was shown in a previous study (Yapura et al., 2016), where GnRH was given concurrently 
with FTAI 24 hours after PGF. We expected that by extending the PGF to FTAI interval by an 
additional 24 hours, it would allow for a rebound in estradiol and increase P/AI. In Chapter 5 it 
was shown that letrozole treatment did not adversely affect granulosa cell function, oocyte 
maturation, or the ability of the oocyte to fertilize in vitro. Thus, it was expected results should 
be similar or even improved compared to currently used FTAI protocols. In Experiment 2, the 
interval from PGF treatment to ovulation was longer in the E2P4 group than in either the LRD or 
5-day Cosynch groups. Similarly, later ovulations were also consistent which resulted in more 
synchronous ovulations in the E2P4 group.  
 Heifers in the LRD group had the largest ovulatory follicle at the time of FTAI among the 
other heifer treatments, and numerically a larger dominant follicle than all cow groups. In dairy 
(Wolfenson et al., 2004) and beef (Tarso et al., 2016) cattle, cows have been shown to ovulate a 
larger follicle than heifers, but circulating progesterone concentrations following ovulation is 
generally lower in lactating dairy cows than heifers (Wolfenson et al., 2004). The difference in 
follicle size and subsequent progesterone production has been explained, at least in part, by the 
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apparent increase in steroid metabolism in lactating cows (Sangsritavong et al., 2002). High 
progesterone concentrations during the growth of the ovulatory follicle decreases LH pulse 
amplitude and frequency (Kinder et al., 1996) which decreases the growth of LH-dependent 
follicles (i.e., ≥8 mm; Adams et al., 1992a). Similarly, using the ovariectomized cow model, the 
administration of a combination of estradiol and progesterone at physiological concentrations 
seen during the luteal phase causes LH-pulse frequency to decrease (Stumpf et al., 1993). With 
the decreased aromatase production of estradiol, increased LH-pulse amplitude in LRD-treated 
heifers (Chapter 5) would be expected to cause the development of larger dominant follicles. To 
our knowledge, this is the first study in which a larger dominant follicle was observed at FTAI in 
heifers than cows, and suggests a dose-effect of letrozole, whereby decreasing estradiol 
production and subsequently increasing LH pulse amplitude in cattle with a smaller mass.   
 Although ovulation rate was high (85%) in Experiment 3, a short-lived CL occurred in 
9/26 (35%) heifers with estrus occurring within 10 days of ovulation. Similarly, plasma 
progesterone 10 days after ovulation averaged 2.9 ng/mL, but 9/26 (35%) were below 1 ng/mL 
which is below expected concentrations of 4 to 6 ng/mL observed in a previous study (Dadarwal 
et al., 2013). Low circulating progesterone and short-lived CL were not observed in Experiment 
1, potentially due to blood sampling and ultrasonography only being done for 8 days following 
post-treatment ovulation. Short lifespan CL have been hypothesized to occur as a result of the 
low concentrations of circulating estradiol at the time of ovulation induction with GnRH. When 
estradiol does not reach optimal concentrations, synthesis of oxytocin receptors in the 
endometrium fail to occur. Therefore, following induced ovulation, as estradiol concentrations 
increase from the dominant follicle of the first follicular wave, oxytocin receptors are 
synthesized and produce PGF resulting in a short-lived CL (Araujo et al., 2009). In any case, the 
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development of short lifespan CL following letrozole treatment may explain the low P/AI in the 
LRD group in Experiment 2. In a previous study, high fertilization rates following estrus 
detection and AI (≥90%) has been demonstrated by embryo development on Day 8 (Diskin and 
Sreenan, 1980). However, the highest rate of embryo mortality has been reported to occur 8 to 16 
days after AI (Diskin and Sreenan, 1980). Therefore, the functionality and lifespan of the CL and 
subsequent maintenance of pregnancy may contribute to early embryo mortality. Reduced 
preovulatory estradiol concentrations following letrozole treatment in Experiment 2 (from the 
shortened proestrus period) may have led to a short lifespan CL and thus, a low P/AI. Both 
heifers and cows in the no GnRH group (i.e., endogenous LH-induced ovulation) in Experiment 
1 had numerically higher plasma progesterone concentrations on the last day of sampling (8 days 
after ovulation) suggesting that the administration of GnRH at 48- and 60-hours after PGF did 
not allow for the normal rise in in estradiol production during the proestrus period. 
Unfortunately, the HeatWatch system was not used in Experiment 1; it may have provided an 
indication of the time of onset of estrus and time of the endogenous LH peak.  
 The newly developed X-LRD outdone the T-LRD in Experiment 3 as shown by higher 
plasma letrozole concentrations (Fig. 6.10a) and a lower vaginal irritation score (Table 6.3). 
Although there was no difference in the surface area of both devices, the increase in drug 
delivery may be because of the design of the X-LRD, specifically the caudal portion (lower half 
of Figure 6.3a and b). In the T-LRD the “wings” of the caudal portion has been observed to fold 
up upon each othe while the caudal portion of the X-LRD, once expelled from the applicator, 
opens up maximizing contact with the vaginal mucosa. Previous studies with the original silicone 
LRD (Chapter 2) have shown that plasma levels of letrozole are positively correlated to the 
surface area, which has also been observed with intravaginal progesterone-releasing devices (van 
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Werven et al., 2013). Similarly, vaginal irritation was greater in the T-LRD because of the 
rigidity of the two points extending laterally in the cranial vaginal. The X-LRD was designed to 
distribute its force over 4 points extending laterally in both the cranial and caudal vagina.  
 In summary, giving GnRH 48 hours after PGF decreased variation in the interval to 
ovulation in cows following a 4-day letrozole treatment in Experiment 1. However, a 4-day 
letrozole treatment followed by GnRH given concurrently with FTAI 48 hours after PGF 
resulted in a lower P/AI compared to an E2P4 and a modified 5-day Cosynch plus PRID protocol 
in Experiment 2. Lastly, there was no benefit of presynchronization before initiating letrozole 
treatment for P/AI in Experiment 3. In addition, a newly designed X-LRD increased letrozole 
drug release and n decreased vaginal irritation numerically. Future studies should address the 
interval to estrus following a 4-day letrozole synchronization protocol to optimize the time of 
GnRH administration and pregnancy success. 
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Relationship of this study to the dissertation 
In Chapter 6, we demonstrated that following a letrozole-based synchronization in cattle, the 
percent of ovulation was high, but following fixed-time artificial insemination, P/AI were low. 
This was shown by a return to estrus (i.e., short-lived CL) after ovulation in a proportion of 
heifers in Chapter 6, potentially as a result of low estradiol before induced ovulation. We 
hypothesized that by extending the period from LRD removal and prostaglandin followed by 
GnRH-induced ovulation, we would reduce the incidence of short-lived CL and subsequently 
increase P/AI.  
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Experiments were conducted to determine if letrozole treatment interferes with luteolysis 
and affects the timing of estrus and ovulation (Experiment 1), whether the stage of the estrous 
cycle at initiation of letrozole treatment affects P/AI (Experiment 2), and to compare a 4-day 
letrozole protocol vs a 5-day Cosynch plus CIDR protocol for fixed time artificial insemination 
(FTAI) in beef cattle (Experiment 3). In Experiment 1, heifers were fitted with a HeatWatch 
sensor and given prostaglandin F2a (PGF). Ovulation (Day 0) was determined by daily 
ultrasonography, and on Day 3, heifers were given an intravaginal letrozole-releasing device 
(LRD) or sham device for 4 days (n=16 per group). Half of the heifers in each group were given 
PGF once on Day 7 (PGF 1x) or twice on Days 7 and 7.5 (PGF 2x). The onset of estrus was 
determined by HeatWatch software. Following PGF, ultrasonography was done twice daily until 
ovulation and for 14 days following ovulation for assessment of ovarian structures. In 
Experiment 2, heifers were assigned to 1 of 3 groups (n=10-11/gp) in which a 4-day LRD 
treatment was initiated during metestrus (Days 0 to 2), diestrus (Days 7 to 9), or proestrus (Days 
15 to 17). PGF was given at device removal and 12 hours later. In Experiment 3, nulliparous 
(n=69) heifers and multiparous (n=151) cows were given either an LRD for 4 days or 100 μg 
GnRH plus a CIDR for 5 days (CIDR/Cosynch). At the time of device removal an estrus patch 
was placed on the tailhead; PGF was given at device removal and 12 hours later. In Experiment 2 
and 3, cattle were given GnRH and inseminated with frozen thawed semen 66 hrs after device 
removal. Pregnancy diagnosis was done 28 to 34 days after ovulation by transrectal 
ultrasonography. In Experiment 1, no main effects or interactions were detected between device 
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or PGF treatment for the onset of estrus following PGF (overall 60.0 ± 2.5 h) or CL diameter 
profiles during luteolysis. The CL diameter following ovulation was greater following ovulation 
in the PGF 2x than in the PGF 1x groups (P=0.03). In Experiment 2, a greater proportion of 
heifers in the proestrus group ovulated ≤24 h after device withdrawal than the metestrus and 
diestrus groups combined (6/11 vs 0/22, respectively; P<0.05). The P/AI tended to be greater in 
the metestrus than the diestrus group (10/11 vs 6/10; P=0.08), with the proestrus group lower 
than either (0/11; P<0.05). In Experiment 3, there was no difference in the overall P/AI (total 
117/218 [53.7%]) between FTAI protocol (P=0.15) or parity (P=0.24). In summary, letrozole 
treatment did not interfere with luteolysis, and PGF given twice at a 12-hour interval on Day 7 
after ovulation decreased variance in the interval to ovulation. No differences were detected in 
P/AI following FTAI between a 4-day LRD vs a 5-day Cosynch plus CIDR protocol and 
letrozole treatment initiated during metestrus and diestrus yielded greater P/AI than starting in 














Elevated plasma estrogen concentrations near the time of insemination are associated 
with increased rate of sperm transport in the female reproductive tract (Hawk, 1983). High 
concentrations of circulating estradiol coincide with peak estrus activity (Lyimo et al., 2000) and 
cattle that display estrus within 24 hours before fixed time artificial insemination (FTAI) have 
higher P/AI than cattle that do not exhibit estrus (Perry et al., 2005, 2007). Due to the effect of 
synchronizing follicular wave emergence, estradiol-based synchronization protocols enabled 
FTAI in cycling and anestrus cattle (Nunez-Olivera et al., 2014). Although these protocols are in 
common use in South America, estradiol-based protocols for FTAI are limited in North America 
by regulations requiring a veterinary prescription (Canada) or complete prohibition (United 
States; AETA, 2019). Similarly, estrogens were banned for ovarian synchronization in food 
producing species in Europe, and in milk-producing animals in Australia and New Zealand in the 
late 2000’s (Lane et al., 2008). Therefore, alternatives to estradiol-based protocols are needed for 
FTAI in cattle in many countries worldwide.  
In the United States and Canada, gonadotropin-releasing hormone (GnRH)-based 
protocols are used extensively for FTAI in both beef and dairy cattle (Colazo and Mapletoft, 
2014). Cosynch, or the administration of GnRH concurrently with FTAI, has been adapted for 
use in beef cattle due to the requirement of only 3 handlings. However, the efficacy of GnRH-
based protocols is dependent on ovulation following the first GnRH which is given at a random 
stage of the estrous cycle. The ovulation rate is low when GnRH is given during early metestrus 
due to the dominant follicle not acquiring luteinizing hormone receptors (Atkins et al., 2008). 
During a high progesterone environment, a GnRH-induced LH surge has been shown to be 
decreased (Colazo et al., 2008; Giordano et al., 2012). Ovulation rates are highest when GnRH is 
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given on Days 5 to 9 of the estrous cycle when the dominant follicle of the first wave is growing 
(Vasconcelos et al., 1999). To manipulate this interval, prostaglandin (PGF) is given prior to 
enrolment into GnRH-based FTAI protocols (Vasconcelos et al., 1999) to increase the number of 
animals in this stage. However, this requires an additional handling, which may increase the cost 
of the protocol. 
Extensive investigations on the development of non-steroidal aromatase inhibitor-based 
methods to control ovarian function in women and cattle (reviewed in Yapura et al., 2018) have 
been done in our laboratory. Recent investigations have examined dose-response relationships, 
timing, mechanism of action, and drug delivery methods with letrozole. Research has also 
involved the development of a unique intravaginal letrozole releasing device (Chapter 2) and 
effects on ovarian superstimulation in cattle (Chapter 4; Zwiefelhofer et al., 2019). No 
deleterious effects of letrozole on oocyte maturation or in vitro fertilization capacity were 
detected (Chapter 5), and synchrony of ovulation was similar between letrozole-treated groups 
given GnRH 48 or 60 hours after PGF treatment (Chapter 6; Zwiefelhofer et al., 2018). Despite 
the synchrony of ovulation, initial breeding trials with the letrozole-based protocol for FTAI at 
48 hours after PGF were disappointing (30% P/AI; Chapter 6). It was speculated that the low 
P/AI may be related to an inadequate duration of proestrus to permit a sufficient increase in 
estradiol (i.e., PGF to AI/GnRH interval of 48 hours) resulting in short-lived (i.e., 8 to 10 days; 
Chapter 6) corpora lutea (CL; Mann and Lamming, 2000).  
It was hypothesized that increasing the rate of luteolysis and extending the interval from 
PGF treatment to GnRH would minimize the incidence of short-lived CL and increase the P/AI 
after FTAI. The objectives were to determine if letrozole treatment interferes with luteolysis and 
affects the timing of estrus and ovulation (Experiment 1) whether the stage of the estrous cycle at 
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initiation of letrozole treatment affects P/AI (Experiment 2), and to compare a 4-day letrozole 
protocol vs a 5-day Cosynch plus CIDR protocol for FTAI in beef cattle (Experiment 3). 
 
7.3. Materials and Methods 
 
Procedures were approved by the University of Saskatchewan’s Animal Research Ethics 
Board in accordance with the guidelines of the Canadian Council on Animal Care. Experiments 
1 and 2 involved the use of sexually mature nulliparous Hereford cross heifers (n=32) aged 16 to 
18 months of age (weight: 486 ± 8 kg; body condition score [BCS]: 3.3 ± 0.05; 1 to 5 scale; with 
1 being emaciated and 5 being obese (Richards et al., 1986)). Heifers were maintained at the 
University of Saskatchewan’s Livestock and Forage Centre of Excellence Goodale Farm during 
the months of October to January. In Experiment 3, sexually mature nulliparous Hereford cross 
and Angus heifers (n=69; weight: 412 ± 6 kg; BCS: 2.7 ± 0.04) and multiparous lactating Angus 
cows ≥42 days post-partum (n=151; weight: 616 ± 8 kg; BCS: 2.6 ± 0.03) were used. Cattle were 
located at the University of Saskatchewan’s Livestock and Forage Centre of Excellence 
Termuende Ranch (Lanigan, Saskatchewan). Prior to each experiment, cattle were examined by 
transrectal ultrasonography to confirm a normal reproductive tract and confirm cyclicity by the 
presence of a CL.  
 
 
7.3.1. Experiment 1. Estrus response and corpus luteum function following letrozole 
treatment 
 
A 2x2 factorial design was used to determine the effects of an LRD vs sham device and 
single vs double administration of PGF on luteolysis (defined as plasma progesterone 
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concentrations ≤1 ng/mL within 24 hours of PGF), estrous behavior, and ovulation. Prior to 
enrollment into the study, heifers were fitted with a HeatWatch electronic sensor (CowChips; 
Manalapan, NJ, USA) to record the time, intensity, and duration of estrus. At random stages of 
the estrous cycle, heifers were given 2 doses of PGF (500 μg cloprostenol each; Bioestrovet; 
Vetoquinol N.A., Lavaltrie, QC, Canada) 12 hours apart to induce luteolysis followed 3 days 
later by GnRH (100 μg gonadorelin im; Fertiline, Vetoquinol N.A., Lavaltrie, QC, Canada) to 
induce ovulation. The ovaries were examined daily by transrectal ultrasonography (7.5 MHz 
linear array probe, MyLab Alpha, Esaote North America, Fishers, IN, USA) to determine the day 
of ovulation (Day 0). On Day 3, heifers were assigned randomly to one of two groups and given 
either an LRD or a sham device for 4 days. On Day 7, devices were removed and heifers in each 
group were again randomly assigned to one of two groups and given 500 μg cloprostenol once at 
the time of device removal or twice at 12 hour intervals (Day 7 and 7.5; 4 groups; n=8/gp; Fig. 
7.1). On Day 7, heifers underwent transrectal ultrasonography at 12-hour intervals for 72 hours 
to measure luteal and follicular dynamics and then daily thereafter to determine ovulation. Daily 
ultrasonography was done for 14 days following ovulation to assess CL diameter. Data on 
intervals to onset of estrus (hours from first PGF to first recorded mount), and peak estrus (hours 
from first PGF to the hour with the greatest number of mounts), estrus intensity (total number of 
mounts), and duration of estrus (interval from the first to the last mount) were collected by 
HeatWatch software. The luteolysis rate was defined as the proportion of heifers with plasma 




7.3.2. Experiment 2. Effect of the stage of the estrous cycle on the efficacy of 
letrozole-based synchronization for FTAI 
 
To determine the effect of initiating letrozole treatment during different stages of the 
estrous cycle, heifers were reused from Experiment 1 and assigned randomly to one of three 
groups (n=10-11/group) in which a 4-day LRD treatment was initiated during metestrus (Day 0 
to 2; Day 0 = ovulation), diestrus (Day 7 to 9), or proestrus (Day 15 to 17; Fig. 7.2). Heifers were 
given PGF at the time of LRD removal and 12 hours later and were inseminated with frozen 
thawed semen concurrently with administration of GnRH 66 hours after device removal. 
Beginning at device removal heifers underwent transrectal ultrasonography at 12-hour intervals 
until ovulation was detected. Transrectal ultrasonography was also done 7 and 14 days after post-
treatment ovulation to determine CL diameter and plasma progesterone concentration. 
Transrectal ultrasonography was used to diagnose pregnancy 28-35 days after ovulation by 
confirming an embryo proper with a heartbeat. Estrus endpoints from HeatWatch were analyzed 
as described in Experiment 1.  
  
7.3.3. Experiment 3. Field trial for FTAI 
 
Using a 2x2 factorial design, heifers and cows were synchronized during the month of 
June using a 4-day letrozole- or a conventional 5-day Cosynch plus CIDR protocol (n= 35 to 78 
per group; n=4 groups; Fig. 7.3). At random stages of the estrous cycle, cattle in the letrozole 
group were given PGF im to induce luteolysis and were given an estrus detection patch 
(Estrotect, Rockway Inc., Spring Valley, WI, USA) which was placed on the tailhead. Five days 
after PGF, the estrus detection patch was scored based on color change (0: unchanged, 1: £50% 
color change, 2: >50% color change, 3: missing; Colazo et al., 2018) and an LRD was inserted 
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for 4 days. Estrus was defined to have occurred if the estrus patch was scored 2 or 3. Cattle in the 
5-day Cosynch plus CIDR group were given GnRH im (100 ug gonadorelin im) followed by an 
intravaginal progesterone device (Eazi-Breed CIDR, Zoetis, Kirkland, QC, Canada) for 5 days. 
At the time of device removal, cattle in both treatment groups were given PGF im twice at 12-
hours apart and an estrus detection patch placed on the tailhead. At 66 hours after device 
removal, cattle were assigned randomly and FTAI with frozen thawed semen containing ≥10 
million progressive motile sperm from one of four different sires, and treated with GnRH. Cattle 
were examined by transrectal ultrasonography at device removal, AI, and 30 hours after AI to 
measure dominant follicle diameter and CL diameter and to confirm ovulation. A subsequent CL 
measurement was done by transrectal ultrasonography 6 days post-treatment ovulation  on a 
subset of cattle (n=20 per treatment per parity). Pregnancy diagnosis was done 28 to 34 days 
after ovulation by transrectal ultrasonography, as in Experiment 2.  
 
7.3.4. Blood sampling and radioimmunoassays  
 
Blood samples were taken by jugular venipuncture into heparinized tubes (Vacutainer; 
Becton Dickinson and Co., Franklin Lakes, NJ), centrifuged <2 hours after collection at 1,500 x 
g and plasma was aliquoted into polypropylene tubes and frozen at -20°C until assay. In 
Experiment 1, blood samples were taken daily from Day 3 to 7, twice daily from Day 7.5 to Day 
10 and daily until Day 12. Blood samples were taken every other day from 2 to 14 days after 
ovulation. In Experiment 2, blood samples were taken daily from Day 0 to 4, twice daily until 
Day 6.5, Day 6.75, 7, and 7.5 and on Days 7- and 14 following post-treatment ovulation. In 
Experiment 3, blood samples were taken from a subset of cattle (n=20/group) at the time of AI 
and 6 days after ovulation. 
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Plasma concentrations of estradiol were determined by radioimmunoassay as previously 
described (Kirby et al., 1997). The minimum detection limit was 0.5 pg/mL. Intra- and inter-
assay coefficients of variation were 6.8 and 9.2%, respectively. 
Plasma concentrations of progesterone were analyzed by a solid-phase 
radioimmunoassay (Coat-a-Count; Diagnostic Products Corp., Los Angeles, CA, USA) with a 
minimum detection limit of 0.1 ng/mL. Intra-assay coefficients of variation in Experiments 1 and 
2 for low, medium, and high samples were 11.0, 9.1, and 10.8%, respectively. Inter-assay 
coefficients of variation for low, medium, and high samples were 11.9, 8.2, 10.7%, respectively. 
Intra-assay coefficients of variation in Experiment 3 for low, medium, and high samples were 
6.7, 6.9, and 9.2%, respectively. Inter-assay coefficients of variation for low, medium, and high 
samples were 11.9, 8.2, and 10.7%, respectively.  
  
7.3.5. Statistical analyses 
 
Data were analyzed using SAS Enterprise Guide (Version 4.2; Statistical Analysis 
System Institute Inc., Cary, NC, USA). Serial data (i.e., CL, dominant follicle, progesterone and 
estradiol profiles) were analyzed by 2x2 ANOVA using a mixed model for repeated measures to 
examine the main effects of LRD vs Sham and PGF 1x or 2x (Experiments 1 and 2), and heifer 
vs cow and LRD vs a 5-day Cosynch plus CIDR protocol (Experiment 3). Numerical scale data 
(onset of estrus, residuals of onset of estrus, peak estrus, length of estrus, total number of 
mounts, ovulation timing, residuals of ovulation timing, and size of ovulating follicle) were 
analyzed by 2x2 ANOVA using the MIXED procedure. Binary were compared by chi-square in 
Experiments 1 and 2 (luteolysis and ovulation rate, and P/AI), and by logistic regression with the 
factorial GLIMMIX procedure comparing parity by FTAI protocol (estrus patch detection score, 
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ovulation rate, estrus rate, double ovulation rate, P/AI) or bull by FTAI protocol using binary 
distribution and link logit function in Experiment 3.  If an interaction was detected, post hoc 
analyses were done using least significant difference. Significance was defined as P£0.05 and 




7.4.1. Experiment 1. Estrus response and corpus luteum function following letrozole 
treatment  
 
One heifer in the LRD PGF 1x group was removed from the experiment due to 
aggressive behavior. One heifer in the LRD PGF 1x group did not display estrus or ovulate 
within 7 days after PGF and was included in the luteolysis rate, but was removed from further 
analysis. No difference was detected among groups in the luteolysis rate as all heifers had plasma 
progesterone concentrations ≤1 ng/mL within 24 hours of PGF. No difference was detected 
among groups in onset of estrus, peak estrus, total number of mounts, and ovulation timing 
(Table 7.1). An interaction between treatments was detected for length of estrus where LRD 
PGF1x and Sham PGF 2x were longer (P<0.05) than Sham PGF 1x (Table 7.1), while LRD PGF 
2x was intermediate. Residuals of onset of estrus tended (P=0.07) to be more synchronous in the 
PGF 2x group than the PGF 1x group (Table 7.1). Similarly, residuals of the interval to ovulation 
were more (P=0.01) synchronous in the PGF 2x than the PGF 1x group (Table 7.1). A device by 
PGF interaction for CL diameter profiles was detected between LRD PGF 1x vs Sham PGF 1x 
and LRD PGF 1x vs LRD PGF 2x (Fig. 7.4). A device-by-day interaction (P=0.05) was detected 
from Days 3 to 7 and a tendency (P=0.08) between PGF treatment was evident from Day 7.5 to 
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10 for plasma progesterone during luteolysis (Fig. 7.5). A larger dominant follicle during 
treatment in the LRD group led to a device-by-day interaction (P=0.04) for dominant follicle 
diameter from Days 7 and 7.5 (Fig. 7.6A). There was an effect of device and PGF treatment on 
plasma estradiol profiles (P=0.04; Fig. 7.6B) with the PGF 1x and Sham groups having increased 
plasma estradiol. A larger CL following ovulation in the PGF 2x group resulted in a treatment 
effect (P=0.03); a tendency (P=0.07) of device-by-PGF interaction for post-ovulation CL 
diameters was due to increased size in the LRD PGF 2x group (Fig. 7.7A). There was no effect 
of device, PGF treatment, or interactions for plasma progesterone post-ovulation (Fig. 7.7B). 
 
7.4.2. Experiment 2. Effect of the stage of the estrous cycle on the efficacy of 
letrozole-based synchronization for FTAI 
 
A total of 6 heifers ovulated during LRD treatment or within 24 hours following LRD 
removal in the proestrus group, which was a greater proportion than in the other groups (P<0.05; 
Table 7.2). Their data for dominant follicle and CL diameter were truncated on Day 3 following 
device insertion. There were no differences between metestrus and diestrus groups in the number 
of double ovulations, intervals to the onset of estrus, estrus to AI, nor in dominant follicle 
diameter at AI or the degree of synchrony of ovulation (Table 7.2). The total number of mounts 
during estrus was greater in diestrus than metestrus (P<0.05) and a tendency (P=0.09) between 
the groups was detected for timing of ovulation following AI/GnRH (Table 7.2). Letrozole 
treatment initiated during metestrus tended (P=0.09) to increase P/AI (91%) compared to diestrus 
(60%), and both were higher (P<0.05) P/AI than proestrus (0%; Table 7.2). A treatment 
(P<0.001) and treatment-by-day interaction (P<0.0001) was shown for CL diameter and 
dominant follicle profiles during treatment and comparisons among days are shown (Fig. 7.8 & 
7.9). A treatment-by-day interaction was detected for CL diameter (P=0.06) and plasma 
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progesterone (P=0.005) profiles 7- and 14-days following post-treatment ovulation. The CL 
diameter and plasma progesterone were greater (P<0.01) in the metestrus vs proestrus group and 
tended (P=0.07) to be greater in the diestrus vs proestrus group (Fig. 7.11). 
7.4.3. Experiment 3. Field trial for FTAI  
 
Data from 2 heifers in the LRD group were excluded because of injury and device loss, 
respectively. A device-by-day and parity-by-day effect on CL diameter was attributed to a larger 
CL on the day of device removal and 66 hours after device removal for the LRD and Cow 
groups, respectively (P<0.05; Fig.7.12A). A device-by-parity interaction for dominant follicle 
diameter was due to a larger dominant follicle in the Heifer LRD group (P=0.01; Fig. 7.12B). A 
parity effect for ovulation detected prior to FTAI was due to an increased proportion of heifers 
that ovulated prematurely vs cows (P<0.001; Table 7.3). At FTAI, a greater (P<0.001) 
proportion of heifers had an estrus detection score of ≥2 than cows (Table 7.3). A lower 
proportion of cattle in the LRD group at FTAI had an estrus score ≥2 compared to the CIDR 
group (P=0.01; Table 7.3). A greater (P=0.05) proportion of double ovulations occurred in cows 
than heifers and in the LRD than CIDR group (P=0.05; Table 7.3). The CL diameter 6 days after 
ovulation was greater (P<0.001) in cows than heifers with no effect (P=0.13) of protocol (Table 
7.3). Plasma progesterone 7 days after AI was greater (P=0.004) in the LRD than the CIDR 
group and in heifers than cows (P<0.001; Table 7.3). A device-by-parity interaction (P=0.04) for 
plasma progesterone 7 days after FTAI was attributed to an increased concentration in the Heifer 
LRD group. Similarly, a device-by-parity-by-day interaction (P=0.01) for plasma progesterone 
profiles on the day of FTAI and 7 days later was attributed to an increased concentration in the 
Heifer LRD group (Fig. 7.13). There were no differences for device (P=0.15) or parity (P=0.24) 
in overall P/AI. Similarly, there were no differences for device (P=0.89) or parity (P=0.57) in 
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P/AI from cattle with an estrus score ≥2 (overall 90/122 [73.8%]). No difference was detected 
for device (P=0.58) or parity (P=0.55) for P/AI from cattle with an estrus score <2 (Table 7.3). 
Cattle with an estrus score ≥2 had a higher (P<0.0001) P/AI compared to an estrus score <2 (Fig. 
7.14). A bull interaction (P<0.05; Table 4) was due to an increase in P/AI in heifers obtained 
with Bull A than Bull B in the 5-day Cosynch plus CIDR group (Table 7.4). No differences were 





Figure 7. 1. Timeline for Experiment 1 in which heifers 3 days after ovulation were either given  
a 4-day letrozole releasing device (LRD) or sham device. At device removal, heifers were 
assigned randomly to one of two groups and given either 500 µg cloprostenol once (PGF 1x) or 
twice at 12-hour intervals (PGF 2x; 4 groups, n=8 heifers/group). Following PGF, blood 
sampling (BS) and transrectal ultrasonography was done twice daily for 3 days. After ovulation, 





























Figure 7. 2. Timeline for Experiment 2 to test the effect of initiating a 4-day letrozole releasing 
device (LRD) regiment during metestrus, diestrus, or proestrus (n=10-11/group). At LRD 
removal, heifers were given 500 µg cloprostenol (PGF) twice at 12-hour intervals and fixed-time 
artificial insemination (FTAI) was done concurrently with 100 µg gonadorelin (GnRH) 66 hours 
after LRD removal. Blood sampling (BS) and transrectal ultrasonography (US) was done daily 
from Day 0 to 4 and twice daily until ovulation. Following ovulation, US and BS were done 7- 
and 14 days later.  
 
 
Figure 7. 3. Timeline for Experiment 3 comparing a newly developed letrozole releasing device 
(LRD) protocol vs a conventional 5-day Cosynch plus CIDR protocol for FTAI in beef cattle. To 
increase the proportion of cattle in the metestrus stage in the LRD protocol, 500 µg cloprostenol 
(PGF) was given 5 days before insertion of the LRD. In the 5-day Cosynch plus CIDR protocol, 
100 µg gonadorelin (GnRH) was given concurrently with CIDR insertion. In both protocols, 
PGF was given at device removal and 12 hours later and GnRH was given concurrently with 
fixed-time artificial insemination (FTAI) 66 hours after device removal. A subset of cattle 
(20/group; 4 groups) had blood sampling done at AI and 6 days after ovulation.   
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Table 7. 1. Estrus and ovulation response (mean ± SEM) in heifers treated with either a letrozole 
releasing device (LRD) or sham device and given PGF 1x or 2x (Experiment 1).  
 LRD  Sham 
Item PGF 1x PGF 2x  PGF 1x PGF 2x 
Heifers (n) 6 8  8 8 
Onset of estrus (h following PGF) 59.0 ± 5.5 60.4 ± 3.3  63.4 ± 6.9 57.0 ± 4.1 
Variation in onset of estrus (residuals) 9.0 ± 3.7 8.2 ± 1.3  12.3 ± 5.2 8.8 ± 2.4 
Peak estrus (hrs following PGF) 64.7 ± 5.7 63.9 ± 4.9  67.2 ± 7.6 60.9 ± 4.2 
Duration of estrus (h) 16.0 ± 1.7 13.5 ± 1.8  10.4 ± 1.7 15.3 ± 1.6 
Total mounts  28.0 ± 5.3 37.3 ± 20  20.8 ± 6.6 35.3 ± 11 
Interval to ovulation (hrs following PGF) 104 ± 6.2 99 ± 3.0  105 ± 6.3 96 ± 4.5 
Variation in interval to ovulation (residuals) 18.7 ± 5.7a 5.3 ± 2.3b  13.5 ± 3.7a 11.1 ± 3.9b 
Maximum diameter of the ovulatory follicle (mm) 15.6 ± 0.9 17.9 ± 0.6  16.1 ± 0.9 15.9 ± 0.8 




Figure 7. 4. Corpus luteum diameter (mean ± SEM) in heifers treated on Day 3 (Day 0 = 
ovulation) with either a letrozole releasing device (LRD) or a sham device for 4 days. Devices 
were removed and 500 µg cloprostenol (PGF) was given on Day 7 (PGF 1x) or Day 7 & 7.5 



































Figure 7. 5. Plasma progesterone concentration (mean ± SEM) in heifers treated on Day 3 with 
either a letrozole releasing device (LRD) or a sham device for 4 days. Devices were removed and 
500 µg cloprostenol (PGF) was given on Day 7 (PGF 1x) or Day 7 & 7.5 (PGF 2x). Data were 
analyzed independently from Day 3 to 7 (treatment period) and Day 7.5 to 10 (luteolytic period) 
in Experiment 1.  
 
Figure 7. 6. Mean (± SEM) dominant follicle diameter (A) and plasma estradiol concentration 
(B) in heifers treated on Day 3 with either a letrozole releasing device (LRD) or a sham device 
for 4 days. Devices were removed and 500 µg cloprostenol (PGF) was given on Day 7 (PGF 1x) 
























































































































Figure 7. 7. Mean (± SEM) corpus luteum diameter (A) and plasma progesterone concentration 
(B) following post-treatment ovulation in heifers treated with a letrozole-releasing device (LRD) 
or sham device for 4 days. Devices were removed and 500 µg cloprostenol (PGF) was given on 
Day 7 (PGF 1x) or Day 7 & 7.5 (PGF 2x). Post treatment ovulation was defined as Day 0. 
Experiment 1. 
Table 7. 2. Estrus, ovulation, and pregnancy in heifers in which letrozole treatment was initiated 
during metestus, diestrus, or proestrus. A portion of estrus and ovulation data are excluded in the 
proestrus group due to ovulations occurring during or within 24 hours following letrozole 
treatment. Mean ± SEM; Experiment 2.  
abWithin rows, values with no common superscript are different (P<0.05) 
*Values tended to differ (P=0.09). 




































































 Metestrus Diestrus Proestrus 
Heifers (n) 11 10 11 
Ovulated during or within 24 hrs following LRD 0/11 (0%)a 0/10 (0%)a 6/11 (55%)b 
Double ovulation 2/11 (18%) 0/10 (0%) 0/11 (0%) 
Interval to estrus (hrs following 1st PGF) 58.7 ± 2.2 56.6 ± 1.3 - 
Total mounts  16.5 ± 5.5a 33.4 ± 5.5b - 
Interval to ovulation (hrs following FTAI/GnRH) 22.4 ± 1.8* 27.6 ± 2.4* - 
Variation in interval to ovulation (residuals) 5.6 ± 0.5 5.8 ± 1.4 - 
Dominant follicle diameter at AI (mm) 17.9 ± 0.6 16.6 ± 0.8 - 
Pregnancy per AI  10/11 (91%)a* 6/10 (60%)a* 0/11 (0%)b 
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Figure 7. 8. Corpus luteum (CL) diameters (mean ± SEM) in heifers in Experiment 2 treated with 
a letrozole releasing device during metestrus, diestrus, or proestrus. Data for the proestrus group 
were truncated at Day 3 due to premature ovulations and inconsistency in detection of regressing 
CL. abcWithin days, values with no common superscript are different (P<0.05). *Values tended to 
be different (P=0.06). ○Values tended to be different (P=0.10). 
 
Figure 7. 9. Dominant follicle diameter (mean ± SEM) in heifers following treatment with a 
letrozole releasing device initiated during metestrus, diestrus, or proestrus in Experiment 2. Data 
for the proestrus group were truncated at Day 3 because of premature ovulations. abcWithin days, 




















































Figure 7. 10. Plasma concentrations of estradiol (mean ± SEM) in heifers following letrozole 
treatment initiated during metestrus, diestrus or proestrus. abcWithin days, values with no 
common superscript are different (P<0.05). *Values tended to be different (P=0.09). 
 
 
Figure 7. 11. Mean (± SEM) corpus luteum (CL) diameter (left) and plasma progesterone (right) 
7- and 14-days following post-treatment ovulation in heifers from Experiment 2 treated with a 
letrozole releasing device during metestrus, diestrus, or proestrus. abWithin days, values with no 














































































































Figure 7. 12. Mean (± SEM) corpus luteum (CL) diameter (A) and dominant follicle diameter 
profiles (B) between heifers (n=69) and cows (n=151) that were treated with either a 4-day 
letrozole releasing device (LRD) or a 5-day Cosynch plus CIDR protocol. Fixed-time artificial 
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Table 7. 3. Endpoints following FTAI comparing a 4-day LRD protocol and a 5-day Cosynch 
plus CIDR protocol in beef heifers and lactating beef cows. Mean ± SEM  
 4-day LRD 5-day Cosynch + CIDR P-value 
Endpoint Cow Heifer Cow Heifer Protocol Parity Protocol x Parity 
Animals (n) 73 34 78 35 - - - 
Estrous detection score ≥2 




(58.9%)   - 0.83 - 
Ovulated to initial GnRH  - - 40/78 (51.3%) 14/35 (40%)  0.27  
Ovulation detected before 
FTAI 1/73 (1.4%) 6/32 (18.8%) 2/78 (2.6%) 7/35 (20.0%) 0.57 <0.001 0.73 









(88.6%) 0.01 <0.001 0.15 
Estrous detection score ≥2 








(91.4%) 0.02 0.04 0.15 









(94.3%) 0.33 0.77 0.94 
Double ovulation  12/73 (16.4%) 2/32 (6.3%) 6/78 (7.7%) 0/35 (0%) 0.05 0.05 0.97 
CL diameter 6 days after 
ovulation (mm) 1 24.4 ± 0.4 21.9 ± 0.6 23.1 ± 0.7 21.5 ± 0.7 0.13 <0.001 0.53 
Plasma P4 6 days after 
ovulation (ng/mL) 1 2.4 ± 0.3
a 4.1 ± 0.3b 2.2 ± 0.2a* 2.8 ± 0.2a* 0.004 <0.001 0.04 






(65.7%) 0.15 0.24 0.76 









(71.0%) 0.89 0.57 0.94 
P/AI estrous score <2 at 
FTAI 
11/43 
(25.6%) 2/11 (18.2%) 
13/38 
(34.2%) 1/4 (25.0%) 0.58 0.55 0.99 









(68.8%) 0.99 0.54 0.62 
P/AI estrous score <2 30 hrs 
after FTAI 4/26 (15.4%) 1/10 (10%) 5/22 (22.7%) 1/3 (33.3%) 0.27 0.98 0.57 
P/AI ovulated to initial 
GnRH   
24/40 
(60.0%) 8/14 (57.1%) - 0.78 - 
P/AI no ovulation to initial 




(71.4%) - 0.22 - 





(78.9%) - - - 0.16 - 
abWithin rows, values with no common superscript are different (P<0.05); P4: progesterone; 
1n=20/group; 2Estrus detection score ³2 at the time of LRD insertion; *P=0.06 
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Figure 7. 13. Plasma progesterone concentrations (mean ± SEM; n=20/group) from lactating beef 
cows and beef heifers treated with either a letrozole releasing device (LRD) for 4 days or a 5-day 
Cosynch plus CIDR protocol. Fixed-time artificial insemination (FTAI) was done concurrently 
with 100 µg GnRH 66 hours after device removal. abWithin days, values with no common 
superscript are different (P<0.05).  
 
Table 7. 4. Effect of sire used for fixed-time artificial insemination in heifers and cows 
synchronized with either an intravaginal letrozole releasing device (LRD) for 4 days or a 5-day 
Cosynch plus CIDR protocol. 
 
abWithin rows and columns, values with no common superscript are different (P<0.05). 



























Days from device removal
LRD Cow CIDR Cow



















Heifers 4-d LRD 5-d Cosynch   
+ CIDR 
Total 
Bull A 8/16 (50%)ab 16/18 (88.9%)a 24/34 (70.6%) * 
Bull B 9/16 (56.3%)ab 7/17 (41.2%)b 16/33 (48.5%) * 
Total 17/32 (53.1%) 23/35 (65.7%) 40/67 (59.7%) 
Cows 4-d LRD 5-d Cosynch   + 
CIDR 
Total 
Bull C 17/36 (47.2%) 23.39 (59.0%) 40/75 (53.3%) 
Bull D 17/37 (45.9%) 20/39 (51.3%) 37/76 (48.7%) 




Figure 7. 14. Pregnancy per AI following fixed-time artificial insemination (FTAI) from cattle 
who displayed (estrus detection score ³2) or did not display estrus (estrus detection score <2) by 
FTAI. The boxed column numbers indicate the total number of cattle per group. abWithin 





Results of Experiment 1 supported the hypothesis that increasing the rate of luteolysis and 
extending the period of proestrus minimizes the incidence of short-lived CL. In contrast to our 
previous studies (Chapter 5), no differences were detected in CL diameter or progesterone 
profiles during luteolysis. Similarly, subsequent progesterone profiles following post ovulation in 
Experiment 1 did not differ between LRD- and sham-treated heifers (i.e. normal lifespan CL).  
We attribute this to 1) no GnRH was given following PGF treatment (i.e. endogenous estradiol 
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occurred at 64 and 72 hours respectively, following PGF (Table 7.1 and Fig. 7.6B). This 
provides support for our notion that treatment with GnRH in the earlier study (Chapter 6) was 
given 16 to 24 hours too early and this resulted in a short-lived CL after ovulation. In a previous 
study, ovariectomized cows were treated with low, medium, or high doses of estradiol for 40 
hours to mimic physiological estradiol concentrations at estrus (Mann and Lamming, 2000).   
Cows in the low and medium estradiol groups had increased oxytocin receptor populations in the 
endometrium at 4- and 6-days after expression of estrus and increased concentrations of 
prostaglandin metabolite following an oxytocin challenge compared to cows treated with a high 
dose of estradiol. These results suggest that when threshold estradiol concentrations are not 
achieved (i.e., GnRH given before peak estradiol), residual endometrial oxytocin receptors 
remain, and may then respond to the estradiol produced from the dominant follicle of the first 
follicular wave increasing PGF production and subsequent luteolysis. 
An unexpected outcome in Experiment 2 was the number of heifers that ovulated during 
LRD placement or within 24 hours of LRD removal in the proestrus group (55%) which was not 
reported in previous studies. Interestingly, in review of the data of a previous study (Yapura et 
al., 2016), letrozole treatment did not prevent ovulation during the proestrus and estrus period, 
where over 40% of heifers ovulated during LRD placement or within 24 hours of LRD removal 
(data from (Yapura et al., 2016)). Collectively, these data suggest that LRD treatment during the 
proestrus or estrus period does not suppress LH surge release, even though no signs of estrus 
were observed. Letrozole treatment may reduce endogenous estradiol concentrations as shown in 
Fig. 10, but this may not be sufficient to prevent a threshold estradiol concentration to achieve an 
LH surge. It is interesting that of the six heifers that ovulated during or within 24 hours of 
letrozole treatment in the present study, two did not show signs of estrus. Similarly, it was shown 
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recently that oral treatment with a single 20 mg dose of letrozole did not prevent ovulation when 
given to women with preovulatory follicles (Allaway et al., 2017). 
In Experiment 2, the numerically larger dominant follicle at FTAI resulted in a larger CL 
and increased plasma progesterone 14-days after ovulation in the metestrus group. The positive 
correlation between ovulatory follicle diameter and both CL diameter- and plasma progesterone 
following ovulation has been reported in beef cows, but it was concluded that the optimal follicle 
size for maximizing pregnancy success was 13 to 15 mm (Pfeifer et al., 2012). It is noteworthy 
that pregnancies resulting from the ovulation of follicles ranging from 15 to 22.5 mm in diameter 
occurred in the present study in heifers in which letrozole treatment was initiated during the 
metestrus period. The large ovulatory follicle diameter was attributed to an increase in LH 
pulsatility (Chapter 5), due to the combination of decreased estradiol (from letrozole) and low 
progesterone during follicular growth of the first wave dominant follicle (Adams et al., 1992a). 
In Experiment 3, FTAI following a newly developed letrozole synchronization protocol 
resulted in a P/AI that did not differ from the 5-day Cosynch plus CIDR protocol. In this study, a 
greater proportion of heifers had estrus scores ³2 on the day of FTAI compared to cows, 
although approximately 20% of cows showed sign of estrus following FTAI compared to <5% of 
heifers. The interval from the onset of luteolysis to ovulation was 14 hours longer in lactating 
Holstein cows than in heifers (Sartori et al., 2004) indicative of slower resumption of estrus in 
cows. It has also been shown previously that beef cows show estrus 7 to 10 hours later than 
heifers depending on the follicular stage when PGF was given (King et al., 1982). Therefore, 
prolonging the interval from PGF to AI past 66 hours may increase the expression of estrus and 
increase P/AI, especially in cows.  
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The current study shows one of the highest P/AI following FTAI in cattle that displayed 
estrus (73.8%). In the present study, P/AI may have been increased even more in cows by 
delaying FTAI by 6 to 12 hours (i.e. AI at 72 to 78 hours after PGF) as has been reported 
recently (Macmillan et al., 2020). Evidence for this was the >20% increase in estrus detection 
score ≥2 between the day of FTAI and the day of ovulation in cows (Table 7.3). In Experiment 3, 
P/AI in the LRD group did not duplicate what was observed in the diestrus and metestrus groups 
in Experiment 2 (51/105 [48.6%] vs 16/21 [76.2%]). An explanation for this may be the 
proportion of cattle that underwent luteolysis to the initial PGF (Presynchronization) and had an 
estrus detection score ≥2 at the time of LRD insertion (65/107 [60.7%]; Table 3). In cattle with 2 
follicular waves (i.e. 20 day interovulatory interval), it is expected that 15/20 (75%) would 
undergo luteolysis and subsequently ovulate to a single dose of PGF (Kastelic et al., 1990). 
Therefore, a larger proportion of cattle in the present study were 0- to 5-days post ovulation 
when the initial PGF was given (42/107 [39.3%]), which may have attributed to the lower estrus 
response after presynchronization and P/AI. 
In summary, PGF given twice at 12-hour intervals on the day of LRD removal resulted in a 
more synchronous onset of estrus and interval to ovulation in Experiment 1. In Experiment 2, 
letrozole treatment initiated during metestrus resulted in the greatest CL diameter and plasma 
progesterone concentrations 14-days following the post-treatment ovulation, as well as the 
highest P/AI. In Experiment 3, there was no difference in P/AI between a 4-day LRD protocol 
and the 5-day Cosynch plus CIDR treatment. Future studies should address lengthening the PGF 
to FTAI interval by 6 to 12 hours to maximize estrus activity, estradiol concentrations, and 
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8. GENERAL DISCUSSION AND CONCLUSION 
 
8.1. General Discussion: 
 
The overall aim of this thesis was to determine the effectiveness of letrozole in 
controlling ovarian function and to use the knowledge gained to develop ovarian synchronization 
protocols use in for advanced reproductive techniques in cattle. Our first study was conducted to 
determine if letrozole could be released from a silicone matrix and have a biological effect on 
ovarian function (Chapter 2). Then, following the use of an intravaginal letrozole releasing 
device in lactating dairy cows, letrozole concentrations were quantified in milk for future use in 
drug depletion studies (Chapter 3). Two trials were subsequently completed to determine if 
letrozole treatment was advantageous during superovulatory protocols (Chapter 4). To better 
grasp the effect of letrozole on the local ovarian environment, and the ability of the cumulus-
oocyte complex (COC) to undergo maturation and in vitro fertilization following letrozole 
treatment, three experiments were done (Chapter 5). The interval to ovulation and initial fixed-
time artificial insemination trials following letrozole synchronization was done next, which was 
followed by the development of a new letrozole releasing device that increased plasma 
concentrations of letrozole (Chapter 6). Finally, the interval to estrus and a fixed time artificial 
insemination field trial using a letrozole-based protocol was done in three experiments (Chapter 
7).   
The concept of the silicone letrozole releasing device (LRD) developed in Chapter 2, 
which was used throughout this thesis, was conceived while researching the development of the 
controlled internal drug release device (CIDR) in cattle (Ogle, 1999). Progesterone, which was 
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impregnated into the silicone matrix of the CIDR, exhibited qualities that were similar to that of 
letrozole (i.e., <350 g/mol and lipophilic molecules). To test the original hypothesis that letrozole 
could be released from a silicone matrix, industrial silicone was purchased and preliminary 
testing was done by mixing the silicone and letrozole (10% wt/wt drug load) and waiting for the 
required 24-hour period for it to cure. Initial fears that the letrozole nitrile group would cause 
cure inhibition i.e., the silicone would never harden were unfounded. Following 24 hours of 
curing, the silicone plus letrozole matrix hardened and initial testing of release into ethanol was 
positive. This initial testing with industrial-grade silicone indicated that letrozole did release 
from the matrix into the ethanol, allowing for initial in vitro and in vivo testing utilizing medical-
grade silicone.  
It is speculated that the development of the silicone intravaginal device resulted in 
decreased variability of manufacturing, drug delivery, and plasma letrozole in comparison to 
previously designed dip-coat device (Yapura et al., 2015). Unfortunately, one of the pitfalls of 
the silicone LRD in Chapter 2 was the decrease in plasma letrozole levels in comparison to the 
dip-coat device (i.e., 80 ng/mL vs >200 ng/mL; (Yapura et al., 2015)). A dose-effect of letrozole 
was observed in Chapter 2 for dominant follicle diameter, CL diameter, and interwave interval. 
The original standard surface area LRD exhibited the same surface area compared to the CIDR 
(120 cm2), which did not result in sufficient letrozole release to affect plasma estradiol or 
dominant follicle diameter. Therefore, the surface area was quadrupled  by developing a large 
surface area device by adding 2 mm thick “wings” on the original device, which increased 
letrozole release. Unfortunately, letrozole plus FSH did not increase the superovulatory response 
in mature cows (Chapter 4), as observed in women (Garcia-Velasco et al., 2005).  
 176 
Moreover, in Chapter 5, treatment with our silicone LRD did not affect the mRNA gene 
expression in granulosa cells obtained from follicles 3 days after wave emergence. In addition, 
the silicone LRD did not suppress estradiol levels sufficiently to prevent ovulation in the 
proestrus heifers in Chapter 8. It was hypothesized that the dose of letrozole delivered by the 
intravaginal device was insufficient to elicit a biological effect. To mitigate this problem and 
increase plasma letrozole concentrations, giving a dose of intramuscular or intravenous letrozole 
(Yapura et al., 2014) at the time of LRD insertion was an option which would result in a 
secondary method of letrozole administration, but this would result in an additional drug 
application and increased expense. The FDA approval process in 2019 was reported to cost 
$950,000 per new drug application, and this does not include the costs of studies associated with 
drug safety, effectiveness, and tissue residue (U.S. FDA, 2018).  
One of the negative aspects of using a drug impregnated silicone intravaginal device is 
high residual drug remaining in the device after use. Past studies in development of the CIDR-B 
(1.9 grams of progesterone) indicated that a high proportion of progesterone was leftover 
following removal; therefore, CIDR-B were re-engineered to minimize the thickness of the 
silicone and subsequently decreased the progesterone load (1.38 grams) to minimize residual 
progesterone while maintaining similar plasma concentrations (Ogle, 1999). The 15% letrozole 
large surface area device developed in Chapter 2, contained 5.6 grams of letrozole per device. 
Therefore, it would have been useful to test residual levels of letrozole after use. Remarkably, 
following autoclaving, a CIDR 1380 device used once resulted in higher concentrations of initial 
plasma progesterone concentrations than a new CIDR 1380 (Zuluaga and Williams, 2008; Melo 
et al., 2018). It was suggested that the autoclaving process modifies the structure of the device or 
distribution of the drug within the device (Zuluaga and Williams, 2008). Autoclaving a once-
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used PRID resulted in a large quantity of crystalline progesterone on the surface, and this was 
hypothesized to increase progesterone availability (McPhee et al., 1983). Future studies 
involving LRD reuse are needed. Following their use in Chapter 7, the LRD were sanitized, 
autoclaved, and could be used in the future for pharmacokinetic studies. 
In Chapter 3, lower mean maximum concentrations of plasma letrozole following the 
intravaginal LRD were observed in lactating Holsteins compared to nulliparous beef heifers in 
Chapter 2 (i.e., 35 ng/mL vs. 70 ng/mL, respectively). These lower concentrations were most 
likely due to a combination of a greater body mass of mature Holstein cows (i.e., 680 kg vs. 422 
kg, respectively), a decrease in the elimination half-life in lactating Holstein cows compared to 
nulliparous heifers (i.e., 15 vs. 33 hours, respectively; Yapura et al., 2013), due to an increased 
metabolism in lactating cows. For the study in Chapter 3, cull, lactating Holstein cows were 
purchased from local producers. As milk production was low (9-12 kg/day, the elimination half-
life was expected to be higher than in high producing dairy cows around the time of first 
insemination (~40 kg/day). This speculated difference in elimination half-life poses an essential 
question as to whether letrozole would even have a biological effect in high producing lactating 
dairy cows. The downfall of the idea of intravaginal dosing, deployed in this thesis, is the 
inability to increase the dose of letrozole on a per kilogram basis; therefore, the same amount of 
letrozole is delivered to a 400 kg heifer compared to an 800 kg lactating dairy cow. This dosing 
is speculated to be the reason why more intravaginal drug delivery systems are not used in food-
producing animals. Therefore, to alter the dose of an intravaginal drug, either surface area or the 
drug load would need to be changed, and this would necessitate more drug testing and costs, as 
described previously. This dose effect of letrozole was observed in our FTAI studies done in 
Chapters 6 and 7. Heifers in the LRD group had dominant follicles that were numerically larger 
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in diameter at the time of AI compared to cows in the LRD group. This likely resulted from 
increased plasma letrozole concentrations in the heifers, resulting in a greater suppression of 
plasma estradiol, which in turn increased LH pulsatility (Kinder et al., 1996) resulting in an 
increased diameter of the dominant follicle. 
 A fascinating revelation in Chapter 3 was that letrozole was excreted into the milk of 
lactating dairy cows. This was the first study done in dairy cattle, as all previous studies utilized 
beef heifers (reviewed in Yapura et al., 2018). In Chapters 6 and 7, both beef heifers and 
lactating cows were used, indicating nursing calves consumed letrozole. Understanding the effect 
of letrozole on prepubertal animals is lacking but is essential for better understanding. Letrozole 
treatment has been used in prepubertal boys with short stature. Following treatment, an increase 
in stature was observed in comparison to placebo-treated controls. Although an increase in 
plasma testosterone concentrations was observed in the letrozole group, no advancement of onset 
to puberty was reported (Hero et al., 2005). The administration of anastrozole, in adolescent, 
growth hormone deficient boys, slowed the epiphyseal fusion caused by blockage of estrogen 
synthesis, which resulted in a significant height increase in comparison to the placebo group 
(Mauras et al., 2008). Therefore, there is potential for calves consuming letrozole-containing 
milk from their dams to grow at faster rates than their non-treated counterparts.  
In Chapter 4, the co-administration of letrozole and FSH did not increase the 
superstimulatory effect in cows, as observed in women (Mitwally and Casper, 2002). In women, 
once-daily oral letrozole is given in combination with recombinant FSH commencing on Day 3 
of menses (Garcia-Velasco et al., 2005). Day 3 of menses correlates to increasing concentrations 
of endogenous FSH and the number of antral follicles ≥ 5 mm in women exhibiting both two- 
and three-follicular waves (Baerwald et al., 2003). Therefore, ovarian stimulation initiated on 
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Day 3 occurs at the time of, or shortly after, wave emergence regardless of women exhibiting 
two- or three- follicular waves per menstrual cycle. In Chapters 4 and 5, letrozole was given to 
cows immediately following the ablation of follicles ≥5 mm (i.e., approximately 1.5 days before 
wave emergence) for 3.5 to 4 days. Therefore, letrozole treatment may be disruptive to early 
follicular growth and result in a lower proportion of ovulations (Chapter 4) and the number of 
follicles aspirated (Chapter 5) following treatment. To resemble letrozole treatment in women, it 
would be necessary to insert the LRD at the initiation of FSH treatment in cattle (i.e., at the time 
of wave emergence). Similarly, a superstimulatory response may be favored utilizing a 
decreasing (i.e., step-down) vs a constant FSH dosage regiment in cattle. Women undergoing 
ovarian stimulation endure daily transvaginal ultrasonography to monitor ovarian stimulation 
with FSH. With the combination of letrozole and FSH in women, a lower dosage of FSH is 
needed to achieve ovarian stimulation in comparison to FSH alone (Goswami et al., 2004). 
Therefore, the superstimulatory outcome in cattle may be comparable with letrozole plus half the 
dosage of FSH (LRD + 200 mg FSH) in comparison to a full dosage alone (400 mg FSH), 
although this speculation assumes that an accumulation of intraovarian androgens upregulate the 
FSH-receptor in granulosa cells, a phenomenon that was not seen in granulosa cells in Chapter 7. 
Although a decrease in estradiol in follicular fluid was observed, no testosterone in follicular 
fluid was assayed in this thesis.       
 With current knowledge of bovine reproductive endocrinology, the negative effect of 
letrozole on early follicular growth immediately preceding wave emergence is speculated to stem 
from two possibilities: 1) increased plasma LH concentrations causing disruption of early 
follicular development (Chupin et al., 1984) or 2) increased inhibin produced from the growing 
dominant follicle before, and at the time of selection suppressing endogenous FSH (Kaneko et 
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al., 1995). Unfortunately, the first hypothesis was not supported in the first experiment in 
Chapter 4. In that study, an LRD was given at the time of wave emergence (i.e., 1.5 days after 
follicular ablation) after the number of antral follicles ≥2 mm were counted. The LRD was 
removed 5 days later, followed by follicular ablation to induce wave emergence following 
treatment (i.e., plasma letrozole and LH concentrations were elevated at this time). There was no 
difference in the number of follicles ≥2 mm before and after letrozole treatment, indicative of no 
effect of elevated LH on early follicle growth. The hypothesis of an increase in follicular inhibin 
concentrations was not tested directly, but not supported indirectly in this thesis either, as 
frequent blood sampling done after 4-days of letrozole treatment did not show a difference in 
plasma FSH concentrations. To understand the effect of letrozole treatment on early follicular 
development before wave emergence more frequent blood sampling should be done immediately 
following follicular ablation and LRD insertion to characterize both LH and FSH concentrations.   
Generally, when co-stimulation with letrozole and FSH is used in women, the study 
population utilizes sub-fertile women with a low ovarian reserve. A study done in women with a 
high antral follicle count indicated no difference in the number of COC recovered between 
letrozole vs no letrozole treatment. A lower pregnancy rate was achieved with letrozole in this 
study, which was attributed to increased plasma progesterone on the day of hCG to induce in 
vivo maturation (Yang et al., 2019). Moreover, a large number of randomized controlled trials in 
women show no difference in the number of oocytes recovered following letrozole treatment 
(Goswami et al., 2004; Ozmen et al., 2009; Davar et al., 2010) with the exception of one 
(Verpoest et al., 2006). These studies could be replicated using the bovine model, as the 
assessment of a low number of antral follicles by ultrasonography correlates to a low ovarian 
response following superstimulation (Singh et al., 2004). The combination of letrozole and FSH 
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may present a viable option in poor-responding cattle undergoing superstimulation, but further 
testing using the bovine model is necessary. 
In Chapter 5, there were no differences detected in granulosa cell mRNA gene expression 
in all genes analyzed between the LRD and sham-treated groups. Although estradiol tended to be 
lower in both the dominant and subordinate follicle follicular fluid, no significant differences 
were detected in CYP19A1 gene expression. Using human luteinized granulosa cells cultured in 
vitro, no difference was detected in either estradiol production or CYP19A1 expression until 
cultured with 285 ng/mL of letrozole (Lu et al., 2012). Therefore, achieving plasma letrozole 
concentrations of 70 ng/mL in Chapter 5 may not have been sufficient to affect gene expression 
of targeted genes. Similarly, unlike described in the literature, no difference was detected in the 
FSHR gene expression between treatment groups in Chapter 5. The hypothesis that letrozole 
would increase intraovarian androgens and upregulate FSHR gene expression was not supported 
using the bovine model in Chapters 4 and 5. Although the number of heifers per group (n=8) was 
low and the high variation in gene expression, the difference is not conclusive. Therefore, 
another study should be done using a greater number of animals and including new reference 
genes to decrease variation.  
Although a decreased number of COC were recovered per LRD-treated heifer in Chapter 
5, a higher proportion of these COC advanced to the metaphase II stage following 24 hours of in 
vitro maturation compared to the sham group. The reason for this is unknown but is likely 
attributed to LH pulse amplitude. Although not recognized for its role in the growth of follicles 
<8 mm, LH may play an integral role in early antral follicle development. The LH-receptors 
have been localized in mural granulosa cells of follicles >9 mm in diameter, but are found in 
theca interna cells of follicles ≥4 mm in diameter (Xu et al., 1995). It has been postulated in 
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humans, that LH acts to accelerate apoptosis of granulosa cells from subordinate follicles by 
downregulating bone morphogenic protein (BMP-4 and -7; (Tajima et al., 2007)). A large 
proportion of the COC collected in Chapter 5 were from follicles approximately 3-5 mm in 
diameter. Therefore, the increase in LH pulsatility may have led to a more substantial proportion 
of small follicles undergoing regression in the letrozole group and a positive relationship exists 
between early follicular regression and oocyte competence (Vassena et al., 2003). The increase 
in LH pulsatility before aspiration may also explain the increased proportion of blastocysts from 
total COC and embryos from compact and cleaved zygotes in the letrozole group following in 
vitro maturation and in vitro fertilization. This difference in oocyte quality was also observed in 
women undergoing ovarian stimulation with both a GnRH-antagonist plus letrozole. Although a 
lower number of oocytes were recovered from women in that group, a significantly higher 
fertilization rate following intracytoplasmic sperm injection was shown (Yarali et al., 2009). 
Therefore, the effect of increased LH pulsatility and whether it is beneficial or determinantal to 
early follicle growth and subsequent in vitro embryo production still requires investigation. 
In Chapters 6 and 7, letrozole synchronization protocols were developed for use in FTAI 
in cattle. Although synchronous ovulation following a 4-day LRD and a 48-hour interval from 
PGF to GnRH was observed, a lower pregnancy per AI was achieved compared to commonly 
used GnRH-based synchronization protocol in Chapter 6. This low P/AI was attributed to a 
shortened interval from PGF to GnRH, not permitting a rebound in circulating estradiol for 
sperm transport and subsequently causing short lifespan CL. By understanding the interval from 
PGF to estrus in LRD-treated heifers, we were able to pinpoint when the rebound in estradiol and 
endogenous the LH surge occurred.  Using the electronic estrus detection data, we could then 
approximate when to perform AI and give GnRH in a FTAI protocol utilizing letrozole 
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treatment. With an interval of 66 hours from PGF to GnRH/AI, a high P/AI was achieved in both 
the metestrus and diestrus group in Chapter 7 (>75%) with a tendency for an increase in the 
metestrus group. Unfortunately, when we applied this protocol in a field trial, the P/AI was 50%, 
and no difference was shown between a 4-day LRD vs. a 5-day CIDR Cosynch protocol. It was 
speculated that the decrease in P/AI was attributed to 2 reasons: 1) Approximately 40% of the 
cattle were in metestrus at the time of PGF presynchronization; therefore, they did not undergo 
luteolysis (to the initial PGF) followed by spontaneous ovulation, and 2) the PGF to AI interval 
was hastened by approximately 6 to 12 hours as evidenced by the estrus detection score at the 
time of AI. Through the use of estrus detection patches in Chapter 7, it was shown that only 60% 
of cattle given PGF at random stages of the estrous cycle showed signed of estrus within 5 days. 
Subsequently, 79% of the heifers that showed estrus following presynchronization with PGF 
before letrozole treatment became pregnant following FTAI, compared to only 58% of cows. 
Evidence for the 2nd speculation was shown by the increased proportion of cows that displayed 
estrus following AI/GnRH (~20%). In a previous study, it was shown that beef heifers display 
estrus significantly earlier than cows following a 7-day CIDR Cosynch protocol (i.e., 50 vs. 54 
hours; Rich et al., 2018). Therefore, by extending the interval from PGF to AI/GnRH from 66 to 
72 or 78 hours may have resulted in a greater proportion of cows displaying estrus before AI, 
which would hypothetically increase pregnancy per AI. Another option would be to give PGF 11 
to 14 days apart to increase the proportion of cattle responding to the presynchronization 
treatment.  
A viable option that has yet to be investigated is the potential use of letrozole 
synchronization for fixed-time embryo transfer (FTET) in cattle. Letrozole for FTET may 
increase P/AI in several different ways. Firstly, letrozole can be used for synchronization of 
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ovulation and would result in a larger preovulatory follicle, attributed to increased LH in 
circulation, as shown in Chapter 5. Following letrozole treatment, a larger ovulatory follicle 
resulted in a CL that produced a higher concentrations of circulating progesterone 6 days after 
ovulation in Chapter 7. Secondly, letrozole is luteotrophic (Chapter 2), indicating that it can be 
used to increase CL size and production of progesterone following ovulation. Lastly, and 
probably the least explored option in cattle, is the effect of letrozole on endometrial thickness. 
Ovarian stimulation with letrozole, in women, has been shown to increase endometrial thickness 
in comparison to clomiphene citrate (Atay et al., 2006) due to decreased estradiol at the time of 
oocyte aspiration. Endometrial thickness at the time of embryo transfer has been shown to be 
positively correlated to pregnancy success in women (Wu et al., 2014), and in a large 
retrospective study in Japan with frozen embryo transfer, ovulation induced with letrozole 
increased pregnancy success (Tatsumi et al., 2017). Ultrasonographic assessment of the 
appearance of the bovine uterus throughout the estrous cycle in cattle, has been done (Pierson 
and Ginther, 1987c). In high producing dairy cows (~40 kg/day), endometrial thickness at the 
time of artificial insemination was positively correlated to pregnancy success, and it was 
suggested that high estradiol and low progesterone led to increased endometrial thickness (Souza 
et al., 2011). Unfortunately, there is a lack of information on the thickness of the endometrium at 
the time of embryo transfer in cattle.  
Therefore, utilizing this knowledge on endometrial thickness, it may be speculated that 
letrozole synchronization would be beneficial for embryo transfer programs, and a 
synchronization protocol could be developed as depicted in Figure 8.1 below. 
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Figure 8. 1. A speculated experimental timeline utilizing letrozole for fixed-time embryo transfer 
in cattle. An LRD is given on Day -8 for 5 days to increase follicular size of the preovulatory 
follicle. A separate LRD is given on Day 0 for 7 days to increase progesterone production from 
the corpus luteum and decrease estradiol concentrations, preparing the endometrium for ET on 
Day 7.   PGF: 500 µg cloprostenol; LRD: letrozole releasing device; GnRH: 100 µg gonadorelin; 
ET: embryo transfer 
 
Using a similar experimental treatment schedule as described in Chapter 7, cattle could 
be presynchronized with PGF on Day -13 and given an LRD 5 days later (Day -8). By increasing 
the length of LRD treatment from 4- to 5-days, it is hypothesized that a larger follicle would be 
present at device removal on Day -3. Similarly, PGF would be given twice 12 hours apart to 
ensure luteolysis and GnRH would be given 72 hours after device removal (Day 0). At the time 
of GnRH, an LRD would be inserted for 7 days prior to embryo transfer. This duration of 
treatment would not impede ovulation (following GnRH), and letrozole’s luteotrophic properties 
would hypothetically increase the size and progesterone secretion of the resultant CL. Moreover, 
by decreasing estradiol and increasing progesterone, letrozole may increase the receptivity of the 
endometrium before embryo transfer and overall increase the P/AI following embryo transfer in 















LRD-5 Days LRD-7 Days
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8.2. General Conclusions 
 
8.2.1. Research and development of a silicone letrozole-releasing device to control 
reproduction in cattle 
 
a) A letrozole-impregnated silicone device provided continuous in vivo release of letrozole 
throughout the 8-day experimental period. 
b) A larger surface area letrozole-releasing device resulted in the highest-circulating 
letrozole concentrations, the largest dominant follicle and most prolonged interwave 
interval, and the largest CL 7 days post-ovulation. 
c) Treatment with the larger surface area letrozole-releasing device decreased plasma 
estradiol concentrations the most in heifers. 
 
8.2.2. Analysis of letrozole milk residues following intravaginal letrozole treatment in 
lactating dairy cattle 
 
a) A new method for measuring letrozole concentrations in milk was partially validated by 
tandem mass spectrometry with a limit of quantification of 5 ng/mL. 
b) Following a 4-day intravaginal letrozole regimen, letrozole concentrations tended to be 
higher in plasma than milk and the maximum concentration of letrozole was higher in 
plasma than milk. 
c) No difference in the interval to ovulation was detected after PGF to induce luteolysis and 
GnRH-induced ovulation following a 4-day letrozole treatment; the interval to ovulation 
was more synchronous in the letrozole group.    
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8.2.3. The bovine model to test the ovarian superovulatory effects of aromatase 
inhibitors 
 
a) Following ablation-induced wave emergence, a 5-day regimen of intravaginal letrozole 
treatment did not increase the number of antral follicles at the subsequent wave 
emergence. 
b) A combination of letrozole plus follicle-stimulating hormone (FSH) failed to increase the 
superovulatory response but lengthened the interval and decreased the variation in the 
time of onset of estrus.  
c) Letrozole plus FSH treatment decreased the proportion of ovulations and the number of 
ovulations 36 hours after GnRH. Similarly, letrozole decreased the number of quality 1 
embryos and tended to decrease the number of total transferable embryos. 
d) Letrozole treatment decreased the concentrations of plasma estradiol at the time of the 
last FSH treatment. 
 
 
8.2.4. The effect of an aromatase inhibitor on the ovarian-oocyte environment in beef 
cattle 
 
a) Following 4 days of intravaginal letrozole treatment, follicular fluid concentrations of 
letrozole were highly correlated and comparable to plasma concentrations. A method for 
quantifying letrozole in follicular fluid was partially validated by tandem mass 
spectrometry as part of this experiment. 
b) Following letrozole treatment and PGF-induced luteolysis on Day 3 of wave emergence, 
plasma progesterone concentrations were elevated, and plasma estradiol concentrations 
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were decreased compared to the sham group. This was indicative of a reduced luteolysis 
following letrozole treatment. 
c) Letrozole treatment tended to decrease both the dominant and subordinate follicle 
concentrations of estradiol on Day 3 after wave emergence.  
d) Letrozole treatment did not affect the expression of genes for steroidogenesis or ovarian 
function in granulosa cells obtained from both dominant and subordinate follicles 3 days 
after wave emergence. 
e) Following letrozole treatment and frequent blood sampling for 8 hours, LH amplitude 
and area under the curve increased. No difference was detected for the FSH area under 
the curve, pulse amplitude, or pulse frequency.  
f) Following cumulus-oocyte complex (COC) aspiration done on Day 4 after wave 
emergence, no difference was detected in the oocyte maturational stage immediately after 
collection in the letrozole vs. sham group. Following 24 hours of in vitro COC 
maturation, the proportion of metaphase II oocytes was higher in the letrozole treatment 
group. 
g) Letrozole treatment increased the proportion of blastocysts and total embryos following 
COC aspiration, in vitro maturation, and in vitro fertilization. 
h) Four days of letrozole treatment decreased the total number of follicles aspirated, total 
COC, and decreased the COC collection rate on 4 days after wave emergence. 
 
8.2.5. Ovulation timing, fixed-time artificial insemination and effect of 
presynchronization on pregnancy results following aromatase inhibitor treatment 
in beef cattle 
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a) Treatment with a letrozole releasing device for 4 days followed by PGF and GnRH at a 
48-hour interval resulted in the most synchronous interval to ovulation in lactating beef 
cows. 
b) Letrozole treatment resulted in a lower pregnancy per AI compared to two commonly 
used synchronization protocols, even though the ovulatory follicle was larger at the time 
of device removal and AI. 
c) Following the development of a new X-LRD, plasma letrozole increased throughout 
treatment, and the vaginal irritation score was numerically lower compared to a T-LRD. 
d) Following presynchronization with PGF 8 days before letrozole treatment, and a PGF to 
GnRH/AI interval of 48 hours, no difference was detected in P/AI or the proportion of 
heifers that returned to estrus within 10 days after ovulation compared to heifers given an 
LRD at a random stage of the estrous cycle. 
 
8.2.6. Estrus timing, corpus luteum function and field trial pregnancy results 
following aromatase inhibitor treatment in beef cattle 
 
a) There was no effect of a 4-day letrozole treatment initiated 3 days after wave emergence 
followed by PGF at device removal on the degree of luteolysis (as assessed by CL 
diameter and plasma progesterone) or the interval to the onset of estrus compared to 
sham-treated heifers.  
b) Giving PGF twice at 12-hour intervals did not increase the degree of luteolysis or the 
interval to the onset of estrus compared to PGF given once. However, PGF administered 
twice resulted in a more synchronous interval to the onset of estrus and ovulation. 
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c) Letrozole treatment initiated during proestrus did not prevent ovulation during device 
placement or within 24 hours of device removal in heifers compared to letrozole 
treatment initiated during metestrus or diestrus. 
d) Letrozole treatment initiated during metestrus followed by a PGF to GnRH/AI interval of 
66 hours resulted in a higher pregnancy per AI compared to treatment initiated during 
proestrus and tended to be higher than diestrus. Following post-treatment ovulation, 
treatment initiated during metestrus resulted in a larger CL and higher plasma 
progesterone 14 days after ovulation compared to treatment initiated during diestrus and 
proestrus 
e) In a field trial with nulliparous beef heifers and multiparous beef cows, a 4-day letrozole 
treatment with a PGF to GnRH/AI interval of 66 hours, resulted in similar pregnancy per 
AI compared to a 5-day Cosynch plus CIDR protocol. Following post-treatment 
ovulation, heifers that received an LRD had higher plasma progesterone levels 7 days 
after AI. 
f) Independent of synchronization, cattle that displayed estrus before AI had a threefold 
increase in pregnancy per AI.  
 
8.3. Future Studies 
 
Based on the results presented in this thesis, I raise the following questions for future 
studies with letrozole that may be done: 
• Can an increase in plasma letrozole concentrations prevent an endogenous LH 
surge following luteolysis in cattle? 
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• What is the magnitude of a GnRH-induced LH and FSH surge following a 
letrozole-based synchronization? Does long-term letrozole treatment exhaust the 
pituitary of LH?  
• What is the elimination half-life of letrozole in high-producing dairy cows (i.e., 
>40 kg/day)? 
• What is the effect of high physiological LH concentrations at the time of follicle 
wave emergence? Does letrozole treatment immediately preceding wave 
emergence affect follicle and oocyte competence of that wave?   
• Will an increase in plasma letrozole concentrations increase mRNA FSHR 
expression and subsequently increase the superovulatory response in cattle? 
• Can the use of letrozole decrease the dose of FSH needed for ovarian 
superstimulation in cattle? Does long-term treatment with letrozole increase 
intraovarian androgens and increase superstimulatory response? 
• Does letrozole treatment increase inhibin production from the dominant follicle 
compared to non-treated cattle?  
• Can letrozole treatment during a time of high circulating progesterone be used to 
induce ovulation of a dominant follicle?  
• What is the impact of suppressed estradiol in prepubertal calves? Can letrozole 
treatment hasten the onset of puberty? 
• Can the luteotrophic properties of letrozole increase the size of the CL and 
progesterone production during the early luteal phase for improving embryo 
transfer results? 
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• What is the effect of letrozole treatment during pregnancy? If abortion does not 
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